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The aim of this investigation was to examine the mechanisms implicated in the
processes of learning and memory in the rodent hippocampus using
electrophysiological recording techniques to monitor CA1 pyramidal cell activity. In
the presence of ionotropic glutamate and y-aminobutyric acid (GABA) receptor
antagonists, stimulation of the septohippocampal cholinergic afferents, in stratum
oriens, produced a slow excitatory postsynaptic potential (EPSP). Subsequent
pharmacological classification established that this response was mediated by
activation of muscarinic acetylcholine receptors (mAChR) and as such this response
was termed an EPSPm-
Specific blockers of voltage-gated Ca2+ channels, co-conotoxin GVIA and w-agatoxin
IVA, revealed that the release of ACh necessary to evoke the EPSPM was mediated
by activation of both N- and P/Q-type Ca2+ channels. Blockade of presynaptic 4-AP-
sensitive K+ channels further enhanced the release of ACh.
A previous report had shown that mAChR-mediated synaptic transmission could be
modulated by adenosine A] receptor activation but had not examined the precise
cellular mechanisms underlying this effect. Investigations have revealed that the
activation of Aj receptors inhibited the EPSPm irrespective of the Ca2+ channel
supporting this response and that there maybe a partial involvement of 4-AP
sensitive K+ channels. As adenosine A] receptors are known to act via the G-protein,
Gj/0, we also investigated the involvement of cAMP in the inhibition of the EPSPm- It
was demonstrated that forskolin stimulated increases in cAMP partially occluded and
8-Br cAMP application fully occluded the adenosine Ai receptor-mediated inhibition
of the EPSPm.
Most synapses are under the regulation of a variety of GPCRs. In this respect we also
demonstrated that opioid receptor agonists could modulate the EPSPM- Interestingly,
it was found that opioid agonists acting at a presynaptic (x-opioid receptor caused an
enhancement of the EPSPm although the mechanism of how this is achieved is
unclear.
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Another G-protein coupled receptor implicated in cholinergic modulation is the
galanin receptor which has been shown previously, and again here, to produce an
inhibition of the EPSPm-
This inhibition was absent in transgenic mice lacking the galanin gene. This result
may have predicted that these mice might learn better. However the opposite was
true. Therefore, we chose to study whether LTP in these animals was impaired since
LTP represents a working model of molecular memory at synapses. Consistent with
their impaired learning ability it was found that LTP induced at synapses in the
stratum oriens was decreased in the Gaf/_ mice.
To establish whether other proteins of varied function could modulate hippocampal
synaptic plasticity, LTP was assessed in other transgenic mice with disruptions to
genes found to be expressed predominantly in the hippocampus. Hpk mice,
possessing a disruption to the Epstein Barr-inducible G-protein coupled receptor,
displayed enhanced LTP whilst other transgenic mice investigated showed no change
in LTP. However, although no change in LTP was observed, mice lacking the gene
encoding Brain Serine Protease 1 (BSP1) displayed increased epileptogenic activity.
In summary, we have demonstrated multiple mechanisms that modulate the
cholinergic input into the hippocampus as well as LTP and general excitability of
glutamatergic synapses. Therefore, this suggests mechanisms that may play an
important role in regulating the processes of memory and learning.
Here, we have discovered new targets with the potential to modulate the processes of
memory and learning via action on the cholinergic input or synaptic plasticity in the
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EBI Epstein-Barr inducible
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EPSP excitatory postsynaptic potential
EPSPa AMPA receptor-mediated EPSP
EPSPm muscarinic acetylcholine receptor-mediated EPSP
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ETZ etonitazene hydrochloride
fEPSP field excitatory postsynaptic potential
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GABA y-aminobutanoic acid
GALR1 galanin receptor 1
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GALR3 galanin receptor 3
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GFAP glial fibrillary acidic protein
G-protein guanine nucleotide binding protein
Iahp calcium activated AHP current
Ik(leak) leak K+ current
IP3 inositol 1,3,5-triphosphate
IPSC inhibitory postsynaptic current
IPSP inhibitory postsynaptic potential
IPSPA GABAa receptor-mediated IPSP
IPSPb GABAb receptor-mediated IPSP
LTP long term potentiation
mAChR muscarinic acetylcholine receptor
mRNA messenger ribonucleic acid
MT-1 muscarinic toxin 1





PH domain pleckstrin homolog domain
PIP2 phosphatidyl-2-bisphosphate
PKA cAMP-dependent protein kinase
PKC protein kinase C





PPD paired pulse depression
PPF paired pulse facilitation
PSFV presynaptic fibre volley
PTP post tetanic potentiation
PZP pirenzipine
s. oriens stratum oriens
s. pyramidali stratum pyramidali
s. radiatum stratum radiatum
S.E.M. standard error of the mean
SCG superior cercvical ganglion
SFA spike frequency adaptation
SH domain src-homology domain
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The aim of this chapter is to present an overview of mechanisms believed to be
involved in the processes of learning and memory formation which are relevant to
the basic synaptic mechanisms studied in this thesis. As such, I will cover the
hippocampus and the molecular mechanisms underlying memory formation and the
contribution of the septohippocampal pathway to this important neural process. Each
individual chapter will contain a more detailed introduction associated with it
focusing on the issue to be addressed.
1.1 The Hippocampus
1.1.1 Historical
In 400 B.C. the great philosophers of Greece debated the function of the brain.
Hippocrates believed that the brain was the seat of consciousness whilst Aristotle
opposed this view, thinking instead that intellectual, perceptual and related functions
originated from the heart. It was Hippocrates that proved to be correct. However,
how the brain functioned remained a mystery and it was not until the nineteenth
century that the concept of "functional localisation" was asserted by Paul Broca.
Since then the trend has been to describe the brain in ever-smaller functional units,
initially based on the sound logic that if it looks different then it probably has a
different function (Finger, 1994). This assumption was supported when, in 1887, it
was shown that damage to the temporal lobes and the underlying hippocampus in
monkeys produced deficits in memory and memory formation (Brown & Schafer,
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1888). This finding was supported when, 12 years later, Bechterew described a
memory deficit in a patient who, upon autopic examination, displayed bilateral
softening of the hippocampus and adjoining temporal cortex (Bechterew, 1900).
However, it was not until 1953 that interest in the hippocampus was renewed when
Case H.M. underwent neurosurgery to alleviate the symptoms of his severe epilepsy
by bilateral removal of parts of the temporal lobe. After lesions to the hippocampus
and a number of associated brain areas, the patient displayed profound anterograde
declarative memory loss as well as some retrograde amnesia extending back for
many years (Scoville, 1954; Scoville & Milner, 1957). Non-declarative or procedural
memory tasks, such as learning a motor skill, were spared and, therefore, this
cognitive process was believed to not be dependent on the hippocampus.
These findings led to a plethora of lesion studies conducted on animals that
confirmed a role for the hippocampus in certain types of memory formation.
1.1.2. Anatomical Structure of the Rat Hippocampus
The hippocampal formation comprises four cortical regions including the dentate
gyrus, the hippocampus proper (divided into the CA1, CA2 and CA3 subfields, the
latter two subfields sharing many connectional characteristics), the subicular
complex and the entorhinal cortex. The three dimensional shape of the hippocampal
formation appears grossly as an elongated structure with its long axis, also referred to
as the septotemporal axis, bending in a C-shaped manner from the septal nuclei
rostro-dorsally to the temporal lobe caudo-laterally (fig. 1.1A). In the perpendicular
transverse section (fig 1.16) the principal pathways can be viewed and have been
determined in classical Golgi studies (Ramon y Cajal, 1893; Lorento de No, 1933,
1934) and degeneration studies (Blackstad, 1956). These studies showed the dentate
gyrus receiving its major input from the perforant path of the entorhinal cortex. The
granule cells of the dentate gyrus, in turn, project mossy fibres that terminate on the
dendrites of the CA3 pyramidal cells. These cells project collateralised afferents that
terminate within the CA3 region as associational connections and provide the major








Figure 1.1 Location and general structure of the hippocampus
A shows a schematic representation of the rat brain and the position of the hippocampus within it. B
illustrates a schematic representation of the transverse hippocampal slice in which the main areas (area
CA1, area CA3, dentate gyrus, subiculum and fimbria) are marked. Note the different scales in the
two figures.
Schaffer collaterals. The majority of these afferents synapse within the apical
dendritic field of the CA1 pyramidal cells in the region known as the stratum
radiatum (fig. 1.2). Per Anderson and coworkers suggested a lamellar organisation of
these pathways, splitting the hippocampus into functional cells that are stacked along
the septotemporal axis (1971). However, it has subsequently been shown that,
besides the mossy fibre projection form the dentate gyrus, the hippocampal
projections are as extensive and highly organised in the septotemporal axis of the
hippocampus as in the transverse axis (Amaral & Witter, 1989).
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Figure 1.2 Synaptic circuitry of the rat hippocampal slice
A schematic representation of the hippocampal slice illustrating the major excitatory pathways which
comprise the trisynaptic circuit. The direction of synaptic connectivity between pathways is: perforant
path —» mossy fibres —> Schaffer collateral-commissural fibres. Note the clear differentiation between
laminae (s. oriens, s. pyramidali and s. radiatum).
However, most electrophysiological experiments performed on the hippocampus
exploit the transverse slice thus severing the septotemporal connections. As the
experimental work within this thesis is performed on transverse slices, the
connections and synapses of the transverse hippocampal orientation will be focused
upon. For a review of the anatomy of the hippocampus and its principal connections
see Amaral & Witter (1989).
The transverse hippocampal slice has proven extremely popular in investigations of
excitatory synaptic transmission due to the conservation of the tri-synaptic circuitry
(see fig. 3.2) and the clear morphological visibility of the different fields that
comprise the hippocampus (Yamamoto & Mcllwain, 1966; Skrede & Westgaard,
1971; Andersen, 1981). This preparation allows the recording of electrophysiological
activity from single cells or populations of cells in a controlled environment.
However, interpretation of such data and its relation to in vivo activity is subject to
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constraints due to the gross severance of convergent extrinsic inputs and intrinsic
septotemporal connections.
In addition to the principal cells of the hippocampus, there exist a variety of
GABAergic interneurons that form extensive connections with the pyramidal and
granule cells. For a review, see Freund & Buzsaki (1996). In conjunction with
inhibition provided by pyramidal cell recurrent collaterals, the GABAergic
interneurons generate the IPSP component of the pyramidal cell response by
feedforward inhibition. This is discussed in greater detail in section 1.1.3.
There are also extrinsic inputs into the hippocampus that utilise different
neurotransmitters to exert their effect, including serotonergic afferents from the
dorsal raphe nucleus, nor-adrenergic afferents from the locus coeruleus and a
heterogeneous population of afferents arising from the medial septum/diagonal band
complex of the basal forebrain (Swanson et al., 1982). These latter connections
consist of GABAergic, peptidergic (in particular, galaninergic afferents) and
cholinergic fibres. The cholinergic pathway has been extensively implicated in
memory and learning related behaviour and is discussed in section 1.2.3.
1.1.3. Synaptic Transmission in the Schaffer-Collateral Commissural
Pathway
During low frequency (<0.1 Hz) stimulation of the Schaffer-collaterals, the evoked
response observed in CA1 pyramidal neurons comprises a fast EPSP followed by a
biphasic IPSP (Kandel et al., 1961; Nicoll & Alger, 1981; Alger & Nicoll, 1982b).
The EPSP is believed to be mediated by AMPA receptors (EPSPA) (Davies &
Collingridge, 1989; Andreasen et al., 1989) whilst the biphasic IPSP is mediated by
GABAa (IPSPa) (Schwartzkroin & Prince, 1980; Alger & Nicoll, 1982a) and
GABAb (IPSPb) receptors (Dutar & Nicoll, 1988b; Soltesz et al., 1988; Lambert et
al., 1989). Blocking the IPSPA using GABAa receptor antagonists reveals an NMDA
receptor-mediated EPSP (EPSPn) (Andreasen et al., 1989). Under a variety of
conditions, e.g. reduced presynaptic inhibition (Wigstrom et al., 1986; Dingledine et
al., 1986), both EPSPAs and EPSPnS can be evoked. In each case it is believed that it
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is the release of L-glutamate from presynaptic terminals that accounts for each
response.
Originally, it was thought that the 1PSP component of the evoked response was
solely caused by recurrent (feedback) inhibition (Kandel et al., 1961; Andersen et al.,
1964; Dingledine & Langmoen, 1980; Knowles & Schwartzkroin, 1981). However,
it was realised that a feedforward inhibitory circuit was also responsible for the IPSP
(Alger & Nicoll, 1982b; Scwartzkroin & Knowles, 1983; Buzski, 1984).
Accordingly, activation of AMPA and NMDA receptors on GABAergic interneurons
were shown to result in the IPSPs observed in CA1 pyramidal neurons (Davies &
Collingridge, 1989; Andreasen et al., 1989; Sah et al., 1990).
The classic, fast hyperpolarising IPSPa, evoked by both recurrent and feedforward
circuits, was characterised by its sensitivity to bicuculline and to changes in both
intracellular and extracellular CP concentrations (Kandel et al., 1961; Andersen et
al., 1964; Allen et al., 1977; Eccles et al., 1977; Dingledine & Langmoen, 1980;
Dingledine & Gjerstad, 1980). Feedforward inhibitory circuits also activate a
GABAb receptor-mediated slow IPSPb (Nicoll & Alger, 1981; Newberry & Nicoll,
1984a), which was originally characterised by its similarity to (-)-baclofen-induced
hyperpolarisations (i.e. both exhibited similar I-V relationships and dependency on
extracellular K+) (Newberry & Nicoll 1984b) and was subsequently confirmed by the
inhibition of IPSPbS using selective GABAb receptor antagonists (Lambert et al.,
1989).
1.1.4. Synaptic Plasticity
It is far beyond the scope of this thesis to discuss synaptic plasticity and LTP in great
depth due to the wealth of literature regarding this subject. A brief outline of the
main points about synaptic plasticity will be reviewed here. For a more detailed
review see Bliss & Collingridge (1993).
Two initial discoveries suggested an important role for the hippocampus in memory
formation. Firstly, it was found that the pyramidal cells could encode information
about space (O'Keefe & Dostrovsky, 1971) and, secondly, that the synapses within
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the tri-synaptic circuit of the hippocampus undergo long-term potentiation (Bliss &
Lpmo, 1973).
Bliss and L0mo found that a high frequency train of action potentials evoked at any
of the three major pathways of the hippocampus produced LTP i.e. an increase in
glutamatergic synaptic strength in that pathway that could last for hours in the
anaesthetised animal and days or weeks in the freely moving, awake animal. In
addition, a theta burst stimulation pattern (several bursts of 4 shocks at 100 Hz
separated by a 200 ms interburst interval) also reliably induced LTP (Larson et al.,
1986) mimicking the firing patterns observed in the hippocampus during learning
tasks (Otto et al., 1991).
The induction of LTP, produced by tetanic stimulation, can be explained by the
properties of the NMDA receptor and the role of synaptic inhibition. It is the voltage-
dependent block of the integral channel by Mg2+ that allows the NMDA receptor to
act as a coincidence detector, i.e. the postsynaptic membrane must be depolarised to
remove the Mg2+ block allowing the entry of Ca2+ through the NMDA receptor upon
the release of glutamate into the synaptic cleft. The frequency dependency of LTP
induction is largely attributable to the susceptibility of NMDA receptor-mediated
currents to GABAb autoinhibition i.e. during a train of stimuli delivered to the
afferents, each subsequent stimulus-evoked release of glutamate produces a larger
NMDA receptor-mediated response in the pyramidal cell due to decreased GABA
release from interneurons as GABA from the previous stimulus inhibits its own
release (Collingridge et al., 1988; Davies et al., 1991).
Upon activation, the NMDA receptor becomes highly permeable to Ca2+ (Ascher &
Nowak, 1988; Jahr & Stevens 1987). Increases in intracellular Ca2+ were shown to be
vital in LTP induction (Lynch et al., 1983) as induction is occluded by the
intracellular injection of EGTA. This was supported by Ca2+ imaging techniques
which visualised this calcium elevation in dendritic spines during high frequency
stimulation (Regehr & Tank, 1990; Muller & Connor, 1991). The Ca2+increase
appeared to last for several seconds and produced Ca2+ gradients from spines to
dendrites lasting for several minutes. This is unnecessary for LTP induction, which
can be induced by Ca2+transients of 3 seconds (Malenka et al., 1992). There is also
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evidence to suggest that the Ca2+ influx is augmented by calcium-induced Ca2+
release and release of Ca2+ from intracellular stores (Alford et al., 1993; Obenaus et
al., 1989; Harvey & Collingridge, 1992). Inhibitors of these stores also inhibit LTP.
Several Ca2+-sensitve enzymes have been proposed to play a part in converting the
induction signal into a persistent change in synaptic efficacy although most interest
has focused on protein kinases. The first such kinase to be implicated in LTP was the
Ca2+/phospholipid-dependent protein kinase (PKC) (Bar et al., 1984). It is generally
thought that PKC activation is not a necessary factor for LTP induction but may be
involved in the conversion of short- to long-term potentiation. The Ca2+/calmodulin-
dependent protein kinase CaMKII has also been implicated in LTP (Malenka et al.,
1989; Malinow et al., 1989) as well as cAMP- and cGMP-dependent protein kinase
(PKA and PKG respectively) (Chetkovich et al., 1991) and protein tyrosine kinases
(O'Dell et al., 1991a).
The use of protein synthesis inhibitors has demonstrated that protein synthesis from
existing mRNA is required for the maintenance of LTP during the first few hours
(Krug et al., 1984; Otani et al., 1989; Frey et al., 1989). However, there is also
evidence for gene transcription and increased mRNA production after tetanisation
(Mackler et al., 1992; Dragunow et al., 1989; Nikolaev et al., 1991). The obvious
proteins to upregulate or modify would be ion channels involved in low frequency
synaptic transmission. Accordingly, there is evidence for AMPA receptor
phosphorylation by protein kinases, particularly PKA, following LTP induction
(Reymann et al., 1990; Greengard et al., 1991; Wang et al., 1991). Alternatively, the
induction of LTP could alter the ratio of flip:flop AMPA receptors or change the
subunit composition resulting in a change in whole cell conductance properties
(Sommer et al., 1990). There is some evidence suggesting NMDA receptor function
can also be enhanced by protein kinase activity, such as PKC providing a means by
which synapses increase their plasticity as well as their efficacy (Kelso et al., 1992).
As well as postsynaptic modifications, presynaptic modifications have been
considered as a locus of expression. This involves diffusable retrograde messengers.
Two such candidates are arachidonic acid and nitric oxide (NO) (McNaughton, 1982;
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Schuman & Madison, 1991; O'Dell et al., 1991b) which could act to increase
glutamate release or decrease glutamate uptake into surrounding glia.
1.2. The Septohippocampal Pathway
The septohippocampal pathway is one of the best examples of a central cholinergic
pathway and provides most of the cholinergic innervation of the hippocampal
formation. It also holds a critical role in the generation and maintenance of various
forms of electrical rhythmic activity, e.g. the theta rhythm, implicated in the spatial
memory acquisition of the rat (Winson, 1978). The septohippocampal pathway is
notably susceptible to the aging process and, furthermore, the target of
neurodegenerative diseases such as Parkinson's and Alzheimer's disease where loss
of cognitive function, particularly memory, is a major symptom.
1.2.1. Anatomical Structure
The septohippcampal afferents arise from large neurons located in the medial septal
nucleus (MS) and the vertical limb of the diagonal bands of Broca (vDBB) (fig. 1.3).
These neurons form a continuum of cells that are difficult to subdivide because of the
absence of clear histological boundaries. The MS/vDBB receives various inputs from
the hippocampal formation, limbic regions and brain stem nuclei (fig. 1.4) and sends
efferents to many brain areas inclusing the cingulate cortex, hypothalamus,
contralateral diagonal band as well as the hippocampal formation (fig. 1.3) (Dutar et
al., 1995).
It has been demonstrated that choline acetyltransferase (ChAT)-positive axons
infiltrate the hippocampus at postnatal day 2 in the rat (Hohmann & Ebner, 1985)
and the intensity of ChAT staining increases until the third to fifth week (Gould et
al., 1991).
The majority of septal neurons innervate the ipsilateral hippocampus via three main
routes: the fimbria, the dorsal fornix, and the supracallosal striae (Gage et al., 1984).
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Figure 1.3 Schematic cross-section of the rat brain showing the major pathways
originating from the rat basal forebrain.
This figure illustrates schematically the major efferent pathways basal forebrain nuclei of the rat,
namely the medial septum (MS), the vertical limb of the diagonal bands of Broca (VDB), the

























Figure 1.4 Summary diagram of brain areas projecting (afferents) to the Medial
septum/vertical limb of the diagonal bands of Broca (MS/vDBB) and of
structures receiving projections (efferents) from this area.
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Figure 1.5 Schematic diagram illustrating the topographical projection of the
septohippocampal pathway.
For ease of illustration the projections for the medial septum (MS) and the projections from the
vertical limb of the diagonal bands of Broca (vDBB) have been shown on opposite hemispheres.
However, both hemispheres of the brain show the above MS/vDBB projections to the hippocampal
formation.
A topographical projection of afferents has been shown, the more laterally the septal
neurons are located the more ventrally the axons terminate within the hippocampus
and the more rostral neurons project to the rostral parts of the hippocampus (Amaral
& Kurz, 1985; Gaykema et al., 1990). In addition, it has been demonstrated that the
CA1 pyramidal cells and granule cells of the dentate gyrus receive afferents from
vDBB whereas the cells of the ventral hippocampus receive afferents from both the
vDBB and the MS (Nyakas et al., 1987) (fig 1.5). Furthermore, two sets of
septohippocampal fibres that terminate on the dendrites of pyramidal and granule
cells have been described: (1) thick, coarse axons with large terminal boutons present
in the strata oriens, radiatum, moleculare, the dentate gyrus and the infragranular
zone of the dentate gyrus and (2) thin fibres displaying varicosities in the
hippocampal pyramidal cell layer, the dentate granular layer and the middle one-third
of the dentate molecular layer (Nyakas et al., 1987; Gaykema et al., 1991).
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1.2.2. Distribution of Neurotransmitters and Neuropeptides
Stimulation and lesion studies as well as histochemical detection of the enzymes
acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) led to the
discovery that a proportion of the septohippocampal pathway was cholinergic.
Lesions of the MS or fimbria/fornix transection resulted in a decrease in ACh,
choline and choline uptake in the rat hippocampus paralleled by a decrease in ChAT
(Kuhar et al., 1973; Potemska et al., 1975; Sethy et al., 1973). In addition, electrical
stimulation of the septum induces an activation of pyramidal cells in the
hippocampus and dentate gyrus (Andersen et al., 1971a, 1971b), supported by in vivo
release of ACh in the hippocampus after medial, but not lateral, septal stimulation
(Dudar, 1975; Moroni et al., 1978).
AChE and ChAT have been detected in the rat hippocampus (Fonnum, 1970; Shute
& Lewis, 1966) at axon terminals that make synaptic contacts on dendrites of
pyramidal and granule cells, mainly on dendritic spines. Immunohistochemical
studies have confirmed the presence of ChAT-positive cell bodies of two types: (1)
small, round neurons of the medial septal nucleus and (2) larger, fusiform neurons of
the vDBB (Mesulam et al., 1983; Amaral & Kurz, 1985; Armstrong et al., 1983).
Staining for ChAT revealed preferential distribution of cholinergic terminals in the
hippocampal pyramidal and dentate granular layers as well as at layers adjacent to
them, with the highest density in the stratum oriens (Frotscher & Leranth, 1985;
Houser et al., 1983). As well as synapsing with the dendritic spines of pyramidal
cells, cholinergic fibres synapse with GABAergic and somatostatin-containing
neurons in the stratum oriens of CA1 and CA3 subfields (Leranth & Frotscher,
1987).
Histochemical studies have also demonstrated a GABAergic subpopulation of
septohippocampal neurons making up 10-30% of the afferents (Kohler et al., 1984).
In contrast to the cholinergic afferents, the GABAergic septal neurons terminate
mainly on GABAergic interneurons (Freund & Antal, 1988).
However, not all of the neurons of the septohippocampal pathway are cholinergic or
GABAergic. As such, it has been demonstrated that medial septal cells contain
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neuropeptides such as galanin and A-acetyl-aspartyl-glutamate (NAAG) which in
some afferents are co-released with ACh (Andersen et al., 1971b; Forloni et al.,
1987; Melander et al., 1985).
1.2.3. Role of Septohippocampal System in Learning and Memory
The involvement of the septohippocampal system in the processes of learning
memory has been ascertained from several lines of investigation including lesion and
pharmacological studies, behavioural performance and behavioural recovery after
lesion.
Lesions of the MS or fimbria-fornix led to a deficit in working memory, especially in
spatial tasks (Poucet & Herrmann, 1990; Olton et al., 1978). However, the exact way
in which the septohippocampal pathway contributes to memory related tasks is
complicated by the fact that the lesions also destroy other pathways en route to the
hippocampus such as the noradrenergic and serotonergic pathways, as well as local
neurons in the case of the MS lesion. However, immunotoxic lesioning of rats using
the specific cholinergic immunotoxin, 192-IgG saporin, produced long lasting spatial
learning impairment after cholinergic denervation (Nilsson et al., 1992).
Microinjection of phenoxybenzamine, an ot-noradrenergic receptor antagonist, or
biccuculine, a GABAa receptor antagonist, caused an impairment of working
memory (Chirobak et al., 1992; Marighetto et al., 1989) suggesting an involvement
of noradrenergic and GABAergic neurotransmission in the functioning of the
septohippocampal system. Cholinergic antagonists, such as scopolamine, also impair
many types of memory tasks (Bartus et al., 1987). Conversely, systemic
administration of cholinergic agonists and drugs that increase hippocampal ACh
improve behavioural performances (Levey et al., 1991; Flood et al., 1984) although
it is hard to assess the exact contribution of hippocampal cholinergic synapses as the
administered drugs could be acting at a number of areas of the brain, not to mention
the periphery (Rush & Streit, 1992).
26
Following learning tasks, increased ChAT and ACh levels have been observed
(Matthies et al., 1974; Jaffard et al., 1985) as well as increases in sodium-dependent
high affinity choline uptake (HACU) in the rat hippocampus and frontal cortex
(Kuhar et al., 1978; Rauca et al., 1980). It has been demonstrated that biochemical
markers of septohippocampal cholinergic activity recover back to control levels
within 6 weeks after lesions limited to the supracollosal pathway (Gage et al., 1983).
In addition, there is a partial recovery of the deficit in passive and active avoidance
10 weeks after fimbria-fornix lesions (Dravid et al., 1986). This evidence
demonstrates a capacity of the septohippocampal system to compensate for loss of
function. One study shows an upregulation of ACh synthesis and storage in the
hippocampus after partial fimbria-fornix lesion (Lapchak et al., 1991) and this
recovery is potentiated by various neurotrophic factors, especially NGF.
1.2.4. Involvement in Aging and Disease
The septohippocampal pathway is vulnerable to aging. In the rat, a decrease in the
number and size of AChE-positive MS-DBB neurons was observed with age (Biegon
et al., 1986; Fischer et al., 1989) whereas only a decrease in the size of AChE-
positive cells was seen in the mouse (Flornberger et al., 1985). This appears to
correlate with a behavioural deficit (especially in learning and memory tasks)
(Fischer et al., 1989). Similar age-related changes seem to occur to the human
nucleus basalis ofmeynert (De Lacalle et al., 1991). In addition to neuronal loss, the
sensitivity of hippocampal neurons to cholinergic agonists is decreased both in vivo
and in vitro (Potier et al., 1992, 1993; Lippa et al., 1981; Segal, 1982c). It was also
shown that the slow EPSP, due to the evoked release of ACh from septohippocampal
neurons, is dramatically depressed in the aged rat (Potier et al., 1992).
Presenile dementia, such as that found in Alzheimer's disease (AD), incorporates
many cognitive impairments including memory loss. Since the 1970's, ACh deficits
have been implicated in the pathophysiology of AD, e.g. a significant and selective
loss of ChAT activity in different parts of AD brain samples (cortex, hippocampus
and amygdala) was demonstrated (Bowen et al., 1976, 1979). This was supported by
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the observation that neurons in the basal forebrain were selectively degenerated in
AD (Whitehouse et al., 1981), explaining the reduced ChAT activity in the cortex
and hippocampus. Other studies have demonstrated reductions in ACh levels
(Richter et al., 1980), ACh synthesis (Sims et al., 1980) and high affinity choline
uptake (Rylett et al., 1983). In addition, an inverse relationship was found to exist
between ChAT and AChE activities in the cortex and the number of senile plaques, a
pathological marker that is argued to correlate with AD progression (Neary et al.,
1986; Perry et al., 1978).
This body of work investigates neural mechanisms that have been reported to play
critical roles in memory and learning behaviour. Specifically, the aims of this thesis
are to:
1. explore the regulation of the septohippocampal cholinergic input into the
hippocampus. This involves the examination of the mechanisms by which ACh
release may be controlled and the neurotransmitters/neuromodulators which may
exert that control. Studying the complex interactions of different
neuromodulators regulating of the cholinergic input may aid in the understanding
of how this pathway is involved in memory formation in the rodent hippocampus.
2. investigate possible mechanisms involved in LTP induction. As LTP has been
demonstrated to be critical in memory and learning performance, we investigated
LTP in a number of transgenic mice possessing mutations in novel genes thought
to be expressed predominantly in the hippocampus and particularly in the CA1
pyramidal cell layer. This work may contribute to our better understanding of the
molecular mechanisms involved in synaptic plasticity with the long term goal of






All experiments were performed using standard intra- and extra-cellular
electrophysiological techniques. Synaptic recordings were made from the CA1
region of transverse coronal rat hippocampal slices obtained from 2-5 week old
female Cobb-Wistar rats. All recordings from transgenic mice were also made from
the CA1 region of transverse coronal mouse hippocampal slices obtained from 1-4
month old male/female C57BL/6 mice.
2.1.2 Preparation of rat hippocampal slices
The rats were cervically dislocated and subsequently decapitated in accordance with
UK Home Office guidelines. The brain was removed swiftly and placed
immediately in ice cold (0—4°C) artificial cerebrospinal fluid (ACSF). The brain,
minus the cerebellum, was hemisected and an agar block fixed to the base of each
hemisphere using superglue. The hemisphere was then fixed to a polypropylene
block for the subsequent cutting of 400 pm thick transverse coronal slices using a
vibroslicer (Campden Instruments, Loughborough, UK). Throughout the slicing
procedure the brain and slices were held in a chamber containing ice cold ACSF.
The slices were then transferred to a glass petri dish containing ACSF at room
temperature (18-24 °C). The hippocampus was cut away from the rest of the brain
slice and the CA3 region cut away to eliminate changes in network function that can
occur due to epileptiform bursting in area CA3 when picrotoxin is applied to the
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slice. Following an incubation period of at least half an hour the resultant CA3-
ectomized slices were placed in the recording chamber upon a nylon mesh at the
interface of warmed (32 ± 2 °C), perfusing (1-3 ml min~l) ACSF and an oxygen-
enriched (95% O2, 5% CO2; BOC Medical Gasses, UK), humidified atmosphere (Fig.
2.1). The slices were then allowed to equilibrate in this environment for
approximately 1-2 h before any electrophysiological recording was attempted.
Surplus slices contained in the petri dishes remained viable for several hours. If
required, these slices could be transferred to the recording chamber at a later time.
The standard perfusion medium comprised (in mM): NaCl, 124; KC1, 3; NaHC03,
26; NaH2P04, 1.25; CaCl2, 2; MgS04, 1; D-glucose, 10; and was bubbled with 95%
02, 5% CO2 to maintain a pH of 7.4-7.5. ACSF was made up using distilled water
filtered (10-18 Cm"1) using the Millipore Milli-Q filter system (Millipore;
Molsheim, France) and all chemicals were analaR grade (BDH Chemicals Ltd.,
Poole, UK).
2.1.3 Preparation of transgenic mouse hippocampal slices
The mouse brains were extracted and maintained as above with the exception that the
CA3 region was not removed. Slices were placed in a submerged recording chamber
perfused (1-3 ml min~l) with room temperature (18-24 °C) ACSF and held in place
by short pieces of silver wire.
2.2 RECORDING SET-UP
2.2.1 Intracellular recording from rat brain slices
The recording chamber and the micromanipulators were mounted on magnetic stands
(Narishige, Japan) supported on a steel plate on an anti-vibration table (Ealing, MA,
USA). A steel Faraday cage, grounded through the amplifier (Axoclamp-2B, Axon
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Instruments, CA, USA), was placed around the recording system in order to isolate it
from extraneous electrical noise. All electrical equipment that was fitted with earth
leads was secured in a rack and earthed through the mains.
The recording chamber was a modified version of an interface electrophysiological
recording chamber designed by (Spencer et al., 1976) (Fig. 2.1). It consisted of an
outer water bath with a centrally mounted platform on which the tri-compartmental
recording chamber was secured. The outer water bath was partially filled with
distilled water and was bubbled with a 95% CF, 5% C02 mixture. The height of the
covering lid was adjusted to allow the oxygen-enriched humidified atmosphere to
flow over the slices.
ACSF was pumped, by means of a peristaltic pump (Watson-Marlow, England), to a
gravity-feed syringe. This fed a constant flow (1-3 ml min"1) of ACSF into the first
well of the recording chamber. The ACSF then flowed around the circumference of
this well and through a small inlet into the recording chamber proper. Here, it
flowed underneath the nylon mesh and was removed through a separate outlet by
suction through a syringe needle connected to a water-powered suction pump
(Brownall, England). If the recycling of drugs was required, the ACSF would be
removed using a multi-channel peristaltic pump (Watson-Marlow 205U, England)
where one channel would provided the inflow and another channel would be used to
remove the ACSF from the recording chamber. By adjusting the height of the
gravity feed and the magnitude of the outlet suction, the level of ACSF in the
recording chamber was maintained so that it was in contact with the mesh but did not
cover the slices. A heated patch connected to a constant current source (Maplin
XG89, Taiwan) was attached to a metal plate in the base of the water bath (Fig 2.1)
to maintain the temperature at 32 ± 2 °C.
The slices in the recording chamber were epi-illuminated with a fiber optics system
(Nachet, France). All stimulating and recording electrodes were mounted on
micromanipulators (Narishige, Japan) which allowed movement in the x, y and z
axes. An additional single axis fine movement hydraulic manipulator (Narishige,









Figure 2.1 The interface recording chamber
This figure shows a schematic representation of the recording chamber as viewed from above (A) and
from the side (fl). ACSF, perfused with 95% CV5% CO2 and maintained at 32°C, was passed through
tubing immersed in the temperature controlled external water bath and into the interface chamber. The
level of ACSF in the interface chamber was maintained just above the level of the nylon mesh which
supported the slice. Waste ACSF was drawn off by suction through a hypodermic needle. The
humidified atmosphere was maintained by passing 95% 02/5% C02 through distilled water
maintained at 32 °C (by a heated plate) to create a fine mist. The reference electrode was grounded
through the Axoclamp 2B.
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advancing the electrode for the impalement of neurones. To enable the positioning
of electrodes in the slice, the slice was viewed using an overhead dissecting
microscope (M3C, Leica, England). Recording microelectrodes were placed, at an
angle of approximately 45° to the vertical, in either stratum oriens (CA1 pyramidal
basal-dendritic layer) or stratum radiatum (CA1 pyramidal cell apical dendritic layer).
2.2.2 Extracellular recording from transgenic mice
As above except extracellular experiments on transgenic mice were performed using
a slightly different set-up as regards the recording chamber itself. This comprised a
recording bath mounted on a fixed stage upright microscope (Olympus). ACSF
flowed into the slice holding chamber by gravity feed and was removed by a suction
needle placed in an adjoining chamber connected to a peristaltic pump (Watson
Marlow, UK). ACSF was not recycled.
2.3 RECORDING TECHNIQUES
2.3.1 Recording electrodes
Microelectrodes were pulled from thick walled (internal diameter: 0.69 mm; outer
diameter: 1.2 mm) borosillicate glass capillaries with an inner filament (120F-10,
Clark Electromedical Instruments, England), on a horizontal Flaming-Brown P-97
micropipette puller (Sutter Instruments Co., USA). Intracellular microelectrodes
were back-filled with 2 M potassium methylsulphate (ICN Biomedicals Inc., USA)
and had resistances ranging 60-120 M£2. Extracellular microelectrodes with
resistances ranging 1-5 were back-filled with 2 M sodium chloride.
Recording microelectrodes were then mounted in electrode holders (Clark
Electrochemical Instruments, England) allowing the electrolyte solution within the
microelctrode to make contact with a silver chloride coated silver wire. The holders
were inserted into unity gain head stages (current gain x 0.1 or x 1.0: Axon
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Instruments, CA, USA) and connected to an Axoclamp-2B amplifier through the
microelectrode 1 (ME1) port for use in "bridge balance" or "discontinuous current
clamp" (DCC) modes. A silver-silver chloride bath reference electrode, submerged
in the recording chamber, was also connected to the head stage and grounded
through the Axoclamp amplifier.
2.3.2 Intracellular recording
Impalement of CA1 pyramidal neurones was achieved by manually advancing the
recording microelectrode through the slice using the hydraulic vertical axis
manipulator, and intermittently applying a 1-2 ms "buzz" from the Axoclamp-2B.
"Buzzing" momentarily increases the capacitance neutralization of the electrode and
causes the headstage to oscillate at high frequency. This procedure aids penetration
of cells when the electrode is opposed to the cell membrane although the mechanism
by which this occurs is unclear. Cell impalement was routinely performed in normal
ACSF (with occassional exceptions where pre-incubation of a slice in a particular
drug was required) and only after a stable recording was obtained for at least 10 min
were drugs administered.
The membrane potential (Vm) of the neurone (as measured by the Axoclamp 2B
amplifier) was measured as the potential difference between the microelectrode and
the bath reference electrode. Prior to searching for cells, when the microelectrode
had been positioned extracellularly in the slice, Vm was set to zero. Immediately
following the end of each experiment this reading was checked again and any
correction in the recorded membrane potential made.
2.3.3 Current injection
Before searching for cells the resistance of the microelectrode was measured in
bridge balance mode. This was done by balancing out the unwanted potential drop
across the microelectrode resistance through a differential amplifier incorporated in
the Axoclamp 2B amplifier. The mode of recording was then switched to
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discontinuous current clamp mode which allowed rapid switching (frequency 3-5
kHz) between current injection and voltage recording. Thus, current was injected
during the first 30 % of the cycle and the resulting potential across the
microelectrode resistance due to charging continually monitored on an oscilloscope.
The capacitance neutralization was increased so that when the cell Vm was sampled,
just prior to the next current injection, the potential across the microelectrode tip had
fully decayed. Low resistance microelectrodes (60-90 M£2) allowed the most
accurate recording of membrane potential during current injection.
2.3.4 Amplification and Filtering
Synaptic potentials recorded through the ME1 port on the Axoclamp-2B amplifier
were amplified 10 fold by an in-built gain. In DCC mode the amplifier set the sample
rate (3-5 kHz switching frequency). Signals above 1-3 kHz were filtered, using a
low-pass filter, which did not noticeably affect the waveform of the synaptic
potentials. Secondary amplification of synaptic responses was provided by variable
gain DC amplifiers (Neurolog, Digitimer, England). The output signals were then
digitally filtered through a Digidata 1200 interface (Axon Instruments Ltd.)
connected to a Dell Dimension P75t IBM personal computer (PC) (Dell, Texas,
USA) (Fig. 2.3). Any further filtering was carried out during off-line analysis with
Clampfit software (Axon Instruments Ltd.).
2.3.5 Data display and storage
Digitized data were captured and simultaneously viewed using pClamp6 software
(Axon Instruments Ltd.) on the PC. Digitized records were stored on the hard disk of
the PC for off-line analysis using Clampfit software (Axon Instruments Ltd
The potential across the microelectrode in discontinuous current clamp mode was
monitored on an analogue oscilloscope (Phillips, Holland). A continuous chart
record or digital tape (DAT) record of the membrane potential of the cell was
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captured by a chart recorder (Gould, Ilford, Essex, UK) or DAT recorder (DTR1404,
Biologic Scientific Instruments, Claix, France). This provided a means to assess the
passive stability of the cell throughout each experiment.
2.3.6 Extracellular recording
Extracellular field potential recordings from the apical and basal dendritic layer of
CA1 pyramidal cells were made with respect to the reference electrode and the rising
slope of the fEPSP was measured (Fig. 2.4). For experiments investigating the
population spike recorded from the cell body region of the CA1 pyramidal cells, the
peak amplitude was measured. The population spike is the summation of action
potentials firing from a group of pyramidal cells characterised by a sharp negative
drop in potential difference followed by a rapid recovery (see fig. 6.1£a).Data were
displayed and stored in a similar manner to that used for intracellular recording. For
the majority of extracellular FTP experiments, a piece of software called "LTP" was
employed which allowed the recording, averaging and on-line analysis of data
(written by William Anderson, University of Bristol). In experiments investigating
the effect of drugs or the induction of LTP on the slope of the field EPSP, the test
field EPSP size was adjusted to approximately 50 % of maximum (maximum being
defined as when a population spike begun to appear superimposed on the field
EPSP).
2.3.7 Differences Between Intracellular and Extracellular Recording
Extracellular experiments were performed in a submerged chamber which provided
more stability during the length of the recording. Additionally, the experiment was
conducted at room temperature.
Intracellular experiments were performed in an interface chamber to increase the
stability of the recording. The temperature was maintained at 32°C as this is the
optimum temperature to maintain stable impalements. The CA3 was removed to
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prevent any spontaneous neuronal activity. This region was not removed from
transgenic mouse slices as there was little observed spontaneous activity even when
NMDA receptor-mediated EPSPs were being recorded. Due to the positioning of the
net that weighted down the slice in the chamber, it is likely that the CA3 region was
damaged and, thus, the slice behaved similar to a CA3-ectomized slice.
2.4 STIMULATION
The septo-hippocampal cholinergic input or the Schaffer collateral-commissural fiber
input to CA1 pyramidal neurones were orthodromically stimulated using bipolar
stimulating electrode(s) which were placed on the surface of the slice in stratum
radiatum and oriens respectively. The stimulating electrodes consisted of two 50 pm
diameter Formvar insulated nickel-chromium (80 %: 20 %) wires (Advent Research
Materials Ltd., England) twisted together and cut at the end to provide a focal
stimulation. Stimuli were produced by constant voltage or constant current isolated
stimulator boxes (Digitimer, England) in turn stimulated by a 5 V pulse produced by
the PC and relayed via the Digidata 1200. In every series of experiments stimuli
comprised square-wave pulses (20-200 ps; 0.1-30 V or 0.1-10 mA) delivered
homosynaptically at a fixed intensity every 15-30 s for ionotropic glutamate and
GABA receptor-mediated responses and every 5-10 min for mAChR-mediated
responses.
2.5 SLICE AND CELL SELECTION CRITIERIA
Slices were selected from the ventral region of the hippocampus. Besides possessing
a clearer morphology (mainly due to the angle of transection being parallel to the
cytoarchetectonic plane of the trisynaptic circuity of the hippocampus), this region of
the hippocampus demonstrates cholinergic responses that are inhibited by galanin. In
addition, taking slices from this region helped to minimise inter-experimental
variability as it is entirely possible that responses will vary depending on whether
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slices are taken from the ventral or dorsal region of the hippocampus, eg the
inhibition of ACh release by galanin.
For both intra- and extra-cellular recordings slices were chosen that evoked only a
single population spike to a low frequency stimulus (0.033 Hz) in standard ACSF.
This was taken as an indicator for healthy synaptic inhibition. For intracellular
recordings the input resistance of the cell was greater than 30 M£2 measured as
described in section 2.6 below. Action potentials overshot 0 mV and the cells
exhibited some degree of SFA (an accommodation of action potential firing when a
positive current step e.g. + 0.3-0.5 nA, 300ms was applied to the cell). In all
experiments care was taken that both the recorded response and the passive
membrane properties of intracellularly recorded neurones were stable for a period of
10-15 min before any physiological or pharmacological protocol was employed. All
cells were held at a membrane potential of -67 mV throughout the experiment using
current injection (except for agonist experiments where changes in the membrane
potential were under examination).
2.6 EXPERIMENTAL DESIGN
During the period between stimuli the input resistance and the extent of SFA of each
neurone were measured routinely using 300-600 ms long negative and positive
current steps (± 0.1-0.4 nA), respectively. In all experiments in which EPSPmS (Fig.
2.4), or sub-threshold stimulation induced reductions in SFA, were evoked, baseline
recordings comprised either successive EPSPs which had peak amplitudes that
differed by no more than 15 %, or reductions in SFA, that were consistent over 20-
30 min, respectively. In all experiments where the effects of drugs on Vm were
assessed, stable baseline recordings, where the Vm and input resistance of the cell
varied no more than 1 mV and 10 % respectively over a period of 10-30 min, were
obtained prior to application of the drug.
In other experiments where it was required to compare the EPSPs evoked in the
presence and absence of a drug at the same Vm, DC was injected through the
electrode to compensate for any drug-induced changes in membrane potential.
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A minimum inter-response interval of 8 min between successive EPSPmS was
required to avoid run-down of the response. This placed limitations on this type of
experiment, for instance, it was very difficult to construct input/output curves and
thus find a 50% maximal response for each experiment as this would take
considerable time and given the difficulty of maintaing a viable cell for the length of
time it takes to conduct an experiment it was deemed to be unfeasible to adopt this
approach. Generally, responses were chosen which exhibited a peak amplitude of
approximately 8-10 mV. In addition, it wasn't possible to examine tonicity, i.e.
inhibitory neuromodulators released during the first stimulation on an EPSPM having
an effect on the second EPSPM.
For all LTP experiments, 4-8 field EPSPs were averaged together in a two minute
period. A 20 minute stable baseline comprised of successive field EPSP slopes that
differed no more than 15 %. At this point a tetanus was delivered to the slice and the
recording of EPSPs was continued for 1-4 h depending on the LTP induction
protocol employed.
2.7 ANALYSIS OF DATA
Analysis of intracellularly recorded responses usually comprised the measurement of
the peak amplitude or the slope of the rising phase of the recorded response
(extracellular field-EPSPs). The synaptic responses analyzed were averages of four
to eight successive responses in the case of ionotropic glutamate and GABA
receptor-mediated responses or single responses in the case of mAChR-mediated
responses. Average responses were used to reduce noise and mean the effects of
biological variation.
The data-handling software package Sigmaplot (Version 3.01; Jandel Scientific,
USA) was run on an IBM PC (Dell) and was used to generate single plots and plots
of means. Pooled data are presented as means ± standard error of the mean (s.E.M.)
and statistical significance was assessed using a paired or unpaired Students t-test
performed on raw data with P < 0.05 being taken as indicating statistical
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significance, n values refer to the number of times a particular experiment was
performed, each in a different slice taken from a different rat or mouse.
2.8 LacZ STAINING
Transgenic mouse hippocampal slices were placed in a frshly prepared fixing
solution comprising of 0.2% (v/v) gluteraldehyde, 5 mM EGTA (pH 7.3), 2 mM
MgCb in a 0.1 M sodium phosphate buffer (pH 7.3). After 7 minutes, the fixed
tissue was transferred to a wash solution comprising 2 mM MgCl2, 0.01 % (v/v)
deoxycholate and 0.02 % (v/v) Nonidet-P40 in a sodium phosphate buffer. They
were left for a further 7 minutes before being transferred to a fresh wash solution.
This procedure was repeated until the slices had been washed 3 times at which point
the tissue was placed in X-gal stain. The stain comprised 1 mg/ml X-gal (Bethesda
Research Labs), 0.212 % (w/v) potassium ferrocyanide (Sigma, UK) and 0.164 %
(w/v) potassium ferricyanide (Sigma, UK) in a 0.1 M sodium phosphate buffer. The
slices were then left overnight at 37 °C whereupon they were transferred into wash
buffer to allow further development of the stain.
2.9 DRUGS
Drugs were stored frozen in stock aliquots (100 pi to 5 ml) of 100 to 10000 times
final concentration and dissolved in ACSF, deionised water, 25 mM NaOH, ethanol
or Dimethyl sulphoxide (DMSO) (Sigma, UK). All drugs were added to the control
ACSF and administered by bath perfusion for at least 15 min to allow their full
equilibration within the slice.
Atropine, 8-bromoadenosine 3,5-cyclic monophosphate (8-Br cAMP), 2-
chloroadenosine (CADO), carbachol (CCh), physostigmine, picrotoxin and [D-Ala2,
N-Me-Phe4, Gly5-ol]-Enkephalin (DAGO) were purchased from Sigma (Poole, UK).
6-nitro-7-sulphamoylbenzo[/]quinoxaline-2,3-dione (NBQX), Oxotremorine M, and
4-Ethylphenylamino-l,2-dimethyl-6-methylaminopyrimidinium chloride (ZD7288)
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were purchased from Tocris Cookson Ltd. (Bristol, UK). 8-cyclopentyl-l,3-
dipropylxanthine (DPCPX), (4-[[[(3-Chlorophenyl)amino]carbonyl]oxy]-N,N,N-




pyrrolidinyl) cyclohexylj-benzeneacetamide hydrochloride (U-50488) were
purchased from Research Biochemicals International (MA, USA).
Muscarinic toxins MT-1, MT-2, MT-3 and calcium channel blockers, oconotoxin
GVIA and co-Agatoxin TK were purchased from Alomone (Israel) through
distributers TCS Biologicals LTD (Botolph Claydon, UK).
Galanin (rat), w-agatoxin IVa and (D-Thr2)-Leu-enkephalin-Thr (DTLET) were
purchased from Bachem (USA).
(+)-Himbacine and N-[2-((/?-bromocinnamyl)amino)ethyl]-5-
isoquinolinesulfonamide dihydrochloride (H-89) were purchased from Calbiochem
(CA, USA).
D-(£)-2-Amino-4-methyl-5-phosphono-3-pentanoic acid (CGP 40116) and [1-(S)-
3,4-dichlorophenyl)ethyl]amino-2-(S)-hydroxypropyl-p-benzyl-phosphonic acid
(CGP 55845A) were gifts from Ciba-Geigy Ltd. (now Novartis; Basle, Switzerland)..
1 l-2[[2-[(diethylamino)methyl]-l-piperidinyl]acetyl]-5,l l,-dihydro-6H-pyrido[2,3b]




Investigation Of MAChR Sub-Types Mediating the
EPSPm
3.1. introduction
Within this chapter I investigated the response generated in CA1 pyramidal neurons
by ACh release from septohippocampal afferents in the hippocampal slice
preparation. As such, a background to ACh receptors, their pharmacology, and the
functional consequences of their activation within the CNS will be covered in some
detail.
3.1.1. Historical
The bioactive nature of acetylcholine (ACh) was first discovered when adrenal
extract reduced blood pressure in rabbits (Hunt & Taveau, 1906). Subsequently,
pharmacological studies distinguished the nicotinic and muscarinic actions of ACh
(Dale, 1914) and firm evidence that ACh acted as a chemical transmitter was
provided in the vagal innervation of the heart (Loewi & Navratil, 1926). Dale and
coworkers later proposed that ACh was acting within the sympathetic and
parasympathetic nervous systems (Dale, 1934; Dale et al., 1936) and also
hypothesised that ACh acted centrally. This theory was based on the presence of
acetylcholinesterase (AChE) in the CNS, the synthesis and release of ACh here, and
its subsequent central effects and those effects of eserine, an inhibitor of AChE
(Dale, 1938; Feldberg, 1945).
However, it was not until Eccles and coworkers (1954; 1956) demonstrated that ACh
acts between motor-axon collaterals and Renshaw cells in the spinal cord that the
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presence of cholinergic synapses was established. The study of cholinergic
mechanisms have been furthered by advances in pharmacological and molecular
cloning techniques (Brann et al., 1993) elucidating the presence of multiple receptor
subtypes of both nicotinic ACh receptors (nAChRs) and muscarinic ACh receptors
(mAChRs) in the central and peripheral nervous system.
Due to the wide range of physiological functions performed by ACh, it is beyond the
scope of this body of work to fully explore this subject. Instead, I will focus on the
actions of ACh in the brain and specifically the cholinergic neurons of the
septohippocampal pathway.
3.1.2. Acetylcholine Receptors
The receptors that mediate nicotinic and muscarinic responses have entirely different
structures and functions. nAChRs are ligand-gated ion channel (ionotropic) receptors
whereas mAChRs are guanine nucleotide binding (G)-protein coupled
(metabotropic) receptors
3.1.2.1. Muscarinic acetylcholine receptors
Muscarinic ACh receptors (mAChRs) belong to the G-protein coupled receptor
superfamily (Hall, 1987). Along with other receptors, such as the adenosine receptor,
the P-adrenergic receptor and rhodopsin, mAChRs possess a structure characterised
by an extracellular N-terminal region, seven transmembrane spanning domains and
an intracellular C-terminal region. Initial classification of the mAChR-mediated
response was by the antagonistic effect of atropine (Dale, 1914). More recently,
pharmacological investigation led to the identification of two subtypes of muscarinic
receptor, termed Mi and M2, based on their relative sensitivities to pirenzipine
(Hammer et al., 1980). This distinction was subsequently clarified when the
molecular cloning of both receptors (termed ml and m2) revealed structural
differences (Kubo et al., 1986). In addition, three more muscarinic receptor subtypes
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have been identified by homology cloning (termed M3, M4 and M5) (Bonner et al.,
1987; Bonner et al., 1988).
Despite this molecular classification the further pharmacological study of these five
mAChR subtypes has been hampered by the limited selectivity of the compounds
available, typically exhibiting a 10-fold selectivity for one subtype over another. For
instance, pirenzipine demonstrates relative selectivity forMi mAChR whereas
AFDX 116 shows selectivity for M2 mAChRs (Giachetti et al., 1986). In addition, 4-
DAMP possesses moderate selectivity for the M3 mAChR (Doods et al., 1987).
These antagonists have been employed to narrow down the identity of the mAChR
mediating a physiological response but fail to conclusively identify the exact subtype
(Pitler & Alger, 1990; Mitchelson, 1988). As such, there is a lack of good evidence
identifying muscarinic receptor subtypes, particularly M4 and M5. As a result there is
some controversy over which subtype(s) may mediate the variety of mAChR-
mediated effects evoked by either carbachol, an agonist of AChRs, or by synaptically
released ACh (Cole & Nicoll, 1984b, Benson et al., 1988; Dutar and Nicoll, 1988a;
Pitler & Alger, 1990). Table 3.1 provides a summary of mAChR subtypes and their
most selective antagonists.
In addition to the poor selectivity of drugs for mAChRs, the existence of allosteric
binding sites further complicates the pharmacology of mAChRs (Tucek & Proska,
1995). Neuromuscular blocking agents, such as gallamine, allosterically inhibit the
actions of mAChR agonists at all five mAChRs and particularly the M2 subtype
(Ellis et al., 1991). In contrast, alcuronium can augment, as well as inhibit, the
binding of mAChR ligands (Tucek et al., 1990).
Recently, it has been found that the polypeptides comprising the green mamba snake
toxin possess varying selectivity and high affinity for specific mAChR subtypes
(Jerusalinsky & Harvey, 1994). Eight such polypeptides have been characterised, of
which three are commercially available. Muscarinic toxin 1 (MT-1) displays
selective agonism for ml and m4 receptors whereas MT-2 displays agonism at the
ml receptor only (Kornisiuk et al., 1995). MT-3 is a selective antagonist of the m4
receptor with some activity at ml (Jolkkonen et al., 1994).
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Table 3.1. mAChR subtypes: Pharmacology and transduction mechanisms.
mAChR Mi m2 M3 m4 Ms
(molecular
subtype)
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f (Brann et at. 1993); t(Levey et al. 1995).
The lack of specificity of muscarinic ligands limits the localisation of mAChRs by
binding and autoradiographical studies (Cortes & Palacios, 1986; Waelbroeck et al.,
1990; Zubieta & Frey, 1993; Levey et al., 1994). However, such studies in concert
with in situ hybridisation and immunocytochemical analysis have elucidated regional
distributions of mAChRs in the CNS, including the subfields of the hippocampus
(Buckley et al., 1988; Weiner & Brann, 1989; Levey et al., 1995). All five subtypes
of mAChR protein and mRNA have been detected in the hippocampus as well as the
cortex, striatum, olfactory tubercle, thalamus and basal forebrain (Brann et al., 1993).
ml predominates in the hippocampus, followed by m2/m4 receptors and then m3/m5
receptors. The cellular distribution of mAChR subtype protein and mRNA is varied
within the hippocampus, with ml and m3 mAChR protein expression prominent in
pyramidal neurons whereas m2 and m4 are localised to non-pyramidal neurons and
fibre pathways (Levey et al., 1995). Interestingly m2 mAChR proteins are expressed
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presynaptically in cholinergic axons, presumably of the septo-hippocampal pathway
(Levey et al., 1995). The localisation of m2 mAChR mRNA in the cells of the
medial septum supports this conclusion (Buckley et al., 1988; Rouse et al., 1997).
As already stated, mAChRs couple to G-proteins. In general, Mi, M3 and M5
mAChRs have been found to exert their effects through the G-protein Gq/n, to
activate phospholipase C (PLC) and thus the inositol triphosphate (IP3) messenger
system whereas M2 and M4 mAChRs act via G-protein Gj/0, leading to decreased
adenylate cyclase activity and, thus, reduced intracellular cAMP (Hulme et al., 1990;
Felder, 1995). It is clear that the functional mechanisms activated by mAChRs are
diverse and could result in numerous physiological effects such as both increased and
decreased neurotransmitter release (see Table 3.1).
3.1.2.2. Nicotinic acetylcholine receptors
Nicotinic acetylcholine receptors (nAChRs) are members of the superfamily of ion
channel receptors which include GABAa and glycine receptors. nAChR-mediated
responses can be pharmacologically distinguished from mAChR-mediated responses
using the competitive antagonist curare (Dale, 1914). A broad classification of
nAChRs can be made based on anatomical location and pharmacology: (1) muscle
nAChRs, (2) neuronal nAChRs that bind a-bungarotoxin and (3) neuronal nAChRs
that do not bind a-bungarotoxin (Lindstrom et al., 1995).
The structure of the ACh-gated cation channel consists of a pentamer of homologous
subunits forming a central ion channel (McCarthy et al., 1986; Hucho et al., 1996).
In addition to the subunits which form muscle and ganglionic nAChRs, eight
neuronal a subunits and three 3 subunits have been cloned (Albuquerque et al.,
1997) and are proposed to form heterooligomeric complexes with a stoichiometry of
2a, 33 or homomeric complexes of a7 or a9 subunits. Receptors of different subunit
composition display different pharmacological and biophysical properties (Deneris et
al., 1991; Alkondon & Albuquerque, 1993; McGehee & Role, 1995; Albequerque et
al., 1995a). Only a7 and to a lesser extent a9 are found in the rat. al nAChR is
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thought to be of particular functional importance due to its high Ca2+ permeability
and presence at presynaptic terminals.
A paucity of selective ligands for the various nAChR subunit assemblies has
restricted their functional characterisation within the CNS. However, it is known that
nAChRs modulate at least three separate cationic conductances, termed types I-III,
(Alkondon & Albuquerque, 1993, Albuquerque et al., 1995a, Albuquerque et al.,
1997) that can be distinguished by their channel kinetics, sensitivity to nicotinic
receptor agonists and antagonists such as methylcaconitine, p-erythroidine, a-
bungarotoxin and mecamylamine (Albuquerque et al., 1995b; Albuquerque et al.,
1997).
Nicotinic AchRs are present pre- and post-synaptically. There is evidence to show
that nAChRs act as modulators of presynaptic neurotransmitter release and glutamate
synaptic transmission in several brain regions, including the hippocampus (Araujo et
al., 1988; Gray et al., 1997; Wonnacott, 1997).
3.1.3. Functional Characterisation of Muscarinic ACh Receptor
Activation in the CNS
Muscarinic AChR activation in the CNS results in a variety of physiological
responses that are both inhibitory and excitatory (Brown et al., 1997). The main
effects include (1) the inhibition/activation of specific K+ conductances, (2) the
inhibition/activation of voltage-dependent Ca2+currents, and (3) activation of non¬
selective cationic currents.
3.1.3.1. Effects on K+channels
mAChR-mediated modulation of K+ channels has been extensively studied in the
hippocampus Synaptic activation of mAChRs on CA1 pyramidal cells produces a
slow depolarisation accompanied by an increase in cell input resistance (Cole &
Nicoll, 1983; 1984a). This response is similar to that seen by the application of
carbachol or exogenous ACh on hippocampal or cortical slices (Dodd et al., 1981;
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Haas, 1982; Segal, 1982a; Cole & Nicoll, 1983, 1984a & 1984b). Evidence suggests
that the depolarisation observed in these studies is due to an apparent inward current
(Halliwell & Adams, 1982; Madison et al., 1987; Benson et al., 1988) which
represents a decrease in a voltage-independent leak K+ current (Ik(leak)) (Benardo &
Prince, 1982b; Madison et al., 1987; Benson et al., 1988).
Another current affected by mAChR activation is the voltage independent and Ca2+
dependent K+ current (Iiqca)) known as the small-K current or IAHP in a variety of
brain regions (Madison & Nicoll, 1984; Constanti & Sim, 1987; Lancaster & Adams,
1986; Sah, 1996) whereas the voltage and calcium-dependent current (maxi-K
current) Ic apparently is not affected (Madison et al., 1987). Hippocampal CA1
pyramidal cells demonstrate a fast and slow afterhyperpolarisation following an
action potential. These responses occur as a result of Ca2+ entry during the
depolarisation phase and are mediated by Ic and IAHp respectively. During a sustained
depolarisation sufficient to generate action potential, the slow AHP following each
successive action potential summates due to the slow inactivation of Iahp (>1s)
resulting in a longer refractory period between action potentials. This phenomenon is
known as Spike Frequency Adaptation (SFA). Carbachol has been shown to
consistently inhibit Iahp and thus the slow AHP resulting in decreased SFA (Bernado
& Prince, 1982a & 1982b; Cole & Nicoll, 1983; Madison et al., 1987; Dutar &
Nicoll, 1988a). Furthermore, the same inhibition of the SFA can be seen after
stimulation of cholinergic afferents resulting in synaptic release of ACh in area CA1
of the rat hippocampus (Cole & Nicoll 1983, 1984a; Nicoll, 1985). Taken together, it
is evident that evoked synaptic ACh release causes a depolarisation of the membrane
potential, accompanied by an increase in cell input resistance due to the inhibition of
Ikcleak) and a decrease in SFA as a result of Iahp inhibition.
Other K+ channels that have been implicated in mAChR-mediated responses include
the M current (Im), a voltage-dependent K+ current which does not inactivate over
time. First described in bullfrog sympathetic neurons (Brown & Adams, 1980;
Brown, 1983), Im was shown to be inhibited by carbachol and other muscarinic
agonists in the hippocampus (Halliwell & Adams, 1982; Brown, 1983; Madison et
al., 1987; Benson et al., 1988; Dutar & Nicoll, 1988a; Halliwell, 1990). Inhibition of
Im was shown to be 10-fold less sensitive to carbachol agonism than the inhibition of
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Iahp (Madison et al., 1987). Consequently, synaptically released ACh did not achieve
inhibition of Im as readily as the inhibition of Iahp or the Ik(leak)- However, in the
bullfrog sympathetic ganglion cells, Im is more readily inhibited than Iahp by
mAChR agonism (Pennefather et al., 1985).
There is also evidence for a mAChR-mediated inhibition of a fast, transient, voltage-
dependent K+ conductance called the A current (Ia) which acts to increase action
potential repolarisation and to slow the firing rate (Nakajima et al., 1986). In
neostriatal neurons mAChR activation inhibits the IA, which at hyperpolarised
potentials tends to reduce action potential firing frequency whereas at depolarised
potentials mAChR activation results in the complete inactivation of Ia thereby
increasing neuronal excitability (Akins et al., 1990).
Two K+ channels whose activation is potentiated by mAChR agonism in the
hippocampus are the delayed rectifier current (Ik) (Zhang et al., 1992) and the
anomalous inward rectifying current (Iq), which is mediated by both K+ and Na+
ions (Colino & Halliwell, 1993).
3.1.3.2. Effects on Ca2+ and nonselective cation channels
There is limited evidence for the involvement of Ca2+channels in mAChR-mediated
responses. Inhibition of Ca2+ currents by mAChR activation has been observed in
area CA3 of hippocampal slice cultures (Gahwiler & Dreifuss, 1982; Gahwiler &
Brown, 1987) as well as in the cortex and neostriatum (Misgeld et al., 1986).
mAChR activation has been shown to inhibit high voltage activated Ca2+ currents in
rat embryonic hippocampal neurones (Toselli & Taglietti, 1995) and in excised
membranes of hippocampal neurons (Toselli & Taglietti, 1994). In the superior
cervical ganglion (SCG) and basal forebrain neurons mAChR-activation inhibits N-
type Ca2+channels (Plummer et al., 1991). In the guinea pig hippocampus, one study
suggests that mAChR activation at mossy fibre-CA3 synapses results in an increased
probability of opening of T- but not N-type Ca2+ channels and a decreased
probability of opening of L-type Ca2+channels (Fisher & Johnston, 1990). There are
also reports of L-type Ca2+channel inhibition in the SCG (Mathie et al., 1992) and
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the cerebral cortex (Boess et al., 1990). In contrast, blockade of L-type Ca2+ currents
inhibited mAChR-mediated membrane depolarisation of CA1 pyramidal cells in the
guinea pig hippocampus (Blitzer et al., 1991).
Using mAChR cDNA-transfected neuroblastoma hybrid cells, it has been suggested
that m2 and m4 but not ml and m3 mAChRs mediate the inhibition of an "N"
current (Higashida et al., 1990; Brown et al., 1993). The "N" current, although
somewhat differing from the current conducted by the N-type Ca2+ channel, is likely
to correspond to the Ca2+ current responsible for neurotransmitter release and
therefore it has been suggested that this is how m2/m4 mAChR activation results in
presynaptic inhibition of neurotransmitter release (Wu & Saggau, 1997).
Conversely, mAChR activation is reported to activate a low threshold transient (T-
type) Ca2+ current in interneurons within the CA1 laculosum-moleculare region of
the hippocampus as well as a novel regenerating current which underlies a plateau
potential involving a high voltage-activated Ca2+ conductance and a Ca2+ activated
nonselective cation conductance (Fraser & MacVicar, 1991). mAChR-mediated
depolarisation of CA1 and CA3 pyramidal neurons through the activation of
nonselective cationic conductances has also been demonstrated in hippocampal slices
and slices cultures (Colino & Halliwell, 1993; Caesar et al., 1993; Guerineau et al.,
1995).
3.1.3.3. Physiological consequences of mAChR activation on
hippocampal function
mAChR activation has been reported to inhibit glutamate and GABA release at
synapses in the CA1 (Hounsgaard, 1978; Valentino & Dingledine, 1981; Dutar &
Nicoll 1988a; Cohen et al., 1991) and CA3 regions (Williams & Johnston, 1988) of
the hippocampus. This presynaptic inhibition can potentially result from K+ channel
activation, Ca2+ channel inhibition or through the modulation of the Ca2+dependent
release machinery (see Chapter 1). It has been suggested that mAChR-mediated
presynaptic inhibition in area CA1 is mainly mediated by the inhibition of voltage-
dependent Ca2+ channels (Qian & Saggau, 1997).
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In addition, cholinergic activity has been implicated in the modulation of synaptic
plasticity. mAChR activation enhances long-term potentiation (Blitzer et al., 1990)
and has been shown to cause a long lasting potentiation, termed LTPM, in its own
right (Auerbach & Segal, 1996). The role that mAChRs may play in LTP and,
consequently, learning/memory has been reviewed in some detail (Krnjevic, 1993;
Aigner, 1995; Segal & Auerbach, 1997).
At the level of neural circuitry, carbachol application can induce a theta-like rhythm
(Konopacki et al., 1987, Bland et al., 1988) which consists of synchronised
membrane potential oscillations and rhythmic action potential firing at a frequency of
4-10 Hz. It is this rhythm that is observed in the EEG of the learning rat learning rat
and, as such, disruption of the theta-rhythm impairs performance in spatial memory
tasks (Winson, 1978). In addition, mAChR activation can induce a related
phenomenon called rhythmic slow activity (RSA). This has been observed in CA3
pyramidal neurons and manifests itself as periodic bursts of 4-8 Hz oscillatory
depolarisations (MacVicar & Tse, 1989; Traub et al., 1992).
At high concentrations of carbachol, Ca2+-dependent changes in the action potential
waveform have been observed (Figenschou et al., 1996). It is clear that cholinergic
action in the hippocampus is complex and important in the functional processing of
neural information within the hippocampus.
The aim of this chapter is to characterise the responses obtained from the rat
hippocampal slice and, further, investigate the different mAChR subtypes that may
be responsible for generating these responses.
3.2. RESULTS
3.2.1. Characterisation of Acetylcholine Receptor Mediated Responses
Brief (approx. 1 min) application of the acetylcholine receptor agonist, 3 pM
carbachol (eg. Morton & Davies, 1997), resulted in a slow depolarisation of the
membrane potential of sufficient magnitude to fire action potentials in CA1
pyramidal cells (fig. 3.1A). Current was injected through the microelectrode to
restore the membrane potential to pre-carbachol levels enabling observation that this
depolarisation was accompanied by increased cell input resistance and decreased
spike frequency adaptation (SFA) (also referred to as Accommodation) in response
to a depolarising current step (fig. 3.1 B&C). After washout of carbachol, the cell
repolarised back to control membrane potential. This was accompanied by a recovery
of SFA and input resistance to control levels.
This effect of carbachol could possibly be via an action at synaptic or extrasynaptic
sites. To examine responses to synaptically released ACh electrical stimulation of
terminals in the stratum oriens of the rat hippocampal slice was employed. Initially, a
glutamate receptor-mediated excitatory postsynaptic potential (EPSP) followed by a
GABA receptor-mediated inhibitory postsynaptic potential (IPSP) were evoked. This
response was subsequently blocked using 1 pM CGP-40116, 5 pM NBQX, 50 pM
picrotoxin and 1 pM CGP-55845A (eg. Morton & Davies, 1997) which are
antagonists of NMDA, AMPA, GABAa and GABAb receptors respectively. In the
presence of this cocktail of antagonists, spike frequency adaptation in response to a
depolarising current step could be inhibited by increasing the stimulation intensity
used to evoke the glutamate/GABA EPSP/fPSP complex (fig. 3.2), i.e. the current
step preceding the stimulus fired action potentials separated by longer intervals than
those evoked by the current step following the stimulus. This compared favorably
with the loss of accommodation seen after carbachol application. This block of spike
frequency adaptation was inhibited by the application of 1 pM pirenzipine (Segal &
Fisher, 1992) (fig. 3.2). Spike frequency adaptation is a robust cellular response to
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Figure 3.1 The effect of muscarinic ACh receptor activation in a CA1 pyramidal cell.
A shows a chart recording of the membrane potential of a CA1 pyramidal cell, current clamped to -67
mV and its responses to depolarising and hyperpolarising current steps. On application of 3 pM
carbachol (CCh) for 1 min, a slow depolarisation of the membrane potential accompanied by
spontaneous action potential firing and an increase in cell input resistance was observed. B illustrates
spike frequency adaptation in response to a depolarising current step and the reduction of SFA in
response to CCh. C shows the change in membrane potential in response to a hyperpolarising current
step before (left) and after (right) the application of CCh. The input resistance of the cell was 35 MQ,
the resting membrane potential was -67 mV and the spike height was greater than 0 mV. Apparent
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Figure 3.2 The effect of electrically released ACh on a CA1 pyramidal cell.
A shows a synaptic trace (top) from a CA1 pyramidal cell and its response to a depolarising current
step preceding and following electrical stimulation of the stratum oriens in the presence of 1 pM
CGP-40116, 5 pM NBQX, 50 pM picrotoxin and 1 pM CGP-55845A. Note that the stimulation is
insufficient to cause depolarisation but does result in a loss of SFA of action potentials during the
second current step. The bottom trace demonstrates that the loss of SFA of action potential firing
during the second depolarising current step is pirenzipine-sensitive and therefore mediated by
activation of mAChRs. The input resistance of the cell was 31 M£2, the resting membrane potential
was -70 mV and the spike height was greater than 0 mV. Apparent variations in spike height were due
to the sampling rate employed (600 ps sampling interval).
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a depolarising current step and the number of action potentials fired during the step is
maintained over time as long as the membrane potential of the cell remains constant
(this was achieved by adjusting the amount of continuous current injected throughout
the experiment or by monitoring the membrane potential and using cells that have a
steady membrane potential) (fig. 3.3).
If the stimulation intensity was further increased and/or the number of stimuli
increased at a frequency of 20 Hz a slow depolarising EPSP was evoked (fig. 3.4A).
The peak amplitude of this response could be increased by increasing the intensity of
stimulation such that the cell fired intense bursts of action potentials during the
response. Sometimes the EPSP depolarised the membrane potential past the action
potential firing threshold and into a region in which action potential generation was
inactivated.
Occasionally, the EPSP was preceded by an IPSP (fig. 3.4A) the nature of which is
unclear. However, the EPSP was significantly blocked by 2 pM atropine (eg. Morton
& Davies) (21.4 ±7.2% of control, n=6; p<0.05) suggesting that it was mediated by
muscarinic ACh receptors. As such, this EPSP was termed an EPSPM (fig 3.46).
Further pharmacological characterisation confirmed that the electrical stimulation of
the stratum oriens released ACh from cholinergic terminals. Thus, fig. 3.5 shows that
50 pM vesamicol, an inhibitor of the vesicular ACh transporter, attenuated the peak
amplitude of the EPSPm, 1 pM eserine, a cholinesterase inhibitor, increased the peak
amplitude of the EPSPm and 50 pM hemicholinium-3, a choline reuptake inhibitor,
decreased the EPSPm (n=3) (eg. Morton & Davies, 1997; Pitler & Alger, 1990).
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Figure 3.3 Spike Frequency Adaptation is a robust phenomena.
This figures shows intracellular reeoidings from CA1 pyramidal cells in response to a depolarising
current step. The left trace shows the response at 0 min and the right hand trace shows the response at
40 min. Note that the number of spikes are the same and occur at similar points along the current step.
The input resistance of this cell was 38 M£2, the resting membrane potential was -70 mV and the
spike heights are greater than 0 mV. The cell was held at -67 mV throughout the experiment.
3.2.2. Determination of the mAChR Subtype Responsible for Mediating
the EPSPm
Since it is not known which postsynaptic mAChR is responsible for the EPSPm, I
examined the EPSPM in the presence of different antagonists of muscarinic ACh
receptors. Pirenzipine possesses selectivity forMl receptors and, at 10 pM (Segal &
Fisher, 1992), inhibited the EPSPm to 37.8 ±13.2% of control (n=3; p<0.05) (fig.
3.6). However, the M1/M4 mAChR antagonist, MT-3, at 100 nM (Jerusalinsky &
Harvey, 1994), had no significant effect on the EPSPm (82 ±19% of control, /?=3)
(fig. 3.7). Zamifenacin is reported to have selectivity for M3 receptors
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Figure 3.4 Atropine inhibits the synaptically evoked slow depolarisation
A Synaptic traces recorded intracellularly from CA1 pyramidal cells, held at -67 mV, illustrates a
synaptically-evoked slow depolarisation in control media (left) and the absence of this depolarisation
in the presence of 2 pM atropine (right). The filled triangles denote the position of the stimulus (10
stimuli at 20 Hz). B shows a bar graph illustrating the mean inhibition of the peak amplitude of the
slow depolarisation by atropine in six experiments. Note that atropine almost completely blocks the
slow depolarisation suggesting the response is mediated primarily by mAChRs and is thus termed an
EPSPm. Values are means ± S.E.M. represented by the error bars. The input resistance of the cell was
39 M£2, the resting membrane potential was -63 mV and the spike height was greater than 0 mV.
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Figure 3.5 The effect of vesamicol, eserine and hemicholinium-3 on the slow EPSP in CA1
pyramidal cells.
Synaptic traces recorded intracellularly from CA1 pyramidal cells, held at -67 mV, illustrates the
effect of 50 mM vesamicol, 1 mM eserine and 50 mM hemicholinium-3 on the slow EPSP providing
evidence that this response is mediated by mAChRs and as such has been termed the EPSPM- The
filled triangles denote the position of the stimulus (10 stimuli @ 20 Hz). The input resistance of the
cell was 33 MlQ, the resting membrane potential was -65 mV and the spike height was greater than 0
mV.
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A Control 10 jliM Pirenzipine
Figure 3.6 The effect of pirenzipine on the EPSPm.
A shows intracellular synaptic traces recorded from CA1 pyramidal cells held at -67 mV before {left)
and after (right) the application of 10 |iM pirenzipine. The filled triangles denote the position of the
stimulus (1 stimulus). The bar graph in B illustrates the mean inhibition of the peak amplitude of the
EPSPm by 10 pM pirenzipine in 3 experiments. Values are means ± S.E.M. represented by the error
bars. The input resistance of the cell was 33 MQ, the resting membrane potential was -64 mV and the
spike height was greater than 0 mV.
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(Watson et al., 1995) and this was confirmed in the guinea pig ileum preparation
(fig. 3.8). However, when applied to hippocampal slices, the effects of zamifenacin
were equivocal. In one cell, 1 pM zamifenacin produced a depression of the EPSPM
peak amplitude whereas in another cell 1 pM zamifenacin had no significant effect
upon the EPSPM which was subsequently shown to be sensitive to pirenzipine (fig.
3.9A). Upon averaging, no significant effect of zamifenacin upon the EPSPm peak
amplitude was observed (n=5) (fig. 3.9B). To rule out the possibility that the
magnitude of block exerted by zamifenacin was a function of the control amplitude
of the EPSPm, a graph plotting these two parameters against each other was
generated, where 100% represents no change from the control amplitude. One high
outlier represented an experiment in which the EPSPM was enhanced by zamifenacin.
However, there appeared to be no correlation between the amplitude of the EPSPm
and the magnitude of block by zamifenacin (fig. 3.9C).
As a parallel study, antagonists were tested against carbachol-induced activation of
postsynaptic mAChRs. Antagonists were applied to slices following carbachol-
induced depolarisation of the cell membrane potential. Following depolarisation of
the cell using 3 pM carbachol, Zamifenacin was titrated upto a final concentration of
1 pM at which there was clearly no inhibition of the carbachol-induced
depolarisation («=3). In contrast, application of 1 pM pirenzipine readily repolarised
the cell (#i=3) (fig. 3.10).
To examine the subtype mediating cell depolarisation, a second series of experiments
were performed. Toxin from the green mamba snake, dendroaspis augusticeps,
possesses very high affinity for mAChRs. Subsequent fractionation of this toxin into
its constituent polypeptides has led to a series of toxins that display high selectivity
for particular subtypes of mAChR (Jerusalinsky & Harvey, 1994). Muscarinic toxin
1 (MT-1) possesses agonist affinity forMi and M4 mAChRs. Application of 100-
1000 nM MT-1 (Jerusalinsky & Harvey, 1994) did not produce any effect on the
membrane potential, input resistance or spike frequency adaptation (n=3) (fig. 3.11).
Subsequent carbachol application resulted in membrane depolarisation. However, in
one experiment (see inset in fig. 3.10) 200 nM MT-1 produced a profound
depolarisation that was reversed by 10 pM pirenzipine. MT-2 is similar to MT-1 in
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that it possesses selective agonism for theMl mAChR. 400-1000 nM MT-2
(Jerusalinsky & Harvey, 1994) produced no effect on the CA1 pyramidal cell (n=3)
(fig.3.12).
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Figure 3.7 The effect of the mucarinic toxin, MT-3, on the EPSPm-
A shows synaptic traces recorded intracellularly from CA1 pyramidal cells before (left) and after
(right) application of 100 nM MT-3. The filled triangles denote the position of the stimulus (10
stimuli at 20 Hz). The bar graph in B illustrates the mean effect of 100 nM MT-3 on the peak
amplitude of the EPSPM in 3 experiments. Values are means ± S.E.M. represented by the error bars.
The input resistance of the cell was 30 M£2, the resting membrane potential was -62 mV and the spike
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Figure 3.8 Zamifenacin displays antagonist activity in the guinea pig ileum preparation
The graph shows dose response relationships for the carbachol-induced contraction of guinea pig
ileum in the presence (closed circles) and absence (closed squares) of 100 nM zamifenacin.
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Figure 3.9 The effect of zamifenacin on the EPSP
A demonstrates the effect of 1 pM zamifenacin on the EPSPM- The top traces show an inhibitory effect
of zamifenacin on the peak amplitude of the EPSPM- The bottom traces illustrate no effect of
zamifenacin upon the EPSPm whereas 10 pM pirenzipine substantially reduced the EPSPM The filled
triangles denote the position of the stimulus (10 stimuli at 20 Hz). The bar graph (B) shows the mean
effect of 1 pM zamifenacin on the peak amplitude of the EPSPM in 5 experiments. Values are means ±
S.E.M. represented by the error bars. C shows a scattergraph plotting the control EPSPM peak
amplitude against the magnitude of block exerted by zaminfenacin. 100% represents no block of the
EPSPm, thus the outlier at the top of the graph represents an experiment in which zamifenacin
enhanced the EPSPM There appears to be no correlation between the two parameters. The input
resistance of all cells was greater than 30 MQ and the spike height was greater than 0 mV.
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Figure3.10Theeffectofzamifenacinandpirenz pi eothcarbachol-i duceddepolarisationfCA1pyramid lc l . Achartrecordingillustratingthmemb anepotenti landthresponsetdepo arisingandhyp rp risi gcurrentsteofaCA1 pyramidalcell.3|iMcarbachol(CC )causesprofounddepolaris t onthemembr nepot nti lacco pa iedbyincre sedi pu resistance.100-1000mMzamifenaci(ZA )hanoeffectonthmagnituddepolaris tiowhereas1pMpirenzipin(PZP) repolarisesthemembr npot nti lalt oughthinputresistanceistillincrea ed.Thi puresistanceofthc llwas35MQ,thresting membranepotentialwas-63mVandthspikheightwasgre terth0mV
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Figure3.11Theeff ctoftmuscarinicxi ,MT-1nhCApyramidalcell. Achartreco dingillustr tingthemembranepo entialandesponseofCA1pyramid llldepol r inganhype pol r sicurr tst ps. Aftera10minbaselinep r od,MMT-1wasppl edtohlicithnoeff ctontmembrapo e tial,SFAin ur ista c .ubs qu nt applicationof3pMcarbach lresultedinprofoundepol i ation.Theins tillust a esinglex er m twher200MT-1c u d convincingdepolarisat onth tw sfullyreversedby10Mpire zipine.Tin uresist ncfllwa32MQ,tr t gm mbr potentialwas-67mVandthspikeheightgre t ra0V.
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Figure 3.12 The effect of the muscarinic toxin, MT-2, on a CA1 pyramidal cell.
A chart recording illustrating the membrane potential and the response of a CA1 pyramidal cell to
depolarising and hyperpolarising current steps. After a 10 min baseline period, 400 nM MT-2 was
applied to the slice with no effect on the membrane potential, SFA or input resistance. Subsequent
application of 3 pM carbachol resulted in a depolarisation of the membrane potential. The input
resistance of the cell was 30 M£2, the resting membrane potential was -63 mV and the spike height
was greater than 0 mV
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3.3. Discussion
In this chapter we have examined mAChR mediated synaptic responses in the rat
hippocampus. Initially, we demonstrated that bath applied carbachol, a mAChR and
nAChR receptor agonist, caused a depolarisation of the membrane potential,
decreased spike frequency adaptation and increased cell input resistance. This is
consistent with previous reports (Dodd et al., 1981; Haas, 1992; Segal, 1982; Cole &
Nicoll 1983, 1984a & 1984b). As this agonist-induced response could be mediated
through extrasynaptic mAChRs, electrical stimulation of putative septohippocampal
cholinergic terminals was used to demonstrate that a similar slow depolarisation of
CA1 pyramidal cells could be evoked. This response was confirmed as mAChR-
mcdiated by the use of muscarinic receptor antagonists. This is consistent with the
findings of Cole & Nicoll (1983; 1984). More recently, Robin Morton (1997)
demonstrated that these mAChR-mediated synaptic responses could be (1) evoked by
a single stimulus (2) evoked in the absence of AChE inhibitors and (3) evoked in
isolation from amino acid mediated synaptic transmission by the use of a cocktail of
glutamate and GABA receptor antagonists. It was under these conditions that we
reproduced the mAChR-mediated synaptic responses.
In addition to confirming that the EPSPm was indeed mediated by mAChRs, we also
demonstrated that inhibitors of choline uptake across the cell membrane and
vesicular membrane also inhibited the EPSPm thus strengthening the evidence for
synaptic release of ACh.
Controversy exists concerning which mAChR subtype(s) is responsible for the
excitatory responses observed in CA1 pyramidal cells. It is with considerable interest
that researchers seek a subtype responsible for the effects of ACh in the hippocampus
as this may aid in the development of more efficacious cognitive enhancers for
sufferers of AD and other diseases involving cognitive impairment.
Here, we have tested several antagonists with some selectivity forMl over M3
mAChRs and vice versa. Initially, we examined the EPSPm for sensitivity to Ml
mAChRs using pirenzipine. We saw a consistent and significant inhibition. However,
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this was unsupported due to the lack of effect of the muscarinic toxin MT-3, an
antagonist at Ml and M4 mAChR subtypes, upon the EPSPM.
Zamifenacin was used to examine the involvement of the M3 mAChR in the
generation of the EPSPM. However, this antagonist proved ineffective at consistently
inhibiting the EPSPm- Furthermore, zamifenacin failed to inhibit the carbachol-
induced cell membrane depolarisation, a response that was, however, reversed by
pirenzipine.
In addition, the muscarinic receptor selective toxins MT-1 and MT-2, selective
agonists of the Ml mAChR, were used to try and mimic carbachol-induced
depolarisation. With the exception of one experiment where MT-1 produced a robust
cell membrane depolarisation, the muscarinic toxins proved ineffectual at producing
depolarisations like those induced by carbachol.
These data argue that it is more likely to be the Ml mAChR that primarily mediates
the action of ACh on CA1 pyramidal neurons in the hippocampus although the
pharmacological tools available are far from ideal. This is supported by
immunocytochemical and in situ hybridisation studies which provide evidence for
the existence of both Ml and M3 mAChRs on pyramidal neurons whilst M2 and M4
mAChRs reside on non-pyramidal cells suggesting that it is more likely that M1/M3
mAChRs are responsible for the generation of the EPSPM.
The hypothesis that the EPSPM is mediated by theMl receptor is supported by
previous studies which demonstrated a similar inhibition of the cholinergic response
by pirenzipine (Segal, 1984) and, furthermore, demonstrated that AF102B, an
agonist with some selectivity forMl receptors, mimicked the effects of carbachol on
pyramidal neurons, e.g. increased the cell input resistance and caused cell membrane
depolarisation which was reversed by atropine (Segal & Fisher, 1992).
However, Pitler & Alger (1990) demonstrated that 4-DAMP, an M3 mAChR
antagonist, was most effective at blocking the synaptically evoked slow EPSP as well
as the carbachol-induced inhibition of the K+(leak) current thought to underlie the
slow cholinergic EPSP in the rat hippocampus.
The debate between Ml and M3 mAChRs mediating cholinergic responses in the
hippocampus is complicated by possible factors such as inter- and intra-slice
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variability coupled with the putative heterogeneity of cholinergic synapses being
activated. Hence, a reasonable conclusion is that there may exist synapses that
mediate the cholinergic slow EPSP via Ml mAChRs whilst other synapses employ
M3 mAChRs and this may vary from animal to animal as well as slice to slice.
It remains unclear which subtype(s) of muscarinic ACh receptor mediate the EPSPM
in the rat hippocampus. This is by no means an exhaustive study and a lot of these
experiments need to be repeated. This is especially true for the toxin studies which
showed some ambiguous results. To further this study would require a greater supply
of the toxins that were available to me at the time and until a range of specific
mAChR agonists and antagonists are commercially available and the appropriate
studies performed, the M1/M3 story will remain unresolved.
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CHAPTER 4
Presynaptic Mechanisms Involved in the Generation
and Modulation of the EPSPm
4.1 Introduction
Another aspect of the generation of electrically-evoked EPSPmS is the presynaptic
mechanisms by which ACh is released from the cholinergic terminals in the
hippocampus and how release can be modulated by heteroreceptor activation. As
such, I have examined the voltage gated Ca2+ channels that may be involved in ACh
release and, in collaboration with Robin Morton, furthered the investigation of
adenosine receptor-mediated presynaptic inhibition of the EPSPm- This involved the
study of the mechanisms by which adenosine could exert its effects upon ACh
release. Accordingly, this chapter introduction will review voltage-gated Ca2+
channels, adenosine receptors, and mechanisms involved in presynaptic inhibition.
4.1.1. Voltage-gated Ca2+channels
Ca2+ entry upon depolarisation of presynaptic terminals is an essential link between
action potential invasion and neurotransmitter exocytosis (Katz, 1969; Augustine et
al., 1987). As such, voltage gated Ca2+ channels have become the focus of
considerable interest as a critical component of the presynaptic release machinery.
Here, I will review the basic structure, subtype classification and implication of
voltage gated Ca2+channels in neurotransmitter release in the CNS, with particular
focus on the hippocampus.
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4.1.1.1 Structure
Ca2+ channels have a putative multimeric composition consisting of at least 4
subunits: at, (3, a2 and 8. The al subunit is the largest of the four and contains four
hydrophobic regions each comprising 6 transmembrane spanning domains. Six
different al subunits have been cloned. Each demonstrates pore formation, contains
the voltage sensor on segment 4 and is responsible for the binding of different
pharmacological compounds. In contrast, the much smaller, entirely cytoplasmic, (3
subunit appears not to form a functional channel but does modify both the
pharmacological and biophysical properties of the channel. Four putative (3 subunits
have been identified and it is believed that this subunit contributes to variability
between channels that contain the same al subunit. In the brain, the a28 subunits are
coded for by a single gene transcript. The a2 subunit is primarily extracellular and is
disulphide bonded to the 5 subunit that spans the membrane and possesses an
intracellular C-terminal domain. These subunits contribute to the properties of the
channel by increasing channel expression and modifying the sensitivity of the
channel to drugs. For a more in depth review of Ca2+channel structure see De Waard
et al. (1996).
4.1.1.2. The classification of Ca2+channel subtypes
Traditionally, Ca2+currents have been classified based on voltage dependency into
low voltage activated (LVA) or T currents and high voltage activated (HVA)
currents (Carbone & Lux, 1984). HVA currents can be further divided into those that
are dihydropyridine (DHP)-sensitive (L-type) and non-dihydropyridine-sensitive
(Tsien et al., 1988) which became classed as N-type Ca2+channels. These channels
showed differing biophysical properties (inactivation kinetics, steady-state
inactivation and single-channel conductance) that appear intermediate between L and
T type channels (Nowycky et al., 1985; Fox et al., 1987). The discovery of selective
toxins that blocked DHP resistant Ca2+ currents demonstrated that N-type currents
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could be further classified into N-, P- and Q-type (McCleskey et al., 1987; Mintz et
al., 1992a).
N-type Ca2+ currents are oo-conotoxin GVIA-sensitive and are typically evoked
above -30 mV, peak near to -10 mV and partially inactivate during depolarising
pulses. However, their inactivation rates vary from less than 100 ms in sympathetic
neurons (Plummer & Hess, 1991), to 600 ms in dorsal root ganglia (DRG) (Regan et
al., 1991) and 1.5 s in supraoptic neurons (Fisher & Bourque, 1995). This difference
in inactivation kinetics may reflect differences in the basal state of the channel (e.g.
G-protein regulation, phosphorylation state) between studies rather than differences
in the channel protein per se although another explanation is that there are multiple
forms of N-type Ca2+channels supported by the existence of alB splice variants
combining with ancillary channel subunits (De Waard & Campbell, 1995)
P-type Ca2+ currents were first described in cerebellar Purkinje cells and showed
resistance to DHPs and co-conotoxin GVIA (Llinas et al., 1989; Regan et al., 1991).
These currents are evoked above -50 mV, peak at -30 to -10 mV but differ from N-
type currents by their lack of inactivation during 50 ms depolarising pulses. These
currents can be inhibited by oo-agatoxin IVA with an IC50 of 2-10 nM (Mintz et al.
1992a; Mintz et al., 1992b). In other cell types, such as cerebellar granule cells, a
Ca2+current was inhibited by a higher concentration (100-200 nM) of agatoxin IVA
and thus Q-type currents were described (Zhang et al., 1993). However, due to
problems of poor selectivity of toxins for Q-type Ca2+ currents and N/P type currents,
the biophysical properties of Q-type Ca2+ channels remain largely unexplored.
R-type currents have been described by Tsien and coworkers as the residual current
left after the blockade of N, L, P and Q currents (Zhang et al., 1993). However, this
putative current is poorly defined and it is not clear whether this is a real subclass of
Ca2+ channel or a mixture of residual currents from incomplete antagonism of N, L,
P and Q currents.
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4.1.1.3. Voltage-gated Ca2+ channels and neurotransmitter release
There exists extensive evidence for the involvement ofmultiple DHP-resistant HVA
Ca2+ currents in presynaptic release of various neurotransmitters in the CNS (Luebke
et al., 1993; Takahashi & Momiyama, 1993; Castillo et al., 1994; Mintz et al., 1995).
In the hippocampus, it has been demonstrated that both N- and Q-type Ca + channels
are involved in glutamate receptor-mediated synaptic transmission at CA3-CA1
synapses in rat slices (Wheeler et al., 1994) as well as synapses in pyramidal cell
cultures (Scholz & Miller, 1995; Reuter, 1995). High potassium-evoked release of
neurotransmitter from rat brain slices demonstrated an important role for P-type Ca2+
channels with N-type channels being partially involved and a lack of involvement of
L-type Ca2+channels (Kimura et al., 1995). In addition, it has been observed that the
proportions of N-type to Q-type Ca2+ channels involved in presynaptic release alters
with age in cultured rat hippocampal neurons (Scholz & Miller, 1995) with N-type
Ca2+ channels being more important at immature synapses and P/Q-type becoming
more significant in older cultures. This finding is supported by the findings of
Verderio and coworkers (1995).
GABA release from the variety of intemeurons within the hippocampus has also
been shown to involve Ca2+ channels (Poncer et al., 1997). In contrast to glutamate
release, it was discovered that neurotransmitter release from intemeurons in the
stratum radiatum was majorly mediated by N-type Ca2+ channels whereas
intemeurons in the stratum oriens and stratum lucidum utilised P-type Ca2+channels
demonstrating that different channel subtypes are employed by different synapses
releasing the same neurotransmitter. However, it has been suggested (Dunlap et al.,
1995) that there may be spare channels that become active at higher action potential
durations or if a subtype of calcium channel is blocked (Wheeler et al., 1996).
Furthermore, one study suggests that there is heterogeneity of Ca2+channels at
different synapses of the same afferent leading to a possible terminal-specific
modulation of synaptic function (Reid et al., 1997).
There have been a couple of studies performed on ACh release in the hippocampus.
Firstly, it was demonstrated that co-conotoxin GVIA completely blocks electrically-
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evoked ACh release in the hippocampus (Dutar et al., 1989a). It has been
subsequently demonstrated that K+-evoked [3H]acetylcholine release can be partially
inhibited by either blocking N- or Q-type Ca2+channels (Saydoff & Zaczek, 1996), a
contradictory result to that of Dutar and coworkers. The lack of effect of verapamil
suggested little involvement of L-type Ca2+ channels in ACh release.
There is evidence for voltage gated Ca2+channels being a target for neuromodulation
of transmitter release by the activation of certain G-protein coupled receptors, e.g.
the adenosine receptor. This modulation sometimes involves direct G-protein-
mediated modulation and sometimes interaction via intracellular protein kinases
(Dolphin, 1996). This is reviewed in more detail within section 4.1.2.4.
4.1.2 Adenosine
4.1.2.1 General
ATP and its precursor, adenosine, act at specific cell surface receptors and are
involved in cellular metabolism (Williams, 1987). These receptors are known as
purinoreceptors (Burnstock, 1978). ATP has been shown to act as a neurotransmitter
at P2 receptors in the peripheral and central nervous system (Edwards & Gibb, 1993;
Fredholm et al., 1994b). In contrast, adenosine is synthesised and released by many
cells (Stone et al., 1990) but is not thought to act as a classical neurotransmitter in
the CNS but rather as a neuromodulator or local hormone (Dunwiddie, 1985; Snyder,
1985; Daval et al., 1991). Its function within the CNS is predominantly inhibitory
resulting in reduced cell firing or excitability and the inhibition of neurotransmitter
release. Only adenosine will be reviewed in any depth in this chapter; however, ATP
and Pt receptors have been extensively reviewed in recent publications (Fredholm et
al., 1994a, Fredholm et al., 1997).
Adenosine was initially discovered to be physiologically active in studies of the
mammalian heart (Drury & Szent-Gyorgyi, 1929) but it was not until it was
demonstrated that caffeine inhibited the action of adenosine that this observation was
given credence (De Gubareff & Sleator, 1965). The actions of ATP and adenosine
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were subsequently distinguished and the P1/P2 receptor classification was
established. (Brunstock, 1978). Adenosine was later found to couple to adenylate
cyclase (AC). Due to the observations that (1) both inhibition and stimulation of AC
was observed and that (2) agonist potencies to adenosine and its related analogues
varied, the classification was divided into two subtypes of adenosine receptor, Ai
(AiR) and A2 (A2R) receptors (Londos et al., 1980; Van Calker et al., 1979). Further
pharmacological characterisation confirmed and extended this classification by
utilising more specific agonists and antagonists (Collis & Hourani, 1993; Dalziel &
Westfall, 1994). Ultimately, on the basis of molecular cloning techniques, the
existence of the adenosine A3 receptor was proposed (Caruthers & Fozard, 1993;
Collis & Hourani, 1993). The current receptor classification is summarised in Table
4.1.
Table 4.1. Adenosine receptor subtypes: Pharmacology and transduction mechanisms.
Subtype AT A2a A2b A3
Selective
agonists













Antagonists dpcpx zm 241385 none known l-abopx
Signal
Transduction
Mechanisms lAC Tac Tac Tac
G-protein
Interaction
g/go gs gs ?
Abbreviations: APNEA: AC2-(4-amino-3-iodophenyl)-ethyladenosine.
4.1.2.2. Adenosine Receptors
The adenosine receptors are found throughout the CNS as well as in peripheral
tissues (Thompson et al., 1992) and belong to the superfamily of G-protein-coupled
receptors possessing the characteristic seven transmembrane spanning domains (Olah
& Stiles, 1992).
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AiRs are negatively coupled to AC and therefore inhibit the turnover of intracellular
cAMP. AiRs can be pharmacologically distinguished from A2RS using the specific
agonist, 2-chloro-N6-cyclopentanyladenosine (CCPA) or the specific antagonist,
DPCPX which has a 700-fold selectivity for A|Rs over A2Rs (Lohse et al., 1987).
A2R were initially distinguished by their ability to stimulate adenylate cyclase and
thus increase the levels of intracellular cAMP (Van Calker et al., 1979). Binding
studies have subsequently shown that A2Rs can be subdivided into the high affinity
A2aR and the low affinity A2bR, both of which positively couple to AC via the G-
protein, Gs (Daly et al., 1983; Bruns et al., 1986; Ongini & Fredholm, 1996). This
was later confirmed by the A2aR selective agonist, CGP 21680 (Jarvis et al., 1989),
and the non-xanthine antagonist, ZM 241385 (Poucher et al., 1995).
The A3R was originally cloned from a cDNA sequence derived from rat striatal cells
(Zhou et al., 1992). When expressed in CHO cells, A3Rs displayed a different rank
order of agonist potencies than that of AjRs and A2Rs. Furthermore, this new
receptor was resistant to blockade by certain xanthine antagonists. A3R was found to
negatively couple to AC.
4.1.2.3. Adenosine: The Neuromodulator
Although there is little evidence to support a neurotransmitter role for adenosine
(Bruns, 1991), adenosine receptors are widely distributed throughout the CNS and
adenosine is released from neurons (Bender et al., 1981; Jonzon & Fredholm, 1985;
Stone et al., 1990; Mitchell et al., 1993; Fredholm et al., 1994b). Consequently, a
neuromodulatory role for adenosine was proposed.
The principle action of adenosine is inhibition of neurotransmitter release at a variety
of excitatory and inhibitory synapses (Dunwiddie, 1990). In addition, adenosine
receptor-mediated effects acting at postsynaptic sites have been reported, e.g.
modulation of postsynaptic K+ or Ca2+ conductances and inhibition of spontaneous
neuronal firing. Furthermore, in vivo and in vitro studies demonstrate that there is an
overall "purinergic inhibitory tone" over neuronal systems that can be alleviated with
adenosine antagonists and exacerbated by the inhibition of adenosine breakdown or
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uptake (Harms et al., 1978; Jackisch et al., 1984; Pak et al., 1994; Dunwiddie &
Diao, 1994).
Although the effects of adenosine are well established the source of adenosine is still
the subject of some debate due to its general production as an integral part of the
process of cellular metabolism and energy production (Arch & Newsholme, 1978).
Stimulation evoked release of adenosine from presynaptic terminals is apparent but is
thought to be a carrier-mediated process rather than exocytosis (Sweeney, 1996). Of
course, ATP is also expelled from cells where it is catabolised by ecto-5'-
nucleotidases into adenosine (Cunha et al., 1998). During periods of hypoxia or if the
cell metabolism is compromised, local extracellular concentrations of adenosine are
dramatically elevated (Hagberg et al., 1987; Rudolphi et al., 1992). Taken together
with the role of adenosine as an inhibitory modulator of synaptic activity, adenosine
has been described as a neuro-protective agent or a "retaliatory metabolite" (Newby,
1984).
4.1.2.4. Adenosine receptor-mediated effects in the CNS
Several interlinked effects of adenosine action have been characterised in the
hippocampus: (1) the inhibition of spontaneous neuronal firing and epileptic bursting
(Phillis et al., 1979; Dunwiddie, 1980; Lee et al., 1984; Schubert & Lee, 1986), (2)
modulation of K+ or Ca2+ conductances, and (3) presynaptic modulation of
neurotransmitter release.
These effects appear to be mediated by postsynaptic AiRs and are thought to involve
the activation of postsynaptic K+ conductances which result in hyperpolarisation and
enhancement of Iahp thus reducing postsynaptic excitability. In addition, it has been
demonstrated that adenosine receptor activation opens a voltage-insensitive K+
conductance in the hippocampus (Okado & Ozawa, 1980, Segal, 1982b; Greene &
Haas, 1985). This effect appears to be mediated by a pertussis toxin-sensitive G-
protein but does not involve cAMP (Trussel & Jackson, 1987). Also, the
enhancement of Iahp by adenosine receptor activation has been reported in CA1
pyramidal neurons (Haas & Greene, 1984). One study also provides evidence of an
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adenosine receptor-mediated activation of a voltage-dependent CI" conductance in
cultured hippocampal neurons (Mager et al., 1990).
The inhibition of Ca2+ channels by adenosine receptor activation has also been
explored in the hippocampus. One Ca2+ conductance underlying regenerative Ca2+-
dependent action potentials (calcium spikes) is reported to be inhibited by adenosine
receptor activation although it is not certain if this effect is direct or due to the
activation of a K+ conductance which in turn inhibits Ca2+ influx (Proctor &
Dunwiddie, 1983). In addition, adenosine receptor activation has been shown to
inhibit N-type Ca2+channels in hippocampal CA3 neurons (Mogul et al., 1993) and
mouse motoneurons (Mynlieff & Beam, 1994). Moreover, it has been shown that the
blockade of co-conotoxin GVIA-sensitive Ca2+ transients attenuated adenosine Ai
receptor-mediated inhibition of glutamate mediated synaptic transmission in area
CA1 of the rat hippocampus (Wu & Saggau, 1994). In cultured DRG neurons,
adenosine receptor activation inhibited the duration of Ca2+ spikes (Dolphin et al.,
1986; MacDonald et al., 1986).
Despite these numerous effects, presynaptic inhibition of transmitter release is
considered the best-recognised neuromodulatory action of adenosine. Presynaptic
inhibition is a phenomenon originally described in the neuromuscular junction
(Ginsborg & Hirst, 1972). Adenosine, acting through presynaptic adenosine
receptors, have been reported to inhibit release of both excitatory and inhibitory
neurotransmitters including ACh, adrenaline, dopamine, GABA, glutamate and 5-HT
(Harms et al., 1978; Harms et al., 1979; Burke & Nadler, 1988, Morton & Davies,
1997). However, this inhibition is not consistent for all brain regions, for example,
GABA release is inhibited by adenosine receptor activation in the cortex and
striatum but not in the hippocampus (Harms et al., 1979; Hollins & Stone, 1980).
Recently, one study showed that presynaptic adenosine A]R activation resulted in an
inhibition of electrically-evoked release of ACh from cholinergic terminals in the
hippocampus (Morton & Davies, 1997) and it was my aim, in conjunction with
Robin Morton, to follow up this investigation by exploring the possible mechanisms
by which adenosine could bring about this inhibition of release. Mechanisms of
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adenosine receptor-mediated presynaptic inhibition remain somewhat controversial
and revolve around three likely putative modes of action:
• The activation of a presynaptic K+ conductance, resulting in a reduction of Ca2+
influx upon invasion of an action potential leading to a reduction in transmitter
release.
• The inhibition of a presynaptic Ca2+ conductance directly and thus a reduction of
transmitter release.
• The modulation of the release machinery per se, somewhere downstream of Ca2+
entry.
The involvement of Ca2+ channel in adenosine receptor inhibition of transmitter
release has received most attention. In this respect, adenosine was shown to reduce
Ca2+ influx into presynaptic terminals measured using Ca2+-imaging techniques in the
guinea pig hippocampus (Wu & Saggau, 1994) and chick ciliary ganglion (Yawo &
Chuhma, 1993). In the hippocampus, it was shown that the Ca2+ conductance
inhibited by adenosine was of the N-type channel and possibly the Q-type. In other
brain areas, such as the rat brainstem, adenosine acting via AiRs causes inhibition of
presynaptic neurotransmitter release predominantly through the inhibition of an N-
type Ca2+ conductance (Umemiya & Berger, 1994). A2R.S function in a somewhat
different manner in that their activation can lead to a facilitation of synaptic
transmission in area CA3 and the brainstem by potentiation of P-type Ca2+currents
(Mogul et al., 1993; Umemiya & Berger, 1994). To date there is a paucity of
evidence suggesting an involvement of K+ channels and/or actions on the presynaptic
release machinery per se in the inhibition of transmitter release by adenosine. In the
latter case, this is probably due to the technical difficulty and lack of
pharmacological tools with which to perform these experiments.
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4.2 Results
4.2.1. The Role of Voltage-Gated Calcium Channels (VGCCs) in the
Generation of EPSPMs
Initially, it was important to assess which Ca2+ channels were responsible for the
release of ACh mediating the EPSPm- Although it is widely accepted that VGCCs are
involved in synaptic transmission, it was necessary to ascertain whether they played
a part in the cholinergic responses generated by stimulation of cholinergic
presynaptic terminals in the hippocampus. It is feasible that the release machinery
was by-passed by the strong stimulation protocol resulting in the direct electrically
evoked release of ACh. CdCl2 was employed to non-specifically block Ca2+
channels. Fig. 4.1 shows that 0.5 mM CdCb caused a total inhibition of the EPSPM
within 30 min («=3). This effect was accompanied by an increase in cell input
resistance (data not shown).
To more specifically identify which Ca2+ channels mediated the release of ACh, co-
conotoxin GVIa (CTX), a specific blocker of N-type VGCCs was studied. 300 nM
(Zhang et al., 1993) CTX produced a partial inhibition of the EPSPM (34.8 ±5.74%
of control; n=5) reaching steady state within 45 min (fig. 4.2). No changes in spike
frequency adaptation (fig. 4.3B) or cell input resistance of a pyramidal cell were
observed in the presence of CTX (106±5.7% of control, n-5).
To ascertain whether or not CTX was producing this inhibition via a pre- or post¬
synaptic locus, it was necessary to examine the effect of the toxin on post-synaptic
mAChR activation alone. A 1 min application of 3 pM carbachol produced (1) robust
depolarisation of the membrane potential to a point where the pyramidal cell fired
trains of action potentials, (2) reduced spike frequency adaptation and (3) increased
cell input resistance. In the presence of CTX little difference was observed in all
three effects of post-synaptic mAChR activation, suggesting a presynaptic locus for
the action of CTX on the EPSPM (fig. 4.3).
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Figure 4.1 The EPSPM is fully blocked by CdCl2
A shows intracellular current clamp recordings of EPSPMs before (left) and 16 min after (right) the
application of 0.5 mM CdCl2. Cell membrane potentials were maintained at -66 mV throughout the
experiment. The filled triangle denotes the time of stimulation (10 stimuli at 20 Hz). B shows the
EPSPm peak amplitude expressed as a percentage of control EPSPm amplitude versus time. Note that
CdCl2 produced a rapid and full inhibition of the EPSPM. The input resistance of the cell was 32 MQ,
the resting membrane potential was -63 mV and the spike height was greater than 0 mV
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Figure 4.2 300 nM co-conotoxin GVIa (CTX) partially inhibits the EPSPm-
A shows intracellular current clamp recordings of EPSPMs before (left) and after (right) the application
of 300 nM CTX. Cell membrane potentials were maintained at -68 mV throughout the experiment.
The filled triangles denote the position of the stimulus train (10 @ 20 Hz). B demonstrates the
inhibition of the EPSPM expressed as the peak amplitude of the EPSPM normalised to 3 responses in
control media plotted versus time. Bar graph (right) illustrates the mean inhibition from 5 experiments
(p<0.05). Values are means ± S.E.M represented by the error bars. The input resistance of the cell was
42 M£2, the resting membrane potential was -65 mV and the spike height was greater than 0 mV.
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Figure 4.3 Effects of CTX on spike frequency adaptation and carbachol-induced
depolarisation of CA1 pyramidal cells.
A shows chart recordings of the membrane potential (Vm) of a CA1 pyramidal cell and its response to
depolarising and hyperpolarising current steps. On application of 3 pM carbachol (Cch) for 1 minute,
a slow depolarisation of Vm accompanied by spontaneous action potential firing and an increase in cell
input resistance were observed. These effects of CCh are unchanged in the presence of 300 nM CTX
(right). B illustrates the response of a cell to a depolarising current step in the absence (left hand trace)
and presence (right hand trace) of 300 nM CTX. The number of action potentials and, therefore, spike
frequency adaptation, is unchanged by 300 nM CTX. The input resistance of the cell was 38 MQ, the
resting membrane potential was -66 mV and the spike height was greater than 0 mV. Variations in
spike height are due to the sampling rate (488 ps sampling interval).
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As CTX only provides a partial blockade of the EPSPm, it was thought that other
VGCCs might contribute to the generation of this response. Initially, Agatoxin TK
was utilised to block P/Q type calcium channels. At 200 nM, Agatoxin TK produced
an inconsistent reduction of the EPSPm (data not shown). Therefore, the more potent
P/Q-type Ca2+ channel inhibitor, co-agatoxin IVa (ATX) was tested. At 400nM, ATX
(Mintz et al. 1992a; Mintz et al., 1992b) produced significant inhibition of the
EPSPm (47±17% of control; n-2), reaching steady state after 100 min. This effect
was accompanied by a small increase in cell input resistance (120±2% of control,
n-2) but no apparent change in spike frequency adaptation (fig. 4.4).
4.2.2. Mechanisms of presynaptic adenosine receptor mediated
inhibition of the EPSPM.
Since the EPSPm was dependent upon presynaptic Ca2+ channel activation it was
hypothesised that broadening of presynaptic action potentials using K+ channel
blockers such as 4-aminopyridine (4-AP) should also enhance the EPSPM. 100 pM 4-
AP (Madison et al., 1987) enhanced the EPSPm peak amplitude by 1171 ±338% of
control (n-4). To establish whether this excitatory effect of 4-AP was pre- or post¬
synaptic I tested whether 4-AP affected carbachol induced depolarisations. It was
found that carbachol-induced depolarisation was unaffected by 4-AP (fig. 4.5C) as
was spike frequency adaptation and cell input resistance (data not shown) which
suggests that 4-AP enhanced the EPSPm by increasing the duration of action
potentials and, therefore, increased the influx of Ca2+ into the cholinergic terminals.
To investigate the role that K+ channels may play in the modulation of ACh release
by adenosine, 4-AP was employed at high concentrations to non-specifically block a
range of K+channels. At 100 pM 4-AP, the EPSPm was greatly enhanced. 1 pM
CADO (eg Morton & Davies, 1997; Davies et al., 1991), a non-hydrolysable
adenosine analogue was subsequently applied. This produced a significant level of
inhibition of the EPSPM (fig. 4.5A). However, this inhibition was significantly less
(46±12% of control; n-4 (p<0.05)) than that observed when CADO alone was
applied (17±5% of control; n=9) (fig 4.55).
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Figure 4.4 400 nM co-agatoxin IVa partially inhibits the EPSPm
A illustrates intracellular current clamp recordings of EPSPMs in control media (left) and after 100 min
application of 400 nM ATX (right). Cell membrane potentials were maintained at-68 mV throughout
the experiment. Filled triangles denote the position of the stimulus (10 @ 20Hz). B (left) shows the
time course of ATX application and its effect on the peak amplitude of the EPSPM. The bar graph
(right) shows the mean inhibition of the EPSPM by ATX for 2 experiments (P<0.05). Values are
means ± S.E.M represented by the error bars. The input resistance of the cell was 40 M£2, the resting
membrane potential was -63 mV and the spike height was greater than 0 mV.
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Figure 4.5 The blockade of 4-AP sensitive K+ channels partially occludes the inhibition of
the EPSPm by CADO.
A shows intracellular current clamp recordings of EPSPMs in control media (left), during 100 jaM 4-
AP application (middle) and after 4-AP + 1 pM CADO application. The cell membrane potential was
maintained at -67 mV throughout the experiment. The filled triangles denote the position of the
stimulus (10 @ 20Hz). B shows a time course graph illustrating the enhancement of the EPSPM peak
amplitude by 4-AP and the subsequent inhibition by CADO and block of CADO-induced inhibition
by 200 nM DPCPX. The bar graph (right) demonstrates the significant difference (p<0.05) in mean
levels of (left) enhancement of the EPSPM amplitude by 4-AP and (right) CADO induced inhibition,
with and without 4-AP present, for 9 and 4 experiments respectively (p<0.05). The input resistance of
the cell was 37 M£2, the resting membrane potential was -67 mV and the spike height was greater
than 0 mV. Values are means ± S.E.M represented by the error bars.
C shows chart recordings of the membrane potential (Vm) of a CA1 pyramidal and its response to
depolarising and hyperpolarising current steps. On application of 3 |iM carbachol (Cch) for 1 minute,
a slow depolarisation of Vm, accompanied by spontaneous action potential firing, was observed. Note
the increase in cell input resistance during carbachol application. These effects ofCCh are unchanged
in the presence of 100 |TM 4-AP (right).
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Since 4-AP caused a partial occlusion of the depressant action of CADO on the
EPSPm it is possible that CADO may also inhibit Ca2+ channel activity. As such, we
compared the effects of CADO on the EPSPM evoked in the presence and absence of
co-conotoxin GVIA. Because CTX only produced a partial inhibition of the EPSPM, it
was possible to assess the extent to which CADO could depress the EPSPm in the
absence of functional N-type Ca2+ channels. As such, it was demonstrated that the
residual EPSPm, subsequent to CTX application, was still inhibited by 1 pM CADO
(fig. 4.6A). A comparison of the level of CADO inhibition in the absence of CTX (17
±5% of control; n-9) revealed that there was no change in the magnitude of CADO
induced depression of the EPSPM after N-type Ca2+channel blockade (24 ±7% of
control; n=3) (fig. 4.6B) suggesting that adenosine modulation does not exert its
actions solely via the N-type Ca2+ channel. In a separate series of experiments CADO
was also found to depress the EPSPM when P/Q type Ca2+ channels were blocked by
400 nM ATX («=2; data not shown).
As N, P and Q type Ca2+ channels appeared not to play a notable role in adenosine
modulation of ACh release and 4-AP sensitive K+ channels only a partial role, it was
possible that the major reason for CADO-induced inhibition of the EPSPm was
inhibition of the release machinery per se. As such, we next explored whether it was
possible to inhibit the CADO-induced depression of the EPSPm by modifying
intracellular signaling mechanisms. In this respect it has been demonstrated that the
adenosine Ai receptors couple to the G-protein, Gi, which negatively regulates
adenylate cyclase. Therefore, we focussed our experiments toward modifying
intracellular cAMP levels to establish its involvement in the process of presynaptic
adenosine modulation of ACh release.
Increasing endogenous cAMP was achieved using 10 pM forskolin. This had no
effect on the EPSPm per se (92 ±14% of control) (fig. 4.7) but reduced spike
frequency adaptation (data not shown). In the presence of forskolin, CADO induced
inhibition of the EPSPM was significantly attenuated (43 ±3% of control, n=4)
compared with control media (17 ±5% of control, n=9 (p<0.05)).
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Figure 4.6 The blockade of N-type Ca2+ channels does not affect the inhibition of the
EPSPm by CADO.
A shows intracellular current clamp recordings of EPSPM evoked in the presence ofCTX before (left)
and after (right) the application of 1 pM CADO. Cell membrane potentials were maintained at -66
mV throughout the experiment. Filled triangles denote position of stimulus (10 @ 20Hz). B illustrates
a time course graph showing the inhibition of the EPSPM peak amplitude by CADO. The bar graph
(right) demonstrates that there was no change in mean CADO induced inhibition, with or without
CTX present, for 9 and 3 experiments respectively (p>0.05). Values are means + S.E.M represented
by the error bars. The input resistance of the cell was 34 M£2, the resting membrane potential was -66
mV and the spike height was greater than 0 mV.
To support this result, the non-hydrolysable analogue of cAMP, 8-Br-cAMP, was
used to activate processes normally activated by cAMP. As with forskolin, 8-Br-
cAMP had no effect on the EPSPM per se (102 ±11% of control, n-5) but succeeded
in completely occluding the depressive effect of CADO on the EPSPM. Thus, in the
presence of CADO plus 8-Br-cAMP, the peak amplitude of the EPSPM was 110 ±5%
of control, n=4 (fig. 4.8).
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Figure 4.7 Increasing endogenous intracellular cAMP partially occludes the inhibition of
the EPSPm by CADO.
A shows intracellular current clamp recordings of EPSPMs in control media (left), during 10 pM
forskolin application (middle) and after 10 pM forskolin plus 1 pM CADO application (right). Cell
membrane potentials were maintained at -68 mV throughout the experiment. Filled triangles denote
the position of the stimulus (10 @ 20Hz). B illustrates a time course graph showing the change in
EPSPm peak amplitude following applications of forskolin, CADO and DPCPX. (C) Bar graph (left)
demonstrates that there was no change in mean EPSPM peak amplitude after forskolin application for
4 experiments (p>0.05). The bar graph (right) shows that there is a significant reduction in mean
CADO induced EPSPM inhibition in the presence of forskolin n=9 and /;=4 for experiments in the
absence of forskolin (p<0.05). Values are means ± S.E.M represented by the error bars. The input
resistance of the cell was 43 MQ, the resting membrane potential was -69 mV and the spike height
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Figure 4.8 8Br-cAMP fully occludes the inhibition of the EPSPm by CADO.
A shows intracellular current clamp recording of EPSPMs in control media (left), during 1 mM 8Br
cAMP application and after 8Br cAMP and 1 |iM CADO application. Cell membrane potentials were
maintained at -65 mV throughout the experiment. Filled triangles denote the position of the stimulus
(single stimulation). B illustrates the time course of a typical experiment showing that the EPSPM peak
amplitude is unchanged by 8Br cAMP and that CADO failed to inhibit the response. The bar graph
(C) demonstrates the lack of effect of 8Br cAMP on the EPSPM in 5 experiments and the total block of
CADO induced inhibition of the EPSPM by 8-Br-cAMP in 4 experiments. Values are means ± S.E.M
represented by the error bars. The input resistance of the cell was 38 M£2, the resting membrane
potential was -65 mV and the spike height was greater than 0 mV.
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4.3 Discussion
4.3.1. Voltage-gated Ca2+channels are involved in the generation of
EPSPmS
Here, we have demonstrated the involvement of multiple subtypes of Ca2+ channel in
the generation of cholinergic responses. Furthermore, we purport that the primary
site of action of these Ca2+ channels is at the presynaptic cholinergic terminal based
on the lack of effect that the blockade of these channels has on postsynaptic mAChR-
mediated responses.
The EPSPm was inhibited by 65% in the presence of the N-type channel blocker, to-
conotoxin GVIA, and by 53% in the presence of the P/Q-type Ca2+ channel blocker,
co-agatoxin IVA. The fact that the amount of inhibition exerted by both toxins
exceeds 100% can be explained by the non-linear relationship between Ca2+ influx
and neurotransmitter release as measured by the postsynaptic effect of the
neurotransmitter. This relationship can be expressed as the following function:
Release=[Ca+]m
Where Release refers to postsynaptic potentials, [Ca2+] refers to the intracellular
Ca2+ concentration (spatially averaged) and m has been found to equal between 3 and
4. Therefore, a small decrease in Ca2+ influx can result in a disproportionately larger
decrease in release. This relationship is described in more detail by Wu and Saggau
(1997). Thus, blocking a proportion of the Ca2+channels mediating Ca2+influx may
result in a large percentage decrease in ACh release disproportionate to the
percentage of Ca2+ channels blocked. Ideally, to assess the proportional contributions
of the different Ca2+ channel subtypes, increases in intracellular Ca2+ should be
measured directly using calcium fluorescent imaging.
Whilst there is evidence to support the findings in this chapter in that Saydoff &
Zaczek (1996) showed a similar involvement of N- and P/Q-type Ca2+ channels in
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K+-evoked ACh release, Dutar and coworkers (1989a) have demonstrated a total
block of the cholinergic response by to-conotoxin GVIA suggesting N-type Ca2+
channels alone were involved in mediating the cholinergic response. However, a
number of differences exist between the experiments of Dutar and the experiments
presented in this chapter. Firstly, Dutar and coworkers evoked cholinergic responses
that were not isolated by the use of antagonists of GABA and glutamate receptor-
mediated synaptic transmission. Secondly, Dutar et al. used eserine to amplify the
cholinergic response. This suggests that they are not evoking the same amount of
ACh release and thus presynaptic Ca2+ influx is lower. It is possible that at lower
levels of Ca2+ influx, blocking N-type Ca2+is all that is necessary to prevent
neurotransmitter release. This infers that P/Q-type Ca2+channels do not become
involved in ACh release until higher stimulation intensities. However, it would be
interesting to observe the effect of oo-agatoxin IVA on the cholinergic responses in
the study of Dutar et al. (1989a).
That there exists a heterogeneous involvement of Ca2+ channel subtypes modulating
ACh release is not unusual. Indeed, Wheeler and colleagues (1994) have
demonstrated that glutamate release in the hippocampus required functional N- and
Q-type Ca2+ channels. This subtype heterogeneity can be explained by either
different cholinergic afferents exhibiting different Ca2+channel subtypes allowing for
more specific modulation of synaptic function, or each terminal utilising multiple
Ca2+ channel subtypes.
4.3.2. Mechanisms involved in the presynaptic modulation of ACh
release by adenosine Ai receptor activation
It has previously been demonstrated that adenosine AiR activation results in a
postsynaptic hyperpolarisation of pyramidal cells by G-protein mediated activation
of a barium-sensitive K+ conductance (Thompson et al., 1992). In addition,
adenosine AiR activation inhibits amino acid-mediated excitatory synaptic
transmission in the hippocampus (but not GABAergic inhibitory synaptic
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transmission). Taken together, these data suggest a powerful inhibitory role for
adenosine in the CNS.
Another inhibitory role was reported by Morton & Davies (1997) who demonstrated
that presynaptic adenosine A]R activation mediated a profound inhibition of ACh
release from septohippocampal cholinergic terminals in the stratum oriens of the
hippocampus. Here, we have extended this finding by exploring the possible
mechanisms by which adenosine A[R activation may cause this presynaptic
inhibition.
Initially, we demonstrated a partial involvement of 4-AP sensitive K+ channels in
adenosine AiR-mediated presynaptic inhibition. The blockade of these K+ channels
did not appear to affect postsynaptic mAChR activation suggesting that they resided
at a presynaptic locus. These data suggest a possible role for 4-AP sensitive K+
channels in adenosine receptor modulation. However, the concomitant increase of
Ca2+ influx due to presynaptic action potential broadening may explain the partial
occlusion of AiR-mediated presynaptic inhibition by 4-AP as this may override the
inhibitory mechanisms invoked by Ai receptor activation.
As we had already established that N- and P/Q-type Ca2+ channels are involved in
mediating ACh release, it was logical to explore if these voltage-gated Ca2+ channels
were also the effector site for adenosine AiR-mediated presynaptic inhibition
especially since Ca2+ channels are intimately involved in ACh release. However, N-
type Ca2+ channels proved not to be involved. Preliminary results showed that P/Q-
type channels appeared not to play a part in adenosine receptor-mediated presynaptic
inhibition of ACh release also, although more experiments need to be conducted to
conclusively rule out this site of action. Interestingly, adenosine A]R activation
causes presynaptic inhibition at granule cell to purkinje cell synapses in the
cerebellum by the modulation of N-,P- and Q-type Ca2+ channels (Dittman &
Regehr, 1996). This result is accompanied by numerous reports of different
neuromodulators presynaptically inhibiting neurotransmitter release from a variety of
different synapses within the CNS by reducing Ca2+influx through voltage-gated
Ca2+ channels (Qian et al., 1995; Wu & Saggau, 1994, 1995; Mintz et ai, 1995).
However, this does not exclude the hypothesis that adenosine is acting at presynaptic
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sites to cause inhibition of ACh release by another mechanism downstream of Ca2+
entry.
It is technically very difficult to examine the functional effect that inhibiting part of
the presynaptic release machinery has on a postsynaptic response. Thus, our initial
experiments began with the second messenger system by which adenosine A]Rs may
mediate their effect. As Ai receptors inhibit adenylate cyclase we looked at cAMP.
Accordingly, we observed an occlusion of presynaptic inhibition by the use of either
8-Br cAMP, a non-hydrolysable analogue of cAMP, or forskolin, a stimulator of
adenylate cyclase. Interestingly, gross increases in cAMP levels appeared not to
affect the cholinergic response supported by the preliminary observation that the
broad spectrum adenylate cyclase inhibitor, SQ 22536, also proved ineffective at
inhibiting the EPSPm- These data demonstrate that cAMP does not play a direct role
in mediating either presynaptic ACh release or postsynaptic mAChR-mediated
responses as increasing or decreasing basal cAMP levels does not alter the
cholinergic response. In contrast, one study demonstrated that an enhancement of
adenylate cyclase results in an increase in evoked and spontaneous release of
glutamate from Schaffer collateral/commissural terminals in area CA1 of the rat
hippocampus (Chavez-Noriega & Stevens, 1994). Taken together, this suggests that
the release and action of some neurotransmitters are sensitive to changes in
intracellular cAMP whilst other neurotransmitters are relatively insensitive to cAMP
and maybe under the control of other second messengers.
These data provide functional confirmation of the accepted notion that adenosine
AjRs act through Gj/0to inhibit adenylate cyclase although the result of increasing or
decreasing cAMP will have differing functional consequences on neurotransmitter
release depending on the type of synapse and the basal level at which cAMP rests in
the presynaptic terminals examined. However, the interpretation of the data is
complex as increased cAMP could be having other effects like simply increasing
neurotransmitter release machinery directly. This could include adenosine AjR
desensitisation and the phosphorylation of ion channels controlling terminal
excitability. Nethertheless, the fact that increased cAMP does not affect the EPSPm
suggests that release cannot be further facilitated by raising intracellular cAMP.
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The logical progression of these experiments is to explore the involvement of cAMP-
dependent protein kinase A by stimulation of this enzyme to try and occlude
adenosine AiR-mediated inhibition of the cholinergic response. As increased cAMP
does not facilitate the evoked cholinergic response then it is unlikely that stimulating
PKA activity would increase an EPSPm unchallenged by adenosine. However, one
possible interpretation for this assumes that the basal levels of cAMP or PKA are
sufficient to produce maximal facilitation of neurotransmitter release. As such, the
use of a PKA stimulator would have no effect on the EPSPM per se but may prevent
adenosine AiR-mediated reductions in cAMP from inhibiting release by artificially
maintaining PKA activity. There is recent evidence to suggest that PKA acts to
facilitate an early step in the secretory machinery at a protein called SNAP25
(Trudeau et al., 1998). Taken together, a clear path can be described connecting
adenosine Ai receptor activation to fusion and release of neurotransmitter-filled
vesicles.
Likewise, another protein kinase, PKC, has been shown to affect adenosine receptor
modulation of presynaptic glutamate release in area CA3 of organotypic
hippocampal slice cultures. PKC activation reduced the ability of adenosine to cause
presynaptic inhibition (Thompson et al., 1992). This study provides another means
by which adenosine may exert its presynaptic effects. It is entirely possible that one




Modulation of Cholinergic Responses by Opioid
receptor Activation
5.1. Introduction
Other G-protein coupled receptors exist in the hippocampus and some may play a
role in the modulation of cholinergic responses. In the previous chapter, we
demonstrated that adenosine receptor activation resulted in a depression of mAChR-
mediated synaptic responses presumably by inhibition of ACh release. Here we have
focused on the effect that opioid receptor activation has upon the generation of
EPSPmS in the hippocampus.
5.1.1. General
The opioid receptor was first thought to exist when it was questioned why the
analgesic actions of morphine and other related opioids required rigid structure and
similar stereochemistry (Beckett & Casey, 1954). It was later thought that more than
one type of receptor existed because nalorphine, a synthetic opioid, antagonised the
actions of morphine but also acted as an analgesic in its own right. It was concluded
that this latter action was mediated by an alternative opioid receptor (Martin, 1967).
Pharmacological profiling of agonist activity in the chronic spinal dog preparation
lead to the classification of the p, K and a opioid receptors (Martin et al., 1976).
Later, the existence of 8-opioid receptors was confirmed by the relative potency of
the non-specific opioid antagonist, naloxone, to reverse the endogenous opioid
peptide inhibition of nerve-evoked contractions of the mouse vas deferens (Lord et
al., 1977).
It is now widely accepted that there are three pharmacologically well defined opioid
receptors: K, 8 and p. A single gene has been cloned for each subtype (Evans et al.,
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1992; Kieffer et al., 1992; Chen et al., 1993; Minami et al., 1993). However,
homology screening of cDNA libraries identified a new opioid receptor, termed
theORLi receptor (opioid receptor-like) (Mollereau et al., 1994).
Cloning has identified the opioid receptors as belonging to the superfamily of G-
protein coupled receptors, closely related to the somatostatin receptors (Evans et al.,
1992; Kieffer et al., 1992). Extensive structural conformity exists between the three
opioid receptor cDNA clones and the predicted proteins are of similar size with a 50-
60% homology at the amino acid level.
Table 5.1 Endogenous opioids and their preferred receptors.
Precursor Endogenous peptide Receptors Reference
Pro¬
opiomelanocortin























Corbett et al, 1993
Pro-nociceptin/OFQ Nociceptin ORL,
receptor







Zadina et al, 1997
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All three receptors share consensus N-linked glycosylation sites at the highly
divergent N-terminal extracellular domain. The transmembrane domains share broad
similarities between receptors especially in the second and third membrane spanning
region whereas the C-terminal intracellular domains are quite different. Like other
peptidergic receptors, the opioid receptors have a small (approximately 25 amino
acid residues) third intracellular loop involved in G-protein binding. The
extracellular loops show a lesser degree of homology between receptors compared to
the intracellular loops which suggests membrane receptors that exhibit varied ligand
binding properties but convergent intracellular signaling mechanisms.
In mammals, the endogenous opioid peptides are mostly derived from four
precursors and tend to be active at more than one receptor subtype (see Table 5.1).
5.1.2. p-Opioid Receptor Subtypes
Two splice variants of the MOR-1 gene, encoding the p-opioid receptor, have been
cloned, one variant having 8 amino acid residues missing from the C-terminal
domain. The variants exhibit differences in agonist-induced receptor internalisation
but show little variation in ligand binding (Koch et al., 1998). Two
pharmacologically defined subtypes of p-opioid receptor, pi and P2, have been
postulated on the basis of biphasic radioligand binding characteristics of p, 8 and k
agonists (Wolozin & Pasternak, 1981). Very high affinity binding of each subtype
agonist to the putative pi-receptor was observed as well as a high affinity binding to
the appropriate receptor (p, 8 or k). Naloxone blocked this very high affinity binding
site. More recent studies have failed to confirm this classification. There is evidence,
however, for a novel form of the p-opioid receptor that binds analogues of morphine
but not morphine itself. The ability of these morphine analogues to bind to this novel
site is not blocked by 8 and k analogues (Rossi et al., 1996). Further evidence comes
from the MOR-1 knockout mouse which still shows antinociception by morphine
analogues but not morphine (Schuller et al., 1999). Two exons exist in MOR-1. The
MOR-1 knockout mouse has a mutation in exon 1. However, another MOR-1
knockout mouse with a disruption to exon 2 was engineered displayed a lack of
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antinociception by morphine or any of its analogues. This points toward an
alternative transcript of exon 1 of the MOR-1 gene to produce a different p-receptor.
5.1.3. 5-Opioid Receptor Subtypes
The DOR-1 gene encodes for the 8-receptor and, based on pharmacological
investigations, two overlapping subdivisions of the receptor have been proposed
(81/82 and Scx/8cnx). The best evidence for a 81/82 subclassification comes from in
vivo supraspinal antinociception experiments. It was found that the antinociceptive
activity of two different 8-agonists was blocked by two different antagonists (Jiang et
al., 1991; Sofuoglu et al., 1993) and showed no cross tolerance (Mattia et al., 1991).
8-opioid receptor-mediated inhibition of adenylate cyclase performed on rat brain
membranes reinforced the 81/82 classification due to differential antagonism of 8-
agonists (Buzas et al., 1994). However, studies on NG108-15 cells (Ho et al., 1997)
or the human neuroblastoma cell line, SH-SY5Y (Connor et al., 1997) have failed to
find functional evidence for 8-receptor subtypes. The pharmacological properties of
the cloned DOR-1 receptor show little evidence of the 81/82 subdivision.
Alternatively, Scx was hypothesised to form a complex with p or K-receptors whilst
Sncx did not. The evidence for this came from the observation that sub-antinociceptive
doses of agonists at the 8CX receptor potentiated p-receptor mediated analgesia
whereas higher doses acted at the 8nCx receptor producing analgesia in its own right
(Rothman et al., 1993). Radioligand binding studies have furthered this classification
of the 8nCx receptor into S(ncx-i) and 8(ncx-2), although more recently it has been
suggested that the S(ncx-i) receptor is synonymous with the 81-receptor and 8CX
receptor the same as the 82 receptor (Xu et al., 1993).
5.1.4. K-Opioid Receptor Subtypes
Due to the poor selectivity of K-agonists, receptor subtype identification is more
tenuous than those proposed for p- and 8-opioid receptor. [3H]-ethylketocyclazocine
binding in guinea-pig spinal cord demonstrated an heterogeneous population of high-
affinity binding sites leading to the first proposal for K)-and K2-sites distinguished by
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their sensitivity to DADLE (Attali et al., 1982). Later, using the specific k-opioid
agonist, U-69593, the K1/K2 subdivision was affirmed (Zukin et al., 1988).
A further subclassification of the ki-site came about when it was shown that
dynorphin B and a-neo dynorphin, which both preferentially bind to the proposed
Kib subtype, displaced [3H]-U-69,593 binding in guinea pig brain (Clark et al., 1989).
It has also been suggested that a U-50,488 insensitive, k3-site, is present and is
postulated to be the receptor mediating the antinociceptive effect of nalorphine (Paul
et al., 1991). The argument for the subdivision of the Ki receptor has been
strengthened by the complex binding of [3H]-U69,593 in mouse brain (Lai et al.,
1994). k2 has also been classified into k2a and k2b (Rothman et al., 1990), the k2b-site
having a higher affinity for (3-endorphin and DADLE. Further subdivisions have
been demonstrated in the guinea pig spinal cord (Ni et al., 1995).
Although binding studies have classified a plethora of k-opioid receptor subtypes,
there is little functional pharmacological evidence to support these findings, a
problem attributed to the lack of subtype specific antagonists available. Also, one
gene each has been identified for the opioid receptor subtypes, k, 8 and p but it is
suggested that the sub-subtypes could be formed by post-translational modifications
or from the interactions of the gene products with associated proteins such as
RAMPs (McLatchie et al., 1998).
5.1.5. Effector Systems
All of the opioid receptors belong to the Gj/G0-coupled superfamily of receptors with
no observed interaction with Gs and Gq G-proteins. Initially it was thought that only
8 and p opioid receptors acted via Gj/0to inhibit adenylate cyclase, activate an
inwardly rectifying potassium conductance and also inhibit voltage-dependent
calcium conductances (VDCCs) whereas k receptors only acted via the latter
mechanism. However, recent evidence has demonstrated that k receptors, in some
cell types, also act via an inwardly rectifying potassium channel (Grudt & Williams,
1993).
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Although it appears that there is convergent signaling of the same downstream
effectors, the heterogeneity of G-Protein subunits which can combine to form
heteromers allows for subtle differences in downstream effector targets. Besides the
direct G-protein (3y or a subunit-mediated cellular response to opioid receptor
activation, there are a number of responses with unknown intermediate mechanisms
including the activation of PLA2, PLCP, MAPkinase.
5.1.5. Opioid receptors in the hippocampus
Histological evidence for the presence of opioid receptors in the hippocampus comes
from several lines of investigation. The majority of opioid binding sites
(approximately 80%) appear to be either p- or 8-receptors (Chang et al., 1981).
Autoradiographical studies demonstrated that high densities of p-receptor binding
was evident in the CA1-3 cell body region and stratum oriens with lower densities of
S-receptors showing a similar distribution (Crain et al., 1986). This distribution
pattern was confirmed by mRNA in situ hybridisation (Mansour et al., 1994). 8-
receptor mRNA was also identified in the granule cells of the dentate gyrus, p-
receptor mRNA was observed in lesser amounts with the exception of certain large
cells, expressing high amounts ofmRNA, scattered throughout the stratum oriens,
pyramidale and radiatum. 8 and p-receptor mRNA is found mainly in the dorsal
hippocampus whilst K-receptor mRNA was restricted to the temporal hippocampus
and localised in the stratum radiatum.
The 8-receptor has been examined in greater detail using immunocytochemistry
(Commons & Milner, 1997). This determined that 8-receptors were present on many
interneurons and non-principal cells, particularly in the stratum oriens, with little
staining of CA1-3 pyramidal cells. Double-staining techniques localised the 8-
receptor with GABA interneurons containing somatostatin. Electron microscopy
localised the receptor to the dendrites and spines of pyramidal cells at or near
postsynaptic densities as well as on a heterogeneous population of axon terminals
and astrocytes. This indicates multiple sites of action of the S-opioid receptor on a
range of cell types, p-receptors have been shown to co-localise with the 8-receptor
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and GABA (Bausch & Chavkin, 1995) and the GABA receptor in the hippocampus
and dorsal raphe (Kalyuzhny et al., 1997) suggesting a similarity of distribution of
the two subtypes of opioid receptor.
It is generally accepted that opioid receptor activation in the CNS leads to activation
of Gj/o which results in an inhibitory effect on neurons by decreasing adenylate
cylcase activity, inhibiting VDCCs (Childers, 1993; Moises et al., 1994) as well as
activating an inwardly rectifying K+ current (Gjrk) causes cell hyperpolarisation
(Williams et al., 1982; Madison & Nicoll, 1988) and an inhibition of a
hyperpolarisation-activated cation conductance (/h) (Svoboda & Lupica, 1998) also
resulting in cell hyperpolarisation. In the hippocampus, pyramidal cell
neurotransmission is enhanced by opioid receptor activation, an effect that can be
explained by the inhibition of local inhibitory GABAergic interneurons which results
in a disinhibition of the pyramidal cells (Zieglgansberger et al., 1979; Lee et al.,
1980; Lupica & Dunwiddie, 1991). Recent studies demonstrated that activation of p-
opioid receptors inhibit a subclass of interneurons that terminate on pyramidal cell
bodies whereas 5-opioid receptor activation inhibits interneurons that terminate in
the dendritic region of the pyramidal cell (Svoboda et al., 1999) suggesting different
sites at which modulation of principal neuron excitatory neurotransmission may
occur, p-opioid receptor activation may increase signal output whilst 5-receptor
activation may amplify afferent signaling to the pyramidal cell dendrites.
Due to its excitatory effects in the hippocampus, the opioidergic system was
examined for a potential role in learning and memory. Dynorphin, injected into the
hippocampus, was shown to act as a reinforcer of operant conditioning in
behavioural tests (Stevens et al., 1991). In addition, endogenous opioids are only
released upon high frequency stimulation (>10 Hz) (Wagner et al., 1990). It was
therefore argued that opioids might play a role in LTP formation, possibly by
inhibiting GABA release. This was confirmed by the inhibition of LTP by naloxone
(Derrick & Martinez, 1994) at synapses of the CA3 region and dentate gyrus.
However contradictory evidence showed no such blockade of mossy fibre LTP
(Weisskopf et al., 1993; Salin et al., 1995). This may be, in part, due to the complex
circuitry of the CA3 region. Using intracellular voltage-clamp recordings of
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characterised synaptic responses it was shown that opioid receptor antagonism does
inhibit LTP formation at mossy fibre-CA3 pyramidal cell synapses (Williams &
Johnston, 1996).
The septohippocampal cholinergic projection is also implicated in memory
processing and could also be a site of action for endogenous opioids. Initial evidence
showed that activation of p-receptors resulted in a decrease of ACh release (Ennis &
Wyllie, 1984). However, various responses to different opioid receptor subtypes have
been reported in different tissues and/or species. For example, activation of K-opioid
receptors decreases ACh release in the rabbit hippocampus (Jackisch et al., 1986)
and guinea pig cortex (Siniscalchi & Bianchi, 1988) but not in rat striatum (Mulder et
al., 1984). In addition, it was shown that only p-opioid receptor activation caused a
decrease in high K+ evoked ACh release (Lapchak et al., 1989) in the rat
hippocampus suggesting a potential inhibitory role for opioids in mnemonic
processing. However, dynorphin A, an endogenous K-agonist which demonstrated no
effect on ACh release, blocked galanin-induced inhibition of ACh release and
reduced the associated impairment of learning and memory in the rat (Hiramatsu et
al., 1996). However, K-agonism did not enhance memory acquisition in the normal
rat.
These reports demonstrate that the opioid system has a role to play in learning and
memory and, specifically, which receptor subtypes may modulate these processes by
regulating cholinergic transmission in the hippocampus. However, to date there has
been no studies that have directly examined the consequences of opioid receptor
activation on synaptic responses mediated by cholinergic afferents in the
hippocampus. Here we have examined the effect of a range of opioid agonists on the
mAChR-mediated slow EPSP in the rat hippocampus.
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5.2. Results
I have shown in previous chapters that cholinergic neurotransmission in the brain is
subject to regulation by adenosine Ai heteroreceptors. By comparison to amino acid-
mediated synaptic transmission it is likely that other receptors also modulate the
EPSPm. For the reasons described in the introduction of this chapter we chose to
investigate opioid receptors since these are known to couple to G i/0 and can inhibit
the release of transmitters such as GABA.
In contrast to the inhibition of the EPSPM by adenosine Ai receptor activation,
DAGO (Zajac et al., 1990) (1 pM), an opioid receptor agonist of moderate
selectivity for the p subtype, produced an enhancement of the EPSPM (208±35% of
control, n=4) within 8 min of being applied (fig. 5.1). The opioid receptor antagonist,
naloxone (Zajac et al., 1990) (5 pM), fully and rapidly reversed this excitatory effect
(99±8% of control, n-3).
As DAGO does not possess high specificity for the p subtypes of the opioid receptor
and since numerous reports suggest different roles for different opioid receptor
subtypes in the regulation of ACh, more subtype specific agonists were tested. 100
nM Etonitazene (May et al., 1999), a potent p-opioid receptor agonist produced a
comparable enhancement of the EPSPm to that of DAGO (186±35% of control, n-3).
In contrast, 1 pM U-50488 (Narita et al., 1999), a K-opioid receptor agonist, had little
effect on the EPSPm (103±11% of control; n-5). Similarly, the 8-opioid receptor
agonist, DTLET (Zajac et al., 1990), had no effect on the EPSPm at 1 pM (109116%
of control, n=5) (fig. 5.2). None of these agonists produced any changes in cell input
resistance, membrane potential or spike frequency adaptation to a depolarising
current step. These data suggest that p-opioid receptor activation alone causes an
enhancement of the EPSPm and that the K- and 8-opioid receptor subtypes appear
not to be majorly involved in the modulation of muscarinic ACh receptor-mediated
synaptic responses in the rat hippocampus (fig. 5.3). To establish whether the effect
of DAGO was mediated pre- or post-synaptically, the effect of DAGO on carbachol
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Figure 5.1 Opioid receptor activation causes an enhancement of the EPSPm-
A shows intracellular current clamp recordings of EPSPMs in control media (left), during 1 pM DAGO
application (middle) and after subsequent addition of 5 pM Naloxone. Cell membrane potentials were
maintained at -67 mV throughout the experiment. Filled triangles denote the position of the stimulus
(10 @ 20Hz). B illustrates the effect of DAGO and naloxone on the EPSPm peak amplitude over time.
The bar graph (right) demonstrates that DAGO caused a mean enhancement of the EPSPM peak
amplitude in 4 experiments (Control vs DAGO, p<0.05). Naloxone fully reversed this mean
enhancement in 2 experiments (Control vs DAGO+Naloxone, p>0.05). Values are means ± S.E.M
represented by the error bars. The input resistance of the cell was 40 MO, the resting membrane
potential was -63 mV and the spike height was greater than 0 mV.
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induced cell depolarisation was assessed. 5 pM DAGO had little effect on the
magnitude of depolarisation that was induced by carbachol (fig. 5.4A). Likewise, the
mAChR-induced loss of spike frequency adaptation and increase in input resistance
were unaffected by opioid receptor activation (fig. 5.45&C). This evidence points
towards a presynaptic locus for the action of DAGO on EPSPm generation. Close
analysis of the opioid receptor enhancement of the EPSPM revealed that opioid
receptor activation predominantly increases the peak amplitude of the EPSPm with
little effect on the duration of depolarisation (fig. 5.5). This is in contrast to the
effects of the potassium channel blocker 4-AP and the AChE inhibitor, eserine,
which produced enhancements of both the peak amplitude and the duration of the
EPSPm.
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Figure 5.2 p-opioid receptor activation alone enhances the EPSPm-
Intracellular current clamp recordings showing the effect of 100 nM Etonitazene (a), 1 pM U-50488
(b) and 1 pM DTLET (c) on the EPSPM. . Cell membrane potentials were maintained between -66 to
69 mV throughout the experiments. Filled triangles denote the position of the stimulus (10 @ 20Hz).
The input resistance of the cells ranged from 33-39 MQ, the resting membrane potential ranged from
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Figure 5.3 p-opioid receptor activation causes a mean enhancement of the EPSPm-
A bar graph to show the mean effect of three opioid receptor subtype selective agonists, 100 nM
etonitazene (ETZ), 1 pM U-50488 and 1 pM DTLET, on the peak amplitude of the EPSPM in three,
five and five experiments respectively (Control vs Etonitazene, p<0.05). Values are means ± S.E.M
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Figure 5.4 Effects of DAGO on spike frequency adaptation and carbachol-induced
depolarisation of CA1 pyramidal cells.
A shows chart recordings of the membrane potential (Vm) of a CA1 pyramidal neuron and its response
to depolarising and hyperpolarising current steps. On application of 3 pM carbachol (CCh) for 1
minute, a large, slow depolarisation of Vm, accompanied by spontaneous action potential firing, was
observed. Note the increase in input resistance also. These effects of CCh were unchanged in the
presence of 5 pM DAGO (right). B illustrates the response of a cell, held at a control membrane
potential, to a depolarising current step in the absence (top left) and presence of carbachol (top right).
This is repeated (bottom traces) in the presence of 5 pM DAGO. Spike frequency adaptation, is
unchanged by 5 pM DAGO. C shows the response of the cell membrane potential, current clamped
back to a control membrane potential, to a hyperpolarising current step in the absence and presence of
carbachol (left) and in the presence of DAGO in the presence of and absence of carbachol (right). The
input resistance of the cell was 31 MQ, the resting membrane potential was -64 mV and the spike
height was greater than 0 mV. Apparent variations in spike height is due to the sampling rate (488 ps
sampling interval).
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Figure 5.5 A comparison of the enhancement of the EPSPm produced by 4-AP, eserine
and DAGO.
Intracellular current clamp recordings illustrating EPSPmS in control media (left) and in the presence
of 1 pM DAGO (top right), 100 pM 4-AP (middle right) and 1 pM eserine (bottom right). Note the
enhancement produced by DAGO appears to be limited to an increase in peak amplitude and not
duration. Cells were held between -65 and -68 mV. The fdled triangles denote the position of the
stimulus (10@20Hz). The input resistance of the cells ranged between 30-40 MQ, the resting
membrane potential ranged between -65 to -68 mV and the spike height was greater than 0 mV.
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5.3. Discussion
The evidence presented in this chapter suggests that opioid receptor activation
enhances cholinergic synaptic responses. Further investigation of this enhancement
pointed towards presynaptic jx-opioid receptor involvement.
In situ hybridisation and autoradiographical studies provide good evidence for the
presence of both |X and 5 opioid receptor within the stratum oriens of the
hippocampus (Chang et al, 1981; Crain et al., 1986; Mansour et al., 1994). A
similarity of distribution of both 8 and |X opioid receptors has been suggested
(Bausch & Chavkin, 1995; Kalyuzhny et al., 1997) localising these receptors to
dendrites and spines of pyramidal neurons as well as to a heterogeneous population
of axon terminals. This evidence supports a presynaptic role for the jx-opioid receptor
in cholinergic neurotransmission in the hippocampus.
Although receptor classification is somewhat unclear for opioid receptors in general,
there does appear to be reasonable evidence for the existence of two subtypes of |x-
opioid receptor. However, the pharmacology of these two binding sites is
controversial and, as such, it is beyond the boundaries of this study to implicate a
specific |X-opioid receptor subtype in the enhancement of cholinergic
neurotransmission.
The activation of |X-opioid receptors has been reported to directly activate the G-
protein, Gj/0, and ultimately resulting in the activation of a variety of intracellular
messengers and effector mechanisms. However, it is generally accepted that these
receptors mediate an inhibitory effect by decreasing neurotransmitter release and cell
hyperpolarisation. In the hippocampus, evidence suggests that opioid receptors
inhibit local inhibitory GABA interneurons and, thereby, result in increased
excitatory amino acid-mediated synaptic transmission at pyramidal cell synapses.
The experiments presented in this chapter are conducted in the presence of GABAa
and GABAb antagonists thus suggesting that the enhancement of cholinergic
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responses is not due to disinhibition of GABAergic interneurons acting to restrict
cholinergic synapses.
If opioid receptor activation produces mainly inhibitory effects upon
neurotransmission in the hippocampus, then how can it be that cholinergic
neurotransmission is enhanced? One possibility is that opioid receptor systems
interact with other receptor systems that act to tonically inhibit cholinergic release.
As such, the adenosine A] or the galanin receptor systems may be inhibited by opioid
receptor activation. Interestingly, all these receptor types act via Gj/0and constant
activation of opioid receptors may possibly utilise G-proteins that ordinarily are
mediating adenosine A]R inhibition or possibly galanin inhibition. Thus, the removal
of adenosine AjR or galanin receptor-mediated inhibition may mask any inhibition
resulting from opioid receptor activation. It is also possible that opioid receptor
activation results in the inactivation of adenosine or galanin receptors without itself
having an inhibitory influence. These theories depend upon the tonic activation of Ai
and galanin receptors or, alternatively, co-activation of these receptors by co-released
adenosine or galanin. Laboratory observations using the adenosine Ai receptor
antagonist DPCPX (Morton & Davies, 1997), suggest a tonic inhibition of the
EPSPm whereas no such tonicity has been tested using galanin receptor antagonists.
Obvious experiments would be to compare adenosine receptor- or galanin receptor-
mediated inhibition of cholinergic responses in the presence and absence of an opioid
agonist such as DAGO. Alternatively, the enhancement of cholinergic responses by
opioid agonists could be compared in the presence and absence of antagonists of
adenosine Ai or galanin receptors.
Another possible explanation for opioid receptor-mediated enhancement of
cholinergic neurotransmission would be an inhibition of acetyl cholinesterase
(AChE) thus increasing the amount of ACh present in the synaptic cleft. However,
on comparison of the action of eserine, a cholinesterase inhibitor, with the actions of
opioid receptor agonists, it is fair to say that each pharmacological agent produces a
different type of enhancement of the EPSPM. Thus, whereas eserine causes an
increase in peak amplitude and duration of the cholinergic response, opioid receptor
activation appears to increase the peak amplitude without affecting the duration of
response. This tentatively suggests that the opioid agonists used in these experiments
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do not exert their effect by cholinesterase inhibition. To confirm this supposition, a
good experiment to perform would be to use ACh to depolarise the cell in the
presence and absence of DAGO. Unlike carbachol, ACh is broken down by AChE
and should DAGO inhibit AChE activity it should increase the magnitude and
duration of the ACh-induced response. It would also be useful to examine the
enhancement of the EPSPM by opioid agonists in the absence and presence of an
AChE inhibitor.
Like AChE inhibition, the blockade of 4-AP sensitive K+ channels resulted in an
increased peak amplitude and duration of the EPSPm contrasting with the
enhancement observed in the presence of opioid receptor agonists. Therefore, it is
unlikely, but not impossible, that opioid receptors are acting via 4-AP sensitive K+ to
enhance the EPSPm for example by allowing an increase in presynaptic Ca2+influx.
Evidence does exist to contradict the enhancement of cholinergic transmission in the
hippocampus observed here. Thus, high K+ evoked ACh release is decreased in the
rat hippocampus by p opioid receptor (Lapchak et al., 1989). However, this method
of ACh release can not be directly compared with synaptically evoked release as
every neuron in the tissue will depolarise, en masse, releasing numerous
neurotransmitters resulting in unphysiological network activity with unpredictable
consequences.
The effect of p-opioid agonists to enhance of cholinergic transmission would be
expected to facilitate memory and learning tasks. This precise hypothesis has not
been formally tested. However, as mentioned in the introduction, it was found that K-
opioid agonists did not improve memory acquisition in the normal rat (Hiramatsu et
al., 1996) but did reverse a galanin-induced inhibition of ACh release and associated
impairment in memory and learning. This suggests opioid receptor activation does
play a role in memory and learning in so far as it can compensate for memory
deficits caused by decreased cholinergic transmission. In the present study we found
that k agonists did not themselves modulate the EPSPm. However, it would be
interesting to investigate whether they overcome the galanin-induced blockade of the
EPSPm. The fact that K-agonists do not modulate the EPSPm might also point to a
lack of endogenous galanin inhibitory tone on the EPSPm-
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Generally, endogenous opioids are released in the CNS in response to pleasurable
stimuli and are heavily implicated in mechanism of addiction but also play a part in
the pain response. It makes sense that during pleasurable experiences memory would
be facilitated, for example, teaching an animal to perform tasks by positive
reinforcement. It is also reasonable to assume that opioids released due to a pain
response would enhance memory in order to prevent the same course or action
resulting in injury. This could be equated with aversion therapy or negative
reinforcement of learning.
Therefore, in addition to the increased excitatory amino acid receptor mediated
neurotransmission caused by the inhibition of GABA intemeurons by opioids,
enhanced cholinergic transmission at septohippocampal terminals could contribute,




Modulation of Cholinergic Responses by Galanin: Is
Galanin Important in LTP Formation?
6.1. Introduction
This chapter aims to investigate the role of galanin in the hippocampus. Galanin has
been localised in the hippocampus and has been shown to modulate cholinergic
function in the rodent hippocampus. The opportunity to study the function of this
neuropeptide in a galanin knockout mouse has allowed the investigation of how
galanin affects the modulation of the cholinergic response as well as examining the
role galanin may play in LTP. As such, galanin, its receptors, and its function in
memory and learning will be reviewed in some detail.
6.1.1. General
Galanin is a peptide comprising 29 amino acids (30 in human) first isolated from the
upper small intestine of pigs (Tatemoto et al., 1983). The name is derived from the
N- and C-terminal residues, glycine and alanine respectively. The peptide is
synthesised as a preprohormone which contains a 59 amino acid C-terminal flanking
region called Galanin Message Associated Peptide (GMAP) which, so far, has no
known function (Rokaeus & Brownstein, 1986). Both galanin and GMAP appear to
belong to a new peptide family. Galanin is involved in the regulation of a variety of
physiological processes including feeding, insulin release, lactation, spinal reflex, gut
contractility, growth, learning, memory and depression (Bedecs et al., 1995; Kask et
al., 1997). Only the role of galanin in cognition will be covered in any depth within
this chapter.
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Structure-activity studies performed on the galanin peptide demonstrated that the N-
terminal 1-16 amino acids are conserved across species and this peptide fragment is
sufficient for receptor recognition (Fisone et al, 1989b). The 17-29 C-terminal
fragment is not recognised by hypothalamic, hippocampal, spinal cord or pancreatic
receptors and appears to have no biological effect. However, this fragment may be
required for galanin binding to receptors in smooth muscle (Rossowski et al., 1990)
suggesting an alternative receptor subtype to that of the neuronal and exocrine tissue.
Gali_i2 is the shortest form of galanin that demonstrates full receptor agonism but
possesses a shorter half life than Gal 1-29. Fluorescence studies suggest that the N- and
C-terminal portions of the Gali-29 polypeptide line up, via a (3 bend, to protect
sensitive bonds from proteolytic cleavage (Rigler et al., 1991).
6.1.2. Galanin Receptors
Using [l25I]-Galanin, autoradiography of brain slices has established the existence of
galanin binding sites in the cerebral cortex, amygdala, hypothalamus, thalamus, pons
and cerebellum in humans (Johard et al., 1992) and the prefrontal cortex, olfactory
bulb, amygdaloidal complex, hippocampus, stria terminalis, nucleus accumbens,
hypothalamus, thalamus and superior colliculus in the rat (Skofitsch et al., 1986;
Fisone et al., 1989a).
Logic dictates that an endogenous ligand apparent in many anatomical areas and
exerting its effects on varied physiological responses must act through multiple
receptor subtypes and/or second messenger systems. Evidence for multiple receptor
subtypes in native tissue comes from both radioligand and functional studies. For
example, Galanin binding sites with a 10-fold difference in affinity for galanin and
galanin 1-16 have been reported in the rat ventral hippocampus. (Fisone et al,
1989b). Also, there is evidence for an NH2-terminal preferring receptor in the rat
dorsal hippocampus, neocortex and neostriatum (Hedlund et al., 1992).
Native galanin receptors have been reported to activate several second messenger
pathways resulting in numerous cellular responses. Some examples include the
inhibition of cAMP production (Amiranoff et al., 1991), inhibition of L-type and N-
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type Ca2+ channels (Kalkbrenner et al., 1995; Palazzi et al., 1991); the activation of
ATP-sensitive K+ channels (Dunne et al., 1989) and inwardly rectifying K+ channels
such as GIRK-1 (Philipson et al., 1995), as well as the stimulation of phosphoinositol
breakdown, calcium mobilisation (Sethi & Rozengurt, 1991), phospholipase A2
(Mulvaney & Parsons, 1995) and MAP kinase (Seufferlein & Rozengurt, 1996).
It is clear that there exists a complexity of physiological responses to galanin binding
but also differences in the functional pharmacology of such responses. Galanin
reduced forskolin-stimulated cAMP with 250-fold greater potency in rat ventral
hippocampus versus dorsal hippocampus suggesting either receptor diversity or
differences in signal transduction pathways (Valkna et al., 1995). Other possible
explanations could be differences in the number of functioning receptors or the
efficiency of receptor/effector coupling in the different regions of the hippocampus.
However, the complex binding and functional profiles for galanin and other galanin-
related peptides such as M35, M32 and C7 with a spectrum of antagonist/agonist
activity are consistent with the existence of multiple receptor subtypes.
To date, three genes encoding galanin receptors have been cloned all of which
possess significant homology to the rhodopsin family of G-protein coupled receptors
including seven predicted hydrophobic membrane-spanning domains.
The cDNA for the human GALR1 encodes a protein of 349 amino acids (Probst et
al., 1992) sharing a high degree of homology to the rat GALR1 receptor ( Burgevin
et al., 1995) and the mouse GALR1 homolog (Wang et al., 1997). The mRNA
distribution of rat GALR1, determined by in situ hybridisation, localised peptide
expression to the brain including the hypothalamus, amygdala, ventral hippocampus,
thalamus, brain stem (medulla oblongata, locus ceruleus, and lateral parabrachial
nucleus) and spinal cord (dorsal horn) (Parker et al., 1995; Gustafson et al., 1996;
1
Burgevin et al., 1995) which appears to be in good agreement with [ I]-galanin
binding. No expression was detected in peripheral tissue.
Upon agonist binding, cloned GALR1 receptors, expressed in CHO cells, mediated a
reduction of forskolin-stimulated cAMP (Parker et al., 1995; Burgevin et al., 1995).
This reduction of cAMP was blocked by pertussis toxin (Parker et al., 1995; Smith et
al., 1997) supporting the involvement of Gj/0-type G-proteins. Also, it has been
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reported that GALR1 activated an inwardly rectifying K+ current when GIRKs 1 and
4 were cotransfected into Xenopus oocytes (Smith et al., 1998). Taken together, it
appears likely that GALR1 may act broadly to inhibit neurotransmitter/hormone
release.
GALR2 displays a low degree of amino acid identity with rat and human GALR1
(Smith et al., 1997; Howard et al., 1997; Wang et al., 1997b). Rat GALR2 cDNA
encodes a protein of 372 amino acids and shares 85% sequence identity with human
GALR2 which contains an extra 15 amino acids on the C-terminus. Unlike GALR1,
GALR2 appears to be transcribed in all tissues examined including brain
(hypothalamus, hippocampus, amygdala, and pyriform cortex) and peripheral tissues
such the vas deferens, prostate, uterus, ovary, stomach, large intestine, dorsal root
ganglia and pancreatic cells (Smith et al., 1997; Sten Shi et al., 1997; Howard et al.,
1997; Wang et al., 1997b).
GALR2 activation appears to produce a variety of cellular responses such as
pertussis toxin-resistant inositol phospholipid hydrolysis, calcium mobilisation
(Smith et al., 1997) and arachidonic acid efflux (Walker et al., 1997) in CHO cells as
well as activating Ca2+-dependent CI" channels in Xenopus oocytes. GALR2
activation did not inhibit forskolin-stimulated cAMP (Smith et al., 1997) in CHO
cells which, taken together, suggest a primary coupling to G-proteins Gq/n activating
phospholipase C.
The GALR3 gene was recently described by two groups (Smith et al., 1998; Wang et
al, 1997c) and is reported by Smith and coworkers to encode a protein of 370 amino
acids sharing a sequence identity of 35 % with rat GALR1 and 52% with rat GALR2.
The human GALR3 receptor is predicted to contain 368 amino acids with 90%
identity to rat GALR3. 83 amino acids are conserved across the three subtypes of
galanin receptor. mRNA transcripts have been detected in the heart, spleen and testis.
However, low levels of mRNA were detected in discrete regions of the rat CNS with
highest levels in the hypothalamus, lower levels in the olfactory bulb, cerebral
cortex, medulla oblongata, caudate putamen, cerebellum and spinal cord, and no
significant detection in hippocampus or substantia nigra. Both rat and human
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GALR3 share a unique consensus phosphorylation site in the third intracellular loop
that may be implicated in G-protein-coupling and receptor function.
GALR3 activation in Xenopus oocytes open GIRKs in response to applied galanin
(Smith et al., 1998). This effect was blocked by pertussis toxin suggesting receptor
coupling to Gj/o (Yao et al., 1998).
6.1.3. Galanin Involvement in Memory Function
Galanin was first hypothesised to act as an inhibitory neurotransmitter co-released
with ACh due to galanin immunoreactivity being present within 50-70% of
cholinergic neurons in the medial septal-diagonal band complex of colchicine-treated
rats (Melander et al., 1985). Further in vivo and in vitro studies strengthened this idea
that galanin acted on presynaptic cholinergic terminals in the rat ventral
hippocampus to inhibit release of ACh and acted at postsynaptic sites to antagonise
the actions of ACh (Fisone et al., 1987; Hokfelt et al., 1987, Crawley et al., 1990).
Central administration of galanin results in performance deficits on a wide variety of
learning and memory tasks in rodents. These deficits have been reported on delayed
non-matching to position in rats (Robinson & Crawley, 1994; McDonald & Crawley,
1996), T-maze delayed alternation (Mastropaolo et al., 1988), star-burst radial maze
(Malin et al., 1992), passive avoidance in mice (Ukai et al., 1995), and Morris water
maze in rats (Sundstrom et al, 1988). This behavioural effect is consistent with the
idea that galanin inhibits cholinergic memory processes. Treatment with a galanin
receptor antagonist alone facilitates performance in the Morris water maze (Ogren et
al., 1992) suggesting that endogenous galanin may tonically inhibit cholinergic
transmission.
Recently, it has been questioned to what extent galanin is co-secreted by cholinergic
neurons. Immunolabelling in colchicine-treated rats may have overestimated the
levels of coexistence. Using colchicine untreated rats and double in situ
hybridisation, it was discovered that relatively few ventral hippocampal projecting
neurons in the cholinergic basal forebrain expressed galanin mRNA. Basal forebrain
neurons projecting to the dorsal hippocampus showed the greatest amount of mRNA
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expression (Gaykema et al., 1990; Miller et al., 1998) although still not as much as
previously thought. This evidence suggests that galanin is not widely co-released
with ACh from cholinergic terminals in the ventral hippocampus and galaninergic
fibres may arise from other brain regions such as the locus ceruleus (Melander et al.,
1986).
The ventral hippocampus expresses high levels of GALR1 mRNA (Burgevin et al.,
1995) and GALR2 is mainly expressed in the granule cell layer of the dentate gyrus
in the dorsal hippocampus (Fathi et al., 1997). Galanin inhibition of evoked [3H]-
ACh release was only apparent in the ventral, not dorsal, hippocampus (Fisone et al.,
1987, 1991). This suggests that the inhibitory effects of galanin on ACh release are
primarily mediated through GALR1 in the rat ventral hippocampus. In contrast, it
has been reported that [H]-ACh release in the dorsal hippocampus is increased by
galanin perfusion in the awake rat (Schott et al., 1998).
Studies performed on the in vitro hippocampal slice preparation showed a galanin
receptor-mediated inhibition of long-term potentiation at the Schaffer-collateral-CAl
synapses in the guinea pig hippocampus (Sakurai et al., 1996) although there was no
effect in the operant delayed non-matching to sample task, a test of short term
memory, in the equivalent region of the rat hippocampus (Robinson & Crawley,
1994). There is no evidence to suggest that galanin causes cognitive impairment in
the dorsal hippocampus.
Recent studies from our laboratory have demonstrated that galanin inhibits LTP, but
not LTD, induced by theta-burst or tetanic stimulation in the apical and basal
dendrites of CA1 pyramidal cells in the rat ventral hippocampus (Coumis & Davies,
1999). Galanin was shown not to affect NMDA receptor- or metabotropic glutamate
receptor-mediated responses implying that the effect of galanin upon LTP is
downstream of these receptors. It is suggested that galanin may be acting via
inhibition of a kinase, possibly protein kinase C.
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6.1.4. Electrophysiological Effects of Galanin on Hippocampal Neurons
Previous studies have demonstrated that bath applied galanin resulted in a slight
hyperpolarisation of the membrane potential in CA1 pyramidal cells without any
changes in input resistance (Dutar et al., 1989b). Galanin did have an effect on
electrically evoked responses. Excitatory amino acid mediated neurotransmission at
Schaffer collateral-CAl synapses was slightly reduced by galanin. However, it was
the inhibition of an atropine-sensitive long lasting depolarisation by galanin that
proved of major interest. Galanin did not show any effect on responses to
exogenously applied ACh suggesting a presynaptic inhibition of galanin on ACh-
releasing nerve terminals. This result is consistent with several studies of galanin
regulation of ACh release and ACh-dependent functions in the hippocampus (Fisone
et al., 1987; Palazzi et al., 1988; Palazzi et al., 1991).
6.1.5. A Transgenic Mouse Lacking a Functional Galanin Gene
In this chapter I have had the opportunity, in conjunction with Urania Coumis, to
examine LTP and the septohippocampal cholinergic projection in hippocampal slices
from mice possessing a null mutation in the galanin gene (Wynick et al., 1998).
There is no evidence to suggest that there is any changes in galanin receptor
expression levels in the Gal"" mice due to the lack of a galanin receptor antisera that
would allow immunohistochemical analysis.
However, Ach function was examined and these mice were shown to possess fewer
cholinergic markers in the medial septum and vertical diagonal band and an increase
in Choline acetyltransferase (ChAT) activity. This implies that the remaining
cholinergic neurons have compensated for the developmental loss by upregulating
ChAT activity which is supported by the lack of behavioural deficits when mutant
mice were tested in the Morris water maze. The loss of cholinergic cells with age is a
process that has been reported in the rat (Luine et al, 1986; Armstrong et al., 1993).
There is no further age-dependent loss of cholinergic neurons in the mutant mice
suggesting that the cholinergic neurons lost with age are the same subset of neurons
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that are lost due to the galanin gene knockout. However, a decrease of ACh release
was observed in aged mutant mice, paralleled by significant deficits in performance
in the Morris water maze.
In this chapter, we have examined LTP and other parameters of basal synaptic
transmission in wt and galanin knockout mice. Also, a study of the effect of bath
applied galanin on cholinergic neurotransmission was completed in the stratum
oriens of rat slices as well as slices taken from wt and galanin deficient mice.
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6.2. Results
Initially, it was necessary to assess the effect of galanin on the EPSPm generated in
the rat hippocampus. Fig 6.1 demonstrated that galanin significantly inhibited the
peak amplitude of the EPSPm to 55 ±6% of control (/7=3; p<0.05) without affecting
spike frequency adaptation or input resistance (n=3; data not shown).
Subsequently, slices prepared from transgenic mice lacking a functional galanin gene
and their wild type littermates were used and intracellular recordings were made
from CA1 pyramidal cells. Firstly, we examined the general passive cell properties
and response to electrically-evoked glutamate and GABA-mediated synaptic
transmission (fig. 6.2). Spike frequency adaptation was not significantly affected by
the absence of functional galanin (wt, n-5; Gal'', n=7), nor was the input resistance
of the cell (wt, 49 ±5 M£2; n-5 and Gal''', 59 ±2 M£2; n-7). In addition, no
appreciable differences in the glutamate/GABA-mediated EPSP/IPSP were observed
between wt (n=5) and Gal '' mice («=7).
Electrical stimulation of the stratum oriens region of mouse hippocampal slices
produced, in CA1 pyramidal cells, a mAChR-mediated slow depolarisation which
appeared very similar to the EPSPm recorded from rat hippocampal neurons (fig.
6.3A). Both wt (/?=3) and Gal '' mice (n=4) exhibited EPSPmS. On application of 400
nM rat galanin (Dutar et al., 1989b), the peak amplitude of the EPSPm was inhibited
by 50 ±3% of control in wt mice (n=3; p<0.05). In contrast, 400 nM galanin had no
significant effect on the peak amplitude of the EPSPm in Gal '' mice (94 ±5% of
control, 77=4; p>0.05) (fig. 6.3B). A significant difference was observed in the
magnitude of inhibition that galanin exerted on the EPSPM in wt compared with Gal'
'' mice (p<0.05).
Extracellular field recordings were used to examine paired pulse facilitation and
long-term potentiation (LTP) of field excitatory postsynaptic potentials (fEPSPs) at
CA3-CA1 glutamatergic synapses in the stratum oriens. No significant difference in
PPF at interpulse intervals of 25 ms and 50 ms was observed between wt and Gal ''
mice (fig. 6.4).
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LTP induced by tetanic stimulation (100 stimuli @ 100Hz) was examined in the
CA3-CA1 synapses of both the stratum oriens and the stratum radiatum (fig. 6.5).
No difference in LTP was observed in the stratum radiatum (wt, 143 ±9 of control
(n=7); Gal~'~, 155 ±13 (n=12)). In contrast, a significant but small deficit in LTP was
observed in the stratum oriens (wt, 158 ±13 (n=8); Gal'/', 130 ±8 (n=8)). This deficit
was apparent from the onset of induction and was maintained as the LTP plateaued.
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Figure 6.1 Galanin inhibits the EPSPm in rat CA1 pyramidal cells
A (top traces) shows synaptic traces of EPSPMs from CA1 pyramidal cells held at -67 mV before
(left) and after (right) 400 nM rat galanin was applied to the slice. The filled triangles denote the
position of the stimulus (10 @ 20Hz). A (bottom traces) illustrates the voltage change of the cell in
response to a depolarising current step before (left) and after (right) the application of galanin. Note
that spike frequency adaptation of action potential firing is unaltered by galanin. Apparent variations
in spike height are due to the sampling rate (sampling interval was 488 ps). C shows a bar graph
illustrating the mean inhibition of the peak amplitude of the EPSPM by galanin in 3 experiments.
Values are mean ± S.E.M. represented by the error bars. The input resistance of the cell was 34 M£2,








Figure 6.2 Comparison of amino acid receptor-mediated neurotransmission and passive
cell properties between wild type and galanin knockout mice
A shows synaptic traces illustrating an EPSP/IPSP complex recorded from CA1 pyramidal cells from
wild type (left) and Gal"'" mouse (right) slices. The filled triangles denote the position of the stimulus
(single stimulus). B illustrates the voltage change of the cell in response to a depolarising current step
in wild type (left) and Gal"'" mice (right). Note that spike frequency adaptation of action potential
firing is unaltered by the galanin gene knockout. Apparent variations in spike height are due to the
sampling rate (sampling interval was 488 ps). Bar graph (Q shows the mean input resistance of CA1
pyramidal cells from wild type and Gal7" mouse slices in 5 and 7 experiments respectively. Values are
mean ± S.E.M. represented by the error bars. The input resistance of the cell was 30 M£2, the resting
membrane potential was -64 mV and the spike height was greater than 0 mV.
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Control 400 nM Galanin
Figure 6.3 Comparison of cholinergic responses in the CA1 pyramidal cells between wild
type and galanin knockout mice.
A shows synaptic traces of EPSPMs recorded from the CA1 pyramidal cell held between -64 and -69
mV. The top traces illustrate the EPSPM from wild type slices before (left) and after (right) the
application of 400 nM rat galanin. The bottom traces show the EPSPM from Gal"'" slices before (left)
and after (right) the application of galanin. The filled triangles denote the position of the stimulus
(single stimulation). Bar graph (B) illustrates the effect of galanin on the mean peak amplitude of the
EPSPm in wild type and Gal"'" mice in 3 and 4 experiments (wt vs Gal"'", p<0.05) respectively. Values
are mean ± S.E.M. represented by the error bars. The input resistance of the cells ranged between 30-
33 MQ, the resting membrane potential ranged between -62 to -66 mV and the spike height was
greater than 0 mV.
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Figure 6.4 PPF are not significantly altered by the galanin gene deletion
The traces in A illustrate fEPSPs recorded from CA3-CA1 synapses of hippocampal slices taken from
a transgenic mouse. The left hand trace demonstrates PPF with a 25 ms interpulse interval and the
right hand trace demonstrates PPF with a 50 ms interpulse interval. Note the facilitation of the second
response in each trace. Bar graph B shows a bar graph which plots the ratio of the second to the first
ffiPSP left hand slope for wt and Gal-/- mice at 25 and 50 ms interpulse intervals recorded from the
stratum oriens. Note that PPF is not significantly altered in Gal ' mice. Values are means ± S.E.M























































Figure 6.5 The effect of galanin gene knockout upon LTP.
A charts the potentiation of fEPSPs induced by high frequency stimulation recorded in the CA1
stratum oriens of slices from Gal'1' (open circles; n=8) and control littermate (wt) mice (closed circles;
n=8; p<0.05). B charts the potentiation of fEPSPs induced by high frequency stimulation recorded in
the CA1 stratum radiatum of slices from Gal'1' (open circles; /?=12) and control littermate (wt) mice
(closed circles; n=7; p>0.05). The baseline stimulation intensity was adjusted to evoke a fEPSP with
an amplitude equal to 50% of its maximum amplitude (without superimposed population spike) and
was not significantly different between Gal'1' and wt mice. LTP was induced by high frequency
stimulation (100 shocks at 100 Hz) at t=0. Each data point represents the average rising slope of 4-8
responses. The magnitude of LTP was measured 60 min post-tetanus. Note the diminished LTP in the
Gal'1' group. Values are means ± S.E.M represented by the error bars.
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6.3. Discussion
Here, we have demonstrated that exogenously applied galanin inhibits synaptically
evoked cholinergic responses in CA1 pyramidal cells. This result is consistent with
several reports regarding the inhibition of ACh release by galanin (Dutar et al., 1989;
Fisone et al., 1987; Palazzi et al., 1988, 1991). Thus, it has been proposed that this
effect is mediated by a presynaptic galanin receptor. Moreover, it is likely that this
effect is mediated by the G;/0 coupled GALR1 as mRNA for this receptor is apparent
in the ventral hippocampus where the inhibition of ACh release is observed. GALR2
is mainly expressed in the dentate gyrus of the dorsal hippocampus and may be
responsible for increased ACh release in the awake rat. GALR3 mRNA is not
expressed in the hippocampus.
Further investigation showed that the galanin receptor-mediated inhibition of
cholinergic responses was apparent in the mouse. In addition, mice lacking the gene
for galanin showed a reduced magnitude of inhibition by exogenously applied
galanin suggesting that cholinergic terminals are less responsive to galanin. It is
unclear whether this lack of galanin-receptor mediated inhibition of cholinergic
responses is due to decreased expression of galanin receptors as the GALR
expression levels in the galanin knockout mice have not been investigated due to the
unavailability of the immunohistochemical tools.
Furthermore, it appears that the galanin mutation does not affect glutamate or
GABAergic synaptic transmission indicating that this knockout mouse exhibits
selective modification of the cholinergic system. Therefore, it is unlikely that this
mutation is causing any major reorganisation of neuronal circuits as tyrosine kinase
knockouts do for example.
The proposed unresponsiveness of cholinergic terminals to galanin in the knockout
mice could be explained by a downregulation or inactivation of presynaptic galanin
receptors. This being the case, one might expect Gal7" mice to exhibit cholinergic
hyper-responsiveness but it is likely that any increase in ACh release, due to reduced
galanin receptor mediated inhibition, is compensated for by other mechanisms that
can inhibit ACh release or possible postsynaptic mAChR desensitisation. However,
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if increased basal cholinergic excitation of hippocampal neurons was apparent then it
may result in increased levels of learning and memory in Gal"'" mice.
To explore this hypothesis of increased memory, we examined LTP in brain slices
from wild type and transgenic Gal7" mice. Contrary to expectations, a reduction in
tetanus-induced LTP was observed in the stratum oriens, but not stratum radiatum,
of mice lacking the galanin gene. It is possible that this correlates with some kind of
alteration to the septohippocampal terminals as the greatest densities of cholinergic
terminals are observed in the stratum oriens. This result is difficult to interpret but
one explanation could be that due to a possible enhancement of the cholinergic input
or glutamatergic neurotransmission in the Gal7" mice, LTP is much closer to
saturation prior to brain removal. Consequently, LTP induced in brain slices from
Gal7" mice would appear less than LTP induced in brain slices from wild type mice.
Furthermore, LTP may be closer to saturation in the stratum oriens than in the
stratum radiatum due to the greater density of cholinergic terminals in the stratum
oriens.
However, one study using atropine to block any muscarinic AChR-mediated activity,
demonstrated no change in LTP recorded from the stratum oriens (Sokolov &
Kleschevnikov, 1995). This does not entirely rule out a role for ACh in LTP in the
stratum oriens. To mimic the putative effect of the galanin deletion in the mouse,
wild-type mice could be injected with a cholinergic agonist prior to brain removal. If
increased chronic mAChR activity decreased LTP observed in the slices, this would
help to support the theory that the absence of functional galanin results in increased
mAChR-mediated modulation of LTP.
The impaired ability of the mice to exhibit strong LTP may have behavioural
consequences in learning and memory tasks. However, no such deficit was apparent
in mutant mice compared with their wild type litter mates at this age. It is possible
that the small reduction in LTP is not detrimental to the ability of the mouse to
perform such tasks.
From this and previous studies, it is clear that galanin plays a role in memory and
learning and facilitates LTP formation. However, in this mutant mouse, the effect of
the galanin gene deletion appears ho have been compensated for by other systems,
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i.e. a reduction in the number of cholinergic terminals is accompanied by an increase
in ChAT activity, resulting in minor phenotypic manifestations (Dawson, Personal
communication). One phenotype demonstrated by these mice is a decrease in ACh
release in aged mice paralleled by significant deficits in behavioural tests. However,
the reasons for this are unclear. It would be interesting to examine LTP in these mice.
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CHAPTER 7
Other Genes Expressed in the Hippocampus that may
be Implicated in LTP
7.1. Introduction
The opportunity arose to further investigate transgenic mice that had a disrupted gene
which was found to be expressed in the hippocampus. Therefore, this chapter
explores the electrophysiology of four such transgenic mice, focussing on LTP
formation in slices obtained from these mice.
7.1.1. Transgenic Mice by p-geo Gene-trap Insertion
The galanin knockout mouse is a transgenic line that has been constructed by
identifying a gene product of interest and disrupting the function of the appropriate
gene. Another approach to investigating the molecular machinery involved in the
formation and/or maintenance of LTP is to employ a random gene-trap insertion
method to disrupt potential proteins involved in this phenomenon. This is a process
whereby a defective reporter gene, in this case lacZ P-galactosidase-neomycin
resistance fusion cassette (fi-geo) (Friedrich and Soriano, 1991; Skarnes et al., 1995)
is randomly inserted into mouse embryonic stem (ES) cells. Successful integration of
the cassette into an endogenous gene not only disrupts the function of that gene but
also supplies promoter and translation initiation signals lacking from the reporter
(Skarnes et al., 1992; Skarnes, 1993) resulting in expression of both neo (G418
resistance) and active (3-galactosidase enzyme. These ES cells are subsequently used
to generate transgenic mice by blastocyst injection.
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A major advantage of this approach is that staining for (3-galactosidase activity in
transgenic mouse tissue reveals patterns of expression of the endogenous gene
rendered dysfunctional by the reporter gene insertion. In this study it was hoped that
by looking for P-galactosidase enzyme activity, it would be possible to screen for
genes with expression restricted to the hippocampal formation. Three mutants were
observed where reporter gene activity was detected within the hippocampus. These
were named obn, kin and hpk.
7.1.2. Features of the obn Gene
X-Gal staining detected patterns of expression that coincided with the cell bodies of
pyramidal neurons of the CA1/CA3 subfields of the hippocampus. However, other
brain regions showing expression were layers II and IV of the entorhinal cortex,
para-subiculum and subiculum. Expression was also apparent in several other brain
regions, most notably in the cortex. Also, a number of organs outwith the central
nervous system displayed levels of obn expression (V. Wilson et al., 1999).
Obn was screened for homology against a human cDNA library. It was found that
there was an 89% homology at the amino acid level between obn and an unknown
human cDNA denoted B2-1 (Liu and Pohajdak, 1992). The function of this gene is
unclear. However, it does possess 42% homology with a yeast protein, SEC7,
required for intracellular protein trafficking (Julius et al., 1984; Tschopp et al.,
1984). Further domains conserved between oZw/B2-l/SEC7 are a guanine nucleotide
releasing factor and a mouse srohomology domain (SH-3). It is argued that this sub-
region is part of a Pleckstrin homology (PH) domain (Haslam et al., 1993) which
allows the protein to anchor itself to cellular membranes (Hyvonen et al., 1995) by
binding to phosphatidylinositol 4,5, bisphosphate (PIP2) (Harlan et al., 1994)
135
7.1.3. Features of the kin Gene
In contrast to obn, kin expression patterns appeared to be displaced within the cell
body layer and substantially, but not exclusively, restricted to the CA1-CA3
subfields of the hippocampus. Reporter gene activity was weakly detected in the
molecular layer of the dentate gyrus and the lateral septum as well as the amygdala
(stronger staining was observed in the interstitial nucleus), striatum and olfactory
bulb. Chromogenic staining revealed punctate expression patterns within the axo¬
dendritic fields of CA1-3. This pattern did not co-localise with glial fibrillary acidic
protein (GFAP) antibody labeling for astrocytes, thus excluding astrocytic glia as an
obvious origin of kin gene expression. In situ hybridisation confirmed the neuronal
origin of kin expression by identifying CA1-3 pyramidal cell bodies as containing (3-
geo mRNA. However, J3-geo mRNA was much more widely spread than enzyme
activity suggesting that, in many brain regions, the fusion gene is transcribed but not
translated.
Striking homology (85% at the nucleotide sequence level) was detected between kin
cDNA and one form of the alternatively spliced gene encoding a non-receptor
tyrosine kinase of the abl family, arg (Kruh et al., 1986, 1990). This argues that kin
is the mouse ortholog of arg, a kinase that has been previously described but not
regionally localised (Perego et al., 1991).
arg is a splice variant whereby an upstream exon is joined to the main body of the
transcript coding the conserved kinase domains (Shtivelman et al., 1986; Ben-Neriah
et al., 1986; Kruh et al., 1990). The upstream part of the kin fusion transcript is
homologous to the upstream arg exon coding region indicating that the kin insertion
is located between exons, thus it is feasible that the endogenous gene function has
not been disrupted in the kin mutant mice.
It has been confirmed (Wang and Kruh, 1996) that type B abl cDNA, with which kin
bears extensive N-terminal homology, is post-translationally myristoylated for
transport to the membrane. Thus, it is inferred that this modification directs transport
of the kin hybrid protein from the cell body to the axo-dendritic region of CA1-3
pyramidal neurons.
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7.1.4. Features of the hpk Gene
Hpk demonstrates a similar expression pattern to that of obn, although, restricted
more to the pyramidal cell bodies of the CA1 subfield of the hippocampus and at
lower levels of expression. Hpk is also expressed in the cortex.
There was a 98% homology (over a 40 nucleotide sequence) with the previously
described mouse G-protein coupled receptor, Epstein-Barr Inducible-1 (EBI-1)
(Schweickart et al., 1994). It is possible that the fusion protein, in hpk mice, might
lack the N-terminal signal sequence that allows insertion of the EBI-l-like protein
into the cell membrane.
7.1.5. Features of the BSP1 Gene
The serine proteases comprise a large family of endopeptidases that function in a
diverse range of physiological processes such as hemostasis, digestion, the immune
response and tissue remodeling (Neurath, 1989; Barrett, 1990). Their name is derived
from a conserved serine residue which, along with a histidine and aspartate residue,
forms the 'catalytic triad' that mediates peptide bond cleavage.
These enzymes have been extensively studied in the periphery. However, their role
in the CNS remains largely unexplored although there is evidence to suggest
important involvement in brain development and function, specifically the outgrowth
and migration of neurons. Cultured neurons overlaid with fibronectin demonstrated
regions of proteolysis located around the growth cone (Krystosek & Seeds, 1981a;
Pittman, 1985; McGuire & Seeds, 1990) suggesting a clearance of substrate is
required for neurite extension.
In support of this involvement in neural growth, other serine proteases, such as
thrombin and the plasminogen activators (t-PA and u-PA) have been held to play
roles in the adult brain. High levels of PA activity are present in migrating neural
crest cells (Valinsky & LeDourain, 1985) and migrating granule cells of the postnatal
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cerebellum (Krystosek & Seeds, 1981b). t-PA is thought to convert inactive zymogen
plasminogen to active plasmin which can degrade most of the extracellular matrix by
either direct means or by the activation of other proteolytic enzymes such as the
metalloproteases (Saksela & Rifkin, 1988)
Plasminogen-dependent proteolysis has been observed in the hippocampus and
cerebral cortex of adult brains (Soreq & Miskin, 1981; Sappino et al., 1993). In
addition, t-PA expression is upregulated following seizure, kindling and LTP in the
dentate gyrus (Qian et al., 1993) suggesting an activity dependent increase in
proteolysis. t-PA null mutant mice, however, showed no gross morphological
abnormalities of the CNS (Carmeliet et al., 1994) but showed an increased level of
GABAergic inhibition and deficits in the maintenance of long lasting (Late) LTP in
the hippocampus (Frey et al., 1996; Huang et al., 1996). These mice were also
resistant to excitatoxic insult (Tsirka et al., 1995, 1996).
Two novel serine proteases have been identified and cloned using degenerate
oligonucleotide primers designed on the conserved residue motifs surrounding the
catalytic triad of the major (chymotrypsin-type) clan of serine proteases. These gene
products were named Brain Serine Protease (BSP) 1 and 2 (Davies et al., 1998).
BSP-2 will not be dealt with in this body of work.
The BSP-1 gene encodes for an enzyme that bares greatest similarity with the trypsin
subfamily of proteases (40% sequence homology and contains the catalytic triad in
the anticipated region). The predicted polypeptide sequence exhibited a trypsin-like
cleavage site, suggesting the liberation of the active enzyme from the inactive
precursor protein. Northern blot analysis identified BSP-1 in the hippocampus only.
Furthermore, in situ hybridisation of BSP1 probes in brain sections localised the
BSP1 transcripts to the CA fields, with significant expression in the CA1 and CA3
and low-level expression in the CA2, dentate gyrus and entorhinal cortex.
BSP1 null mutant mice were consequently engineered and, due to evidence
supporting the role of serine proteases in synaptic plasticity and BSP1 expression
being restricted to the hippocampus, were examined for differences in synaptic
transmission and plasticity using in vitro extracellular recordings of fEPSPs from the
CA1 region of the hippocampus.
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7.2. Results
7.2.1. Obn Gene Knockout
Stimulation of the Schaffer/collateral commissural pathway of the hippocampus in
slices obtained from obn mice produced a field EPSP preceded by a presynaptic fibre
volley in the stratum radiatum dendritic field of the CA1 pyramidal cell. A half
maximal response was attained by adjusting the stimulus intensity. Paired pulse
stimulation with a 25 and 50 ms interpulse interval, produced facilitation of the
second fEPSP. This phenomenon is termed paired pulse facilitation (PPF). The ratio
of the rising slope of the second fEPSP to the rising slope of the first fEPSP was used
as an index of this facilitation. No significant difference (p<0.05) was observed in
PPF between wild type (1.77 0.±16 at 25 and 1.88 ±0.33 at 50 ms (»=6)) and obn
knockout mice (1.72 ±0.1 at 25 ms and 1.71 ±0.13 at 50 ms (n—1)) (fig. 7.1A) at
either a 25 ms or 50 ms interpulse interval.
Moving the recording electrode to the CA1 pyramidal cell body layer permitted the
recording of population spikes. A paired pulse protocol applied at a 15 ms interpulse
interval produced a marked depression of the second population spike such that its
amplitude was reduced by more than 50%. A ratio of peak amplitude of the second
population spike to the first population spike was used a measure of paired-pulse
depression in different slices. No significant difference was noted between wt (0.48
±0.05 (n=16)) and obn mutant mice (0.47 ±0.06 (n-6)) (fig. 1ABb).
To establish whether any of the genetic mutations affected LTP recordings from the
stratum radiatum were made and a tetanus of 100 shocks at 100 Hz was delivered to
the Schaffer/collateral commissural pathway. LTP was apparent in seven out of nine
mice tested. The potentiation immediately following tetanisation, termed Post-
Tetanic Potentiation (PTP), was unchanged between wt and obn mice (218 ±14%
(n=ll) and 232 ±41% of control in wt and obn mice respectively («=7)) (fig. 7.1C).




























Figure 7.1 The effect of obn gene disruption on basal neurotransmission and synaptic
plasticity at glutamatergic synapses in the stratum radiatum.
Aa shows extracellular recordings of field EPSPs from the apical dendritic region of CA1 pyramidal
cells evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. Filled
triangles denote the time at which the stimulus was delivered in all figures showing trace recordings.
(.Ab) The bar graph plots the ratio of the left hand slope of the second flEPSP to that of the first fEPSP
comparing wt mice with obn null mutants at 25 (grey) and 50 ms (black) interpulse intervals. Ba
shows extracellular recordings of population spikes from the CA1 pyramidal cell body layer evoked
by paired pulse stimulation of the Schaffer/collateral commissural pathway. (Bb) This bar graph plots
the ratio of the second to the first population spike peak amplitude for pooled wt and obn data at 15
ms interpulse interval. C charts the potentiation of fEPSPs induced by high frequency stimulation (100
shocks @ 100Hz) recorded in the CA1 stratum radiatum of slices from obn1' (open circles; n=7) and
control littermate (wt) mice (closed circles; n=l 1; p>0.05). The baseline stimulation intensity was
adjusted to evoke a fEPSP with an amplitude equal to 50% of its maximum amplitude (without
superimposed population spike) and was not significantly different between obn1' and wt groups. LTP
was induced by high frequency stimulation (100 shocks at 100 Hz) at t=0. Each data point represents
the average rising slope of 4-8 responses. The magnitude of LTP was measured 60 min post-tetanus.
Values are means ± S.E.M represented by the error bars.
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the field EPSP at 30 min post-tetanus was also comparable in both wt and obn mice
(148 ±4 % of control in wt (n=ll), 143 ±10% in obn (n=7)). Long-Term Potentiation
(LTP) as measured 60 min post-tetanus also showed no significant difference
between wt (153 ±5% of control (n=ll)) and obn mice (140 ±9% of control (n-1)).
7.2.2. Kin Gene Knockout
Initially, it was only possible to examine properties of synaptic transmission and LTP
in kin heterozygous mutants due to the poor survival rate of the kin homozygous
mutant mice. Paired pulse facilitation, at 25 and 50 ms interpulse intervals, was
unaffected in kin+/~ mice (1.69 ±0.08 at 25 ms, 1.66 ±0.06 at 50 ms (n=9)) compared
with wt mice (1.77 ±0.16 at 25 ms, 1.72 ±0.1 at 50 ms (n=ll)) (fig. 7.2A). Paired
pulse depression proved not to be significantly affected across a range of interpulse
intervals (25-200 ms) employed in kin+/~ mice (fig. 7.25). PTP, STP and LTP were
comparable between kin+l~ (230 ±21% of control, PTP; 152 ±9% of control, STP; 163
±13% of control, LTP (n=7)) and wt mice (218 ±14% of control, PTP; 148 ±4% of
control, STP; 153 ±5% of control, LTP (n=ll)) (fig. 7.2C).
The breeding difficulties exhibited by this transgenic mouse were eventually
overcome allowing the investigation of kin1'. As with heterozygous mice no
significant difference in paired pulse facilitation in the stratum radiatum
Schaffer/collateral commissural pathway at 25 and 50 ms interpulse intervals
(p>0.05) was observed between wild-type (1.77 ±0.16 at 25 ms, 1.72 ±0.1 at 50 ms
(n-l 1)) and homozygous kin mutants (1.87 ±0.08 at 25 ms, 1.7 ±0.02 at 50 ms
(n=7)) (fig.7.3A).
A range of interpulse intervals, from 15 ms to 200 ms, was used to assess paired
pulse depression in the CA1 pyramidal cell body layer of kin'' mice (fig. 7.35).
Depression of the second population spike in both wild type and kin ' mice was only
apparent up to an interpulse interval of 25 ms. With longer duration interpulse
intervals, facilitation of the second population spike was prevalent. There was a






















































Figure 7.2 The effect of kin heterozygous gene disruption on basal neurotransmission and
synaptic plasticity at glutamatergic synapses in the stratum radiatum
Aa shows extracellular recordings of field EPSPs from the apical dendritic region of CA1 pyramidal
cells evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. Filled
triangles denote the time at which the stimulus was delivered in all figures showing trace recordings.
(.Ab) The bar graph plots the ratio of the left hand slope of the second fEPSP to that of the first fEPSP
comparing wt mice with kin heterozygous mutants at 25 (grey) and 50 ms (black) interpulse intervals.
Ba shows extracellular recordings of population spikes from the CA1 pyramidal cell body layer
evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. (Bb) The line
graph plots the ratio of the peak amplitude of the second to that of the first population spike for pooled
wt (closed circles) and kin+,~ (open circles) data against the interpulse interval. C charts the
potentiation of fEPSPs induced by high frequency stimulation (100 shocks @ 100Hz) recorded in the
CA1 stratum radiatum of slices from kin*1' (open circles; n=l) and control littermate (wt) mice (closed
circles; n=ll; p>0.05). The baseline stimulation intensity was adjusted to evoke a fEPSP with an
amplitude equal to 50% of its maximum amplitude (without superimposed population spike) and was
not significantly different between kin1' and wt mice. LTP was induced by high frequency stimulation
(100 shocks at 100 Hz) at t=0. Each data point represents the average rising slope of 4-8 responses.
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Figure 7.3 The effect of kin homozygous gene disruption on basal neurotransmission and
synaptic plasticity at glutamatergic synapses in the stratum radiatum.
Aa shows extracellular recordings of field EPSPs from the apical dendritic region ofCA1 pyramidal
cells evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. Filled
triangles denote the time at which the stimulus was delivered in all figures showing trace recordings.
(Ab) The bar graph plots the ratio of the left hand slope of the second fEPSP to that of the first fEPSP
comparing wt mice with kin null mutants at 25 (grey) and 50 ms (black) interpulse intervals. Ba shows
extracellular recordings of population spikes from the CA1 pyramidal cell body layer evoked by
paired pulse stimulation of the Schaffer/collateral commissural pathway. (Bb) The line graph plots the
ratio of the peak amplitude of the second to that of the first population spike for pooled wt (closed
circles) and kin (open circles) data against the interpulse interval. C charts the potentiation of fEPSPs
induced by high frequency stimulation (100 shocks @ 100Hz) recorded in the CA1 stratum radiatum
of slices from kin'1' (open circles; n=l) and control littermate (wt) mice (closed circles; n=l 1; p>0.05).
The baseline stimulation intensity was adjusted to evoke a fEPSP with an amplitude equal to 50% of
its maximum amplitude (without superimposed population spike) and was not significantly different
between kin'1' and wt mice. LTP was induced by high frequency stimulation (100 shocks at 100 Hz) at
t=0. Each data point represents the average rising slope of 4-8 responses. The magnitude of LTP was
measured 60 min post-tetanus. Note the enhanced PTP in the kin'1' group. Values are means ± S.E.M
represented by the error bars.
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compared with kin'' mice (n=3). However, this proved statistically insignificant
(p>0.05 for all interpulse intervals). All mice tested demonstrated robust LTP. Short
and Long- Term Potentiation were comparable between wt (148 ±4% of control,
STP; 153 ±5% of control, LTP (n=ll)) and kin'' mice (144 ±5% of control, STP;
142 ±12% of control, LTP (n=4)). However, PTP in kin'' mice was significantly
decreased (p<0.05) (wt, 218 ±14% of control (n=ll); kin'', 142 ±12% of control
(n=4)) (fig. 7.3C).
7.2.3. Hpk Gene Knockout
Similar to obri'~ and kin~'~, hpk''' mice displayed no significant changes in paired
pulse facilitation of fEPSPs recorded from the apical dendritic field of CA1
pyramidal cells (fig. 7.4A). At a 25 ms interpulse interval, comparable levels of
facilitation were observed in wt (1.77 ±0.16 (n=5)) and hpk mutants (1.64 ±0.09
(n=9)). The same was true for an interpulse interval of 50 ms (wt, 1.72 ±0.1 {n=5);
hpk, 1.73 ±0.08 (n='9)).
Paired pulse depression of population spikes at 15 ms intervals was reduced in hpk
mice (fig. 7.45) but not significantly (wt, 0.53 ±0.06 (n=16); hpk, 0.81 ±0.11 (n=9)
(p>0.05)). At the 20-25 ms interpulse interval, the depression of the second
population spike was no longer apparent and, at longer intervals, small levels of
facilitation were evident in both wt and hpk mutants.
Out of 12 slices that were tetanised, 10 exhibited LTP. LTP in hpk mice was larger
than in wt (fig. 7.4C). Thus the magnitudes of potentiation observed in wt and hpk
mice were: during PTP (wt, 218 ±14% of control(n=l 1); hpk, 319 ±15% of control
(n=10) (p<0.05)), STP (wt, 148 ±4.3% of control(«=l 1); hpk, 185 ±15% of control
(/2=10)(p<0.05)) and LTP (wt, 153 ±4.5% of control (n=11); hpk, 196 ±17% of
control (n=10) (p<0.05)).
To further investigate this apparent increase in LTP magnitude observed in hpk null
mutants, a second group of hpk mice were studied to explore whether they exhibited




















































Figure 7.4 The effect of hpk gene disruption on basal neurotransmission and synaptic
plasticity at glutamatergic synapses in the stratum radiatum.
Aa shows extracellular recordings of field EPSPs from the apical dendritic region of CA1 pyramidal
cells evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. Filled
triangles denote the time at which the stimulus was delivered in all figures showing trace recordings.
(Ab) The bar graph plots the ratio of the second fEPSP to the first fEPSP left hand slope comparing wt
mice with hpk null mutants at 25 (grey) and 50 ms (black) interpulse intervals. Ba shows extracellular
recordings of population spikes from the CA1 pyramidal cell body layer evoked by paired pulse
stimulation of the Schaffer/collateral commissural pathway. (Bb) This line graph plots the ratio of the
second to the first population spike peak amplitude for pooled wt (closed circles) and hpk (open
circles) data against the interpulse interval. C charts the potentiation of fEPSPs induced by high
frequency stimulation (100 shocks @ 100Hz) recorded in the CA1 stratum radiatum of slices from
hpk'1' (open circles; n=7) and control littermate (wt) mice (closed circles; n=l 1; p>0.05). The baseline
stimulation intensity was adjusted to evoke a fEPSP with an amplitude equal to 50% of its maximum
amplitude (without superimposed population spike) and was not significantly different between hpk'1'
and wt mice. LTP was induced by high frequency stimulation (100 shocks at 100 Hz) at t=0. Each
data point represents the average rising slope of 4-8 responses. The magnitude of LTP was measured
60 min post-tetanus. Note the enhanced LTP in the hpk'1' group. Values are means ± S.E.M
represented by the error bars.
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Fig. 7.5A provides an example of an NMDA receptor-mediated fEPSP evoked in the
presence of 50 pM picrotoxin, 1 pM CGP-55845A and in the absence of Mg2+.
Characteristically, this response was longer in duration (approx. 100 ms) compared
to the AMPA receptor-mediated fEPSP (approx. 25 ms). An input/output curve was
generated for this response by stepping up the stimulus intensity and measuring the
peak amplitude of the resultant evoked presynaptic fibre volley and fEPSP (fig.
7.55). No differences in input/output curves for this component of glutamatergic
synaptic transmission for wt and hpk mice were observed.
7.2.4. Brain Serine Protease 1 (BSP1) Gene Knockout
To investigate the effect of disrupting the function of BSP1 on basal synaptic
transmission in the hippocampus, three parameters were examined: input/output of
fEPSPs, paired pulse facilitation of fEPSPs and paired pulse depression of population
spikes.
By increasing the amplitude of the stimulus intensity and measuring the evoked
presynaptic fibre volley (PSFV) (a measure of the number of axons and synapses
recruited by the stimulus) and field EPSP peak amplitude, an input/output curve was
constructed (fig. 7.6). At low stimulus strengths, the fEPSP amplitude increased with
increased PSFV amplitude. At higher strengths, there was little or no increase in the
fEPSP as the maximum peak amplitude of the fEPSP was reached. BSP1 mutants
(n=9) showed no difference in their input/output characteristics compared with wild-
type litter mates (n=6).
Paired pulse facilitation in the stratum radiatum was examined over a range of
interpulse intervals, from 15 to 300 ms for both wt and BSP1 null mutants.
Facilitation was observed over the entire interval range in both groups of mice.
Generally, BSP1 mice exhibited larger facilitation, however, this only proved
significant at an interpulse interval of 200 ms (wt, 1.22 ±0.06 (n=6); BSP1, 1.42 42
±0.09 (/z= 10) (p<0.05)) (fig. 7.75). As this coincided with the time interval when





























PSFV Peak Amplitude (mV)
NMDA glutamate receptor (NMDAR) mediated field EPSPs in hpk and wt
A illustrates a NMDAR-mediated field EPSP recorded from the stratum radiatum of hpk mutant mice
evoked by stimulation of the Schaffer/collateral commissural pathway in the presence of 2 pM
NBQX, 50 pM picrotoxin, 1 pM CGP 55845A and the absence of Mg2+. The filled triangle denotes
the time at which the stimulus was delivered. B shows an input/output graph plotting NMDAR-
mediated fEPSP peak amplitude against presynaptic fibre volley peak amplitude for pooled wt (closed
circles) versus hpk (open circles) data. Values are means ± S.E.M represented by the error bars.
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Figure 7.6 The disruption of the BSP1 gene has no effect on low frequency basal synaptic
transmission in the stratum radiatum.
The line graph plots the field EPSP peak amplitude against the presynaptic fibre volley peak
amplitude over a range of stimulus strengths. Closed circles denote wt and open circles denote BSP1
mutant group data. Values are means ± S.E.M represented by the error bars.
the second fEPSP of the pair were measured and expressed as a ratio of the decay
half time of the first fEPSP (fig. 7.7C). However, upon examination, no significant
difference was detected between the half times for wt (1.01 ±0.1 (n-6)) and BSP1
(0.95 ±0.08 (n=10) (p>0.05)) knockout mice. Population spikes were evoked by
stimulation of the Schaffer/collateral commissural pathway and recorded from the
CA1 pyramidal cell body layer. Two interpulse intervals for PPD were employed, 15
and 200 ms, to allow the investigation of both GABAa and GABAb (Nathan et al.,
1990; Olpe et al., 1993) neurotransmission during low frequency stimulation in BSP1
mice. Initially, the most striking observation was that slices from both wt and BSP1
mutants displayed little or no PPD at either interpulse interval (fig. 7.8B). At a 15 ms
interval, PPD was unchanged between the two groups of mice (wt, 0.97 ±0.03 (/i=6);
BSP1, 1.05±0.05 (n-9) (p>0.05)). Similarly, at 200 ms interval, PPD was no
different in BSP1 (1.07 ±0.02 (»=9)) compared to wt (1.03 ±0.05 (n=6) (p>0.05)).
Since other protease knockouts have caused changes in inhibitory tone we further
explored the possibility that the balance between synaptic excitation and inhibition
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might be altered in BSP1 mutant mice by examining the effects of repeated
stimulation (30 shocks at 1 Hz) on the population spike. Multiple population spikes,
or polyspiking, were observed during the train of stimuli. The amplitudes of the
second, third and sometimes fourth spikes were measured, summated and expressed
as a percentage of the first population spike and plotted against its position in the
train of stimuli (fig. 7.9). Throughout the entire train it was apparent that the BSP1
mutants exhibited greater amounts of polyspiking than wt mice.
I also examined whether LTP was affected by the BSP knockout. Late-LTP was
induced by using four trains of stimuli (100 shocks for 1 s) with an intertrain interval
of 5 minutes (fig. 7.10). This protocol successfully produced potentiation lasting for
4 hours at which point there was no significant difference (p<0.05) in L-LTP
between wt (136 ±15% of control, n-5) and BSPl(167 ±15% of control, n-1)
mice.
7.2.5. Examination of Activity-Dependent Gene Expression
The mutant mice used in this body of work all possess the P-galactosidase gene
which was inserted into the native gene whose function we were studying. As both
the native gene and the P-galactosidase gene are under the control of the same
promoter region, increased P-galactosidase expression can be equated with increased
native gene expression. Thus we used X-gal staining to visualise expression in
hippocampal slices. Using the K+ channel blocker, 4-AP (100 pM), to induce
spontaneous neuronal synaptic activity, we investigated the expression of obn, hpk,
kin genes. For all genes, no change in the level or pattern of expression was observed
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Figure 7.7 The effect of BSP1 gene disruption on paired pulse facilitation.
A illustrates a recording of fEPSPs from the stratum radiatum of BSP1 mutant mice, evoked by a
paired pulse stimulation of the Schaffer/collateral commissural pathway. (B) A line graph, which plots
the ratio of the second to the first fEPSP left hand slope against the interpulse interval. Note the
significant difference (p<0.05) between wt (closed circles) and BSP1 (open circles) mice at an
interpulse interval of 200 ms. Values are means ± S.E.M represented by the error bars. C shows a bar
chart measuring ratio of the second to the first fEPSP half time to decay at an interpulse interval of






Figure 7.8 The effect of BSP1 gene disruption on paired pulse responses from the CA1
pyramidal cell body layer.
A shows a recording of population spikes from the CA1 pyramidal cell body layer of BSP1 mutant
mice, evoked by paired pulse stimulation of the Schaffer/collateral commissural pathway. (B) A bar
graph that shows the ratio of the second to the first population spike peak amplitude for wt versus









Figure 7.9 BSPl-deficient mice exhibit in vitro epileptiform activity.
A Example of field potentials evoked by stimulation of the Schaffer collaterals and recorded in the
stratum pyramidale of the CA1 area. After repetitive stimulation (1 Hz for 30 s), slices from BSP1'1'
mice exhibit an increase in polyspiking (i.e. multiple population spikes, arrow) in contrast to
littermate control mice. B shows a time course of the appearance of polyspikes during repetitive
stimulation (amplitudes of the secondary spikes expressed as a percentage of the first population
spike) in slices from BSP1~'~ (open circles', n=4 animals) and from littermate control mice (closed
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Figure 7.10 The effect of BSP1 gene disruption on Late-LTP
The graph shows the fEPSP slope expressed as a percentage of control responses over time. All data
points represent 5-10 averaged fEPSPs. At time 0, 4 trains of stimulation, consisting of 100 shocks at
100 Hz separated by five minutes in between each tetanus, were delivered to the Schaffer/collateral
commissural pathway. Values are means ± S.E.M represented by the error bars. Open circles represent
wt pooled data and closed circles represent BSP1 pooled data.
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Control Post 4 hr 4-AP
Figure 7.11 Obnkin ", and hpk" mice demonstrate no change in gene expression
following 4-AP exposure.
This figure shows photographs of transgenic mouse hippocampal slices that have been stained for p-
galactosidase activity using X-gal. X-gal staining shows up as dark areas. Note that expression of the
P-galactosidase, is largely restricted to the cell body region of the CA1 subfield in hpk" mice (C) and
to the CA1 and CA3 cell body regions in obn" mice (A). Kin " mice (B) show an X-gal staining
pattern that encompasses the dendritic regions and the cell body regions of the CA fields and the
dentate gyrus. The left hand photographs demonstrate expression of the transgene in slices perfused
with control media whilst the right hand photographs demonstrate expression of the transgene
following a 4 hr perfusion of 100 jliM 4-AP. Note there is no difference in the levels or patterns of P-
galactosidase expression in these three transgenic lines.
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7.3. Discussion
The transgenes under investigation in this study were found to have homologues that,
in some cases, are characterised to a certain extent.
7.3.1. Obn
The Obn gene was found to correspond to uncharacterised cDNA denoted B2-1 (Lui
& Pohajdak, 1992). This cDNA encodes a protein that bears a strong resemblance to
the yeast protein, SEC7. SEC7 appears to be involved in transport between
functional compartments of golgi (Achstetter et al., 1988; Franzusoff & Schekman,
1989) and may be a component of non-clathrin coated vesicles that cycle to and from
the cell surface (Franzusoff et al., 1992; Kean et al., 1993). Obn also shows a
pleckstrin homology (PH) domain which is conserved between the homologs
identified. PH domains possess the ability to bind (3y subunits of G-proteins (Touhara
et al., 1994), phosphatidylinositol 4,5 bisphosphate (Harlan et al., 1994) as well as
tether the protein to cellular membranes. This argues that the obn gene encodes a
membrane associated protein with the capacity to interact with other intracellular
second messenger systems whilst such a protein might be expected to affect synaptic
plasticity because of the strong involvement of biochemical cascades in this
phenomenon. However, this gene appears to play no part in tetanus-induced LTP or
basal excitatory amino acid-mediated synaptic transmission in the hippocampus.
7.3.2. Kin
The kin gene was found to be homologous to the Abelson (aW)-related tyrosine
kinase, arg, a non-receptor tyrosine kinase. aW-deficient mice show major deficits in
their immune system and die shortly after birth (Schwartzberg et al., 1991;
Tybulewicz et al., 1991) whilst no phenotype of arg-deficient mice has been
reported.
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Initially, kin appeared to be an ideal candidate to be involved in LTP formation in the
hippocampus as other non-receptor tyrosine kinases, such as fyn, have been
implicated in LTP (Grant et al., 1992; Moon et ah, 1994; Rosenblum et al., 1996)
and src in regulating NMDA receptor function (Lancaster & Rogers, 1998) and
GABAa receptor function (Moss et al., 1995). In addition, the arg binding protein,
ArgBPl, is highly expressed in the brain.
Because of the selective transmission deficit of the heterozygous transgene,
homozygous kin mutant mice were difficult to breed. As such, we examined LTP in
the heterozygous kin mutants. All parameters tested displayed no phenotypic
differences which suggests that the functional disruption of one kin gene has no
effect upon LTP formation.
Sufficient homozygous kin mutant mice were eventually bred. These mice
demonstrated little differences in synaptic transmission and LTP formation although
there was a small decrease in post-tetanic potentiation. This was not accompanied by
a decrease in paired pulse facilitation. The implication of this finding is that the non¬
receptor tyrosine kinase, arg, does not have a direct role in tetanus-induced LTP
formation in the hippocampus.
7.3.3. Hpk
The hpk gene encodes a protein which is likely to be the mouse homolog of the
Epstein-Barr virus (EBV)-inducible G protein-coupled receptor, EBI-1. EBI-1
appears to belong to a subfamily within the G protein-coupled receptor superfamily
which also includes C-C chemokine, somatostatin, interleukin-8 (IL8) and
neuropeptide Y receptors (Birkenbach et al., 1993). Little is known about this
receptor except that its expression is upregulated in cells of the immune system by
Epstein-Barr virus (Birkenbach et al., 1993) and Herpes virus infection (Hasegawa et
al., 1994) and this is the first time it has been reported that the EBI-1 receptor is
expressed in neural tissue (Steel et al., 1998).
Whilst low frequency amino acid-mediated synaptic transmission remains intact in
the hpk mutant, high frequency stimulation produced significantly larger LTP. There
156
appeared to be no change in GABAergic neurotransmission as paired pulse
depression of population spikes was unchanged and similarly there was no obvious
presynaptic enhancement of basal release as determined by changes in paired pulse
facilitation of fEPSPs. The next obvious locus of enhancement would be a change in
NMDA receptor-mediated neurotransmission. The stimulation/response relationship
of NMDA receptor-mediated fEPSPs was unaffected by the hpk mutation.
Thus, it remains unclear how the hpk gene contributes to an inhibitory modulation of
LTP. A simple explanation would involve the EBI-1 receptor acting via a G-protein
to inhibit some part of the molecular signaling pathway that is involved in LTP
formation downstream of NMDA-receptor activation. However, the possibility that
the hpk mutation had an effect during the neural development of the mouse cannot be
unequivocally ruled out.
7.3.4. BSP1
BSP1 appears to be exclusively expressed in the hippocampus and encodes a
polypeptide that bears a resemblance to the trypsin subfamily of proteases.
Furthermore, the expression pattern of this serine protease centers around the CA1
and CA3 subfields.
Other serine proteases, such as tissue plasminogen activator (t-PA), have been
implicated in long lasting (Late) LTP (Qian et al., 1993; Frey et al., 1996; Huang et
al., 1996) where t-PA played a facilitatory role. Taken together, this evidence
suggests that BSP1 may also be involved in Late LTP.
The deletion of the BSP1 gene in mice had no effect of basal transmission properties
such as stimulation/response relationships, paired pulse facilitation of fEPSPs and
paired pulse effects on population spikes. A stimulation protocol of 4 tetani of 100
shocks for 1 sec at 5 minute intervals was used to induce Late LTP. No differences in
LTP magnitude were observed after four hours post-tetanus suggesting that the BSP1
gene product does not play a role in this form of LTP.
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One effect of the BSP1 gene deletion was observed during the repeated low
frequency (1 Hz) stimulation of population spike responses. The BSP1 null mutants
displayed a greater propensity towards polyspiking, i.e. multiple action potential
firing after a single stimulus, suggesting an increase in excitability of the CA1
pyramidal neurons. Several mechanisms may contribute to this including increased
GABAb autoinhibition and increased GABAa receptor desensitisation. In support of
this increased susceptibility toward epileptogenic activity in the hippocampus,
preliminary studies using kainic acid have shown that mice lacking the BSP1 gene
are more prone to excitatoxic insult. However, how the precise mechanisms by
which this gene contributes to regulating excitability of neurons in the hippocampus
remain unclear. It is feasible that this gene is involved in the development of the
hippocampus and although no gross morphological changes were observed between
wt and BSP1~~ mice, a difference at the ultrastructural level is possible. A follow-up
study might look at GABAergic function within the hippocampus in more detail.
7.3.5. Activity-dependent gene expression
The K+ channel blocker, 4-AP, was used to increase spontaneous firing in the
hippocampal slice. It was hypothesised that increasing neuronal activity could be
used to examine activity dependent increases in gene expression in the mutant mice.
This relied on the ability of the (3-geo gene insertion to be expressed under the same
promoter region as the native gene it had been inserted into. Upon X-gal staining for
(3-galactosidase expression, no changes in expression levels or patterns were detected
for obn, kin, hpk or BSP1 mutant mice.
The lack of changes in expression levels could be due to the indiscriminate activation
of all excitatory, inhibitory and modulatory neurons within the hippocampal
circuitry, i.e. inhibitory neurons could be subduing excitatory synaptic transmission.
A better method would be to activate a pathway using electrical stimulation and look
for increased expression within a population of neurons. If a gene was found to be
upregulated then this could be used as a histological tool to determine patterns of




The aim of this thesis was to use electrophysiological techniques to examine the
mechanisms implicated in the synaptic processes of memory and learning in the
rodent hippocampus. In this respect, two of the major mechanisms currently thought
to play a role in these functions are the septal cholinergic input to the hippocampus
and long-term synaptic plasticity within the tri-synaptic pathway of the hippocampus.
Stimulation of the putative septohippocampal cholinergic terminals produced
EPSPms recorded from CA1 pyramidal cells. An investigation into the identity of
postsynaptic mAChR subtype mediating this response proved inconclusive as the
pharmacological tools available provided equivocal data. Consequently, it was
decided that this study required a more thorough investigation which would be costly
and would not necessarily unequivocally resolve the issue.
Therefore, the research focus was shifted to investigating the mechanisms
responsible for the release of ACh from cholinergic terminals and how this process is
modified by other G protein coupled receptors. As such, we decided to examine the
involvement of voltage gated Ca2+channels that are known to be implicated in the
neurotransmitter release process. It was discovered that both N-type and P/Q-type
Ca2+ channels contributed to presynaptic calcium influx at cholinergic terminals, a
heterogeneity which is not at all unusual in CNS presynaptic terminals. There are
numerous reports of neurotransmitter release involving multiple HVA Ca2+ channels
in the hippocampus and other brain regions. Also, evidence has demonstrated
changes in the proportion of Ca2+channel subtypes at synapses with increasing age.
This dynamic heterogeneity may indicate a synapse-specific point of control for
neurotransmitter release.
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It is logical to assume that a strong excitatory input like the cholinergic pathway
should have some kind of inhibitory check to guard against detrimental events such
as epileptogenesis. It had previously been demonstrated that adenosine AiR
activation caused a profound presynaptic inhibition of ACh release. To further this
investigation, we examined the cellular mechanisms by which adenosine may exert
its effect. Our studies determined that there may be a partial involvement of 4-AP
sensitive K+ channels whilst there was no evidence to suggest that a single sub-type
of voltage-dependent Ca2+ channel mediates the inhibitory effect of AiR activation.
Moreover, we discovered that increasing the levels of intracellular cAMP by
stimulating adenylate cyclase resulted in a significant reduction in the levels of
inhibition provided by adenosine receptor activation. Using a non-hydrolysable
analogue of cAMP confirmed this result by producing a full blockade of adenosine
receptor-mediated inhibition of ACh release. This result is consistent with AjRs
acting via Gj to affect a reduction in AC activity. The logical progression of these
experiments would explore how cAMP may act within the cholinergic terminal to
bring about this reduction in release. This would involve looking at PKA and, if
possible, the phosphorylation/dephosphorylation of elements of the vesicular release
machinery, e.g. SNAP25. Elucidating the mechanisms by which neurotransmitter
release is regulated in the physiological state would provide a useful standard by
which to compare the same functions within diseased brains to ascertain how
neurological illnesses alter brain function at the synaptic level. This could possibly
result in the development of some remedial therapy to correct or compensate for any
such abberrations. That psychiatric diseases are caused by disturbances in
neurotransmitter release is suggested by Selective Serotonin Reuptake Inhibitor
therapy in depression, dopamine replacement therapy for the treatment of
Parkinson's disease as well as the lack of ACh release in Alzheimer's disease.
Although these diseases often result from a progressive neurodegeneration, there
may be mechanisms to increase the efficiency of the remaining healthy synapses.
A recent study has shown that the septohippocampal cholinergic pathway atrophies
in aged rhesus monkeys (Smith et ai, 1999). Furthermore, it was demonstrated that
this neuronal atrophy could be reversed by grafting fibroblasts genetically modified
to produce and secrete human nerve growth factor (NGF) into a region of the basal
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forebrain containing the cell bodies of the cholinergic neurons that project to cortical
regions of the brain involved with cognition and memory function. This kind of gene
therapy holds promise for the future treatment of neurodegenerative diseases such as
presenile dementia. Obviously, the more we understand about the septohippocampal
cholinergic pathway the most the future treatment can be refined to produce
beneficial reatment with minimal associated side effects.
It is generally accepted that most synapses in the CNS are under the control of
multiple types of G-protein coupled receptors. In this respect we determined that
activation of presynaptic p-opioid receptors produced an enhancement of the EPSPM.
It was unclear as to the mechanism by which this was achieved as the accepted action
of opioid receptor activation is to inhibit GABAergic interneurons therefore
"disinhibiting" excitatory neurons such as the glutamatergic CA1 pyramidal cells.
This could not be the case the present study as GABAergic neurotransmission was
blocked by antagonists. It is most likely that p-opioid receptors inhibit the release of
other neurotransmitters which negatively regulate the EPSPm- This aside, an
enhancement of processes that contribute to memory and learning is a reasonable
role that opioids could fulfill. This is because, generally, opioid release is associated
with pleasurable or painful stimuli and it is at these times that animals want or need
to remember the context in which they experienced this sensory information so that
they can repeat or avoid the same situation in the future. Therapeutically this receptor
may not provide an optimal drug target because of the widespread distribution of p-
opioid receptors in the CNS as well as the tolerance and dependence effects
associated with m-opioid drugs. However, the p-opioid receptors regulating
mAChR-mediated neuromodulation may be associated with other regulatory
proteins, e.g. RGS, which may be unique and enable more targeted intervention by
small molecule drugs.
In contrast to the opioid-mediated enhancement of the EPSPm, galanin, a
neuropeptide linked to ACh release in the hippocampus, was reported to produce an
inhibition of ACh release. In this respect, we seized the opportunity to investigate the
effect of galanin upon cholinergic transmission in the hippocampus of mice lacking a
functional galanin gene. As predicted, galanin produced little inhibition in Gal ''
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mice. However, the hypothesised improvement in learning that this mutation might
be expected to result in was not apparent. In fact, quite surprisingly the opposite was
found to be the case. We therefore chose to examine whether there was an
impairment in LTP in these animals since LTP represents a working model of
molecular memory at synapses. Consistent with their impaired learning ability, a
deficit in LTP was evident at CA3-CA1 synapses in the s. oriens. This reduction in
LTP could be a result of general septohippocampal cholinergic overexcitation within
the 5. oriens so placing LTP much closer to saturation in the Gal''' mice prior to brain
removal. An LTP saturation study would be useful in confirming this theory. Also, it
would be interesting to examine the status of LTP in cortical areas which are devoid
of ACh function to establish whether these synapses are similarly affected by the
galanin gene deletion. Furthermore, the investigation of other learning phenomena
that involves hippocampal cholinergic function, e.g. theta and gamma rhythm
oscillations, would provide a more in depth insight into how the galanin gene
mutation could be affecting learning ability in these mice.
Long-term potentiation is undoubtedly under the control of many regulatory
elements which function in concert to fine tune memory formation at the synaptic
level. A increasingly useful and recognised method of exploring proteins involved in
the expression and control of synaptic plasticity is to screen transgenic mice,
produced by random gene trap insertion, for genes that are expressed in the
hippocampus. LTP in a number of these transgenic mice was examined and it was
found that one line of mice possessing a disruption of to the EBI-1 G-protein coupled
receptor demonstrated enhanced LTP. It is unclear how this receptor may contribute
to the inhibitory modulation of LTP. A full study would be required to examine this
issue further. This may involve the development of specific agonists/antagonists to
explore the transduction pathway of this novel G protein-coupled receptor as well as
the development of a specific antibody raised against the EBI-1 receptor thus
allowing the use of immunohistochemical techniques to more accurately pinpoint the
location of this receptor.
It had previously been demonstrated that serine proteases may play a role in the
expression of late LTP by facilitating the remodeling of synaptic connections in the
hippocampus. However, a transgenic mouse possessing a disrupted gene encoding a
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brain serine protease that is uniquely expressed in the hippocampus did not display
any change in Late LTP. However, the BSP1mice did display increased
epileptogenesis demonstrated by an increased number of action potentials fired
following a single stimulus at CA3-CA1 synapses. This is likely to result from an
increase in GABAergic autoinhibition via presynaptic GABAb receptors on
glutamatergic terminals or a increased desensitisation of postsynaptic GABAa
receptors. Follow-up experiments would explore GABAergic function in BSP1' in
greater detail.
Recently, it has been reported that an adult transgenic mouse which overexpressed
the N2RB subunit of the NMDA receptor, a subunit that is associated with young
mice, demonstrated enhanced LTP and improvements in a number of behavioural
tests designed to measure learning and memory (Tang et al., 1999). Although this
report primarily shows the importance of the NMDA subunit composition in synaptic
plasticity and memory function, it also points towards a therapeutic target that may
be exploited in the future. For instance, increasing the relative proportion of N2RB
subunit- to N2RA subunit-containing NMDA receptors in the hippocampi of AD
sufferers may compensate for their cognitive impairments.
In order to have any chance of finding an effective treatment for any of the
neurological diseases that impair cognition, it is essential that we have a clear
understanding of how the numerous elements of the brain act and interact to carry
out these higher functions. This thesis just touches on some possible mechanisms
that, in time, when put in context with research around the world may provide us
with the knowledge to devise more beneficial treatments for a population of patients
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